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Abstract 
Rationale Kappa opioid receptor (KOPr) activation by traditional agonists has been 
shown to produce anti-addiction behaviours. However, adverse effects such as sedation, 
aversion and depression have limited their clinical development. Recently, salvinorin A 
(Sal A), an active component of the plant Salvia divinorum was shown to be a potent 
and selective KOPr agonist. Sal A has a short duration of effect and quick onset of 
action. It also produces similar behavioural pharmacology to traditional KOPr agonists. 
However, little is known about the anti-addiction profile of Sal A. If Sal A and its 
structural analogues produce anti-addiction properties with fewer adverse effects 
compared to traditional KOPr agonists, they have potential to be developed into anti-
addiction pharmacotherapies. Therefore, Sal A and its structural analogues (DS1, MOM 
Sal B, EOM Sal B, herkinorin) and Mu opioid receptor (MOPr) antagonist/partial KOPr 
agonist, nalmefene were tested for their behavioural anti-addiction and adverse effect 
profiles in rats. 
Methods To test the anti-addiction profile, a within session cocaine prime induced 
reinstatement paradigm was used. The selectivity of KOPr agonists in attenuating 
cocaine seeking behaviours was tested using sucrose reinforcement (anhedonia) and 
cocaine induced hyperactivity in self-administering rats (sedation during reinstatement 
test). Furthermore, behavioural adverse effects were screened using spontaneous open 
field activity (motor suppression), conditioned taste aversion (aversion) and forced 
swim test (depression) in rats. To further quantify the anti-addiction behaviours, the 
effect of KOPr agonists which attenuated drug seeking selectively without producing 
motor suppression by themselves were tested for cocaine produced motor function 
(hyperactivity and behavioural sensitization) in rats. The effect of serotonin transporter 
blockade on KOPr agonist induced depressive behaviour was also tested. The effects of 
KOPr activation on in vitro serotonin transporter function were also determined. 
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Results Sal A, DS1 and nalmefene attenuated cocaine prime induced drug-seeking, in 
a selective manner, via KOPr activation. MOM Sal B, a more potent and long acting Sal 
A analogue attenuated cocaine seeking in a non-selective manner. Sal A, DS1 and 
nalmefene did not induce aversion, however nalmefene suppressed motor function, 
which was not seen with Sal A and DS1. Furthermore, Sal A and DS1 suppressed 
cocaine behavioural sensitization. All three compounds (Sal A, DS1, nalmefene) 
produced depression. The depressive effects produced by Sal A and DS1 were 
diminished by blocking the serotonin transporter. Live-cell serotonin transporter assays 
showed potential differences between traditional (U50488H) and novel (Sal A, DS1) 
KOPr agonists in their ability to modulate serotonin transporter function. 
Conclusion Out of six KOPr compounds tested, Sal A, DS1, MOM Sal B and 
nalmefene produced anti-addiction behaviours. However, MOM Sal B exposure also 
suppressed natural reward seeking behaviour. Sal A and DS1 had a better adverse effect 
profile than nalmefene. Thus, the order of efficacy for the compounds tested were DS1 
≥ Sal A > nalmefene > MOM Sal B. However depression was noted with all three 
compounds tested (Sal A, DS1, nalmefene) and our study provides evidence to suggest 
the involvement of the serotonin system in Sal A and DS1 induced depression. 
Moreover, a difference in modulation of serotonin transporter function by novel and 
traditional KOPr agonists was observed. 
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Addiction is defined as “compulsive physiological need for and use of a habit-
forming substance (as heroin, nicotine, or alcohol) characterized by tolerance and by 
well-defined physiological symptoms upon withdrawal; broadly : persistent compulsive 
use of a substance known by the user to be physically, psychologically, or socially 
harmful” (addiction. 2011. In Merriam-Webster.com). Drugs of abuse, such as 
psychostimulants produce a general sense of euphoria or hedonism which determines 
their abuse potential (Eddy et al., 1965; Koob and Le Moal, 1997). Initial exposures to 
these compounds produce strong reinforcing properties which have been characterised 
as a sense of well-being (Koob and Bloom, 1988; Gawin, 1991). The reinforcing 
properties change the complexion of normal brain function which is evident by the 
alteration in normal brain anatomy, biochemistry and underlying molecular and cell 
biology (Verdejo-Garcia et al., 2007; Nestler and Aghajanian, 1997; Wexler et al., 2001; 
Chang and Chronicle, 2007; Koob and Le Moal, 2005). These alterations are 
responsible for withdrawal effects such as anxiety, depression and stress, which 
predispose the addict to relapse back to the use of these drugs of abuse (Eddy et al., 
1965; Sinha, 2001; Van Bockstaele et al., 2010; Valentino et al., 2010).  
Apart from alcohol and nicotine use, commonly abused illegal drugs include 
psychostimulants (cocaine, amphetamine, methamphetamine), opioids (heroin, 
morphine) and recreational hallucinogens (lysergic acid diethylamide, psilocybin, 
cannabis) (Substance Abuse and Mental Health Services Administration 2008; World 
Drug Report, 2007). Among these illegal drugs of abuse, cannabis is most abused in 
The United States, Europe, Australia and New Zealand (World Drug Report, 2007; 
Substance Abuse and Mental Health Services Administration 2008; Australian Drug 
and Alcohol Use Survey 2007; New Zealand Alcohol and Drug Use Survey, 2010). The 
next most abused illegal drug in Europe and the United States is cocaine (Substance 
Abuse and Mental Health Services Administration 2008; The state of drug problem in 
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Europe, Annual report 2009). In New Zealand, around half of the population between 
16-64 years of age had abused illegal drugs (excluding alcohol, nicotine and party pills) 
at least once in their lifetime. Moreover, the prevalence of psychostimulant use was 
comparatively lower than cannabis use, with fewer than 4% of the surveyed population 
abusing psychostimulants (cocaine, methamphetamine and prescription stimulants) as 
compared to 46.4% using cannabis (New Zealand Alcohol and Drug Use Survey, 2010). 
These surveys indicate that use of illegal drugs is widespread.  
Substance abuse is associated with social, economic and civic disabilities (New 
Zealand Alcohol and Drug Use Survey, 2010; World Drug Report, 2007). The societal 
effects of substance use include loss in school hours, work hours, and unemployment 
(New Zealand Alcohol and Drug Use Survey, 2010). Moreover, increased crime and 
violence burdens healthcare and justice resources and add to the social and economic 
cost associated with substance abuse (World Drug Report, 2007). Furthermore, drug 
abuse contributes to an increase in co-morbid mental illnesses and infectious diseases 
such as acquired immune deficiency syndrome and hepatitis C, which are mainly caused 
by drug users sharing needles (Morton, 1999; Murrill et al., 2001; Sorenson et al., 2002). 
In 2008, the financial loss associated with substance abuse in the United Kingdom was 
over 20 billion pounds (The state of drug problem in Europe, Annual report 2009). Due 
to the large social and economic cost of addiction many strategies, such as strict law 
enforcement have been undertaken to control this menace (World Drug report 2007). 
From a medical perspective, one of the ways to tackle this problem is to develop 
pharmacological approaches to reduce or prevent addiction.   
Numerous studies have been conducted to determine how drugs of abuse bring 
about the long lasting changes in brain physiology (Weiss et al., 1992; Pierce and 
Kalivas, 1997; Koob et al., 2004; Koob and Le Moal, 2008; Koob and Volkow, 2009). 
It is well accepted that drugs of abuse function by modulating the mesocorticolimbic 
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dopamine system (MDS; Di Chiara and Imparato, 1988a; Wise and Bozarth, 1984; 
Wise and Rompre, 1998; Kuhar et al., 1991; Spanagel et al., 1992; Koob, 1992). The 
MDS comprises of dopamine (DA) cell bodies located in the ventral tegmental area 
(VTA) and projections to the nucleus accumbens (NAc), amygdala and the pre-frontal 
cortex (PFC) (Olds and Milner, 1954; Olds, 1956, 1977; Bozarth, 1987). Almost all 
drugs of abuse act by increasing the DA levels in the MDS (Wise and Rompre, 1989). 
This finding formed the basis of the ‘dopamine theory of addiction’, which links the 
increase in reinforcing properties of the drugs of abuse to the elevated DA levels in the 
MDS (Wise and Bozarth, 1984; Wise and Rompre, 1989; Kuhar et al., 1991; Spanagel 
and Weiss, 1999). However, recent evidence also suggests that DA plays a role in 
craving, incentive learning for drug induced enhancement in reward experience and its 
sensitization (Robinson and Berridge, 1993; 2003; Di Chiara, 1995; Lambert et al., 
2006). Long term use of drugs of abuse alters the normal reward and motivational 
behaviour by bringing alterations in normal reward circuitry (Weiss et al., 1992; 
Spanagel et al., 1994; Nestler et al., 2001). These long term neuronal adaptations can 
lead to withdrawal related behaviours such as depression and stress, which are 
implicated in relapsing back into substance use (Bruchas et al., 2010; Nestler et al., 
2001). In addition to their effect on the reward pathway, drugs of abuse also bring about 
changes in brain regions involved in memory processing, decision making and learning 
novel tasks (Grant et al., 2000; Schneider et al., 2008; Schenk et al., 2010). The 
following section will describe various therapeutic strategies applied to tackle addiction 
at the clinical level.     
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1.1. Current pharmacotherapies for addiction  
Addiction is a chronic relapsing disorder; therefore treatment strategies involve 
multiple behavioural and/or pharmacological interventions with intensive patient 
monitoring (DeRubeis and Crits-Christoph, 1998; Carrol and Enken, 2005). This makes 
for long term patient management rather than short term therapy (McLellan et al., 2000). 
Although, treatment choice varies between individuals, most treatment strategies 
include cognitive behavioural therapy in combination with pharmacological agents 
(Jupp and Lawrence, 2010). Behavioural therapy includes group counselling, social 
involvement (family and friends) and motivational therapy to enhance self-abstinence 
from drug taking (Carrol and Enken, 2005; Carrol et al., 2006). The role of 
pharmacological treatment is to tackle the patho-physiological alterations caused by the 
abused drugs, and to prevent the addict from relapsing back to drug use (Jupp and 
Lawrence, 2010; Lobmaier et al., 2010).  
This section discusses some currently available pharmacotherapeutic strategies 
for drug of abuse including opioids, alcohol, nicotine and psychostimulant abuse. 
Opiate maintenance or replacement therapy for heroin addiction aims to reduce 
withdrawal related adverse effects such as depression, craving and preventing the abuser 
from relapsing back to drug use (Kreek et al., 2000; 2005). This therapeutic approach 
uses MOPr agonists such as methadone and methadone derivatives which reduce the 
craving effect of heroin addiction (Stimmel and Kreek, 2000). Because methadone is 
given via an oral route, the “high” produced by methadone is much less than heroin 
(Hickman et al., 2003; Lobmaier et al., 2010).  This may account for its overuse and 
potentially fatal toxicity (Perret et al., 2000; Reingardiene et al., 2009). Recently, 
buprenorphine, a mixed opioid compound (MOPr agonist/antagonist and partial KOPr 
antagonist) has also been used in the opioid maintenance therapy (Soyka et al., 2008). 
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However, in clinical settings, methadone is still more widely used over buprenorphine 
(Mattick et al., 2008).  
Similar to opiates, nicotine replacement therapy has been applied to manage the 
withdrawal effects associated with smoking cessation (Silagy et al., 2004). The 
principle behind this is to make nicotine available via delivery systems other than 
cigarette smoke such as nicotine patches, inhalers, chewing gums and lozenges (Silagy 
et al., 2004). However, high rates in relapse back to smoking have been noted within a 
short period with nicotine replacement therapy (Borgne et al., 2004). Thus, nicotine 
replacement therapy seems to fail in providing long term abstinence from quitting 
smoking. Other pharmacological approaches include the use of partial α4β2 nicotinic 
agonists, varenicline and bupropion (nicotinic receptor blocker and DA/nor-epinephrine 
(NE) neurotransmission modulator) (Jorenby et al., 2006). Both of these agents increase 
the period of abstinence (Jorenby et al., 2006) by decreasing craving and withdrawal 
effects (Coe et al., 2005). However, recent reports suggest the development of 
depression and suicidal tendencies with these pharmacotherapies (Gunnel et al., 2009; 
Wrightman et al., 2010).  
Modulation of drug metabolism is often used in the treatment of alcohol 
addiction and disulfiram, via inhibiting enzyme acetaldehyde dehydrogenase has been 
used to prevent alcohol intake (Kitson, 1977). It produces acute aversive symptoms 
such as flushing, irritability, tachycardia, nausea and vomiting if alcohol is ingested, 
thus, preventing the abuser from consuming alcohol (Kitson et al., 1977). Although 
there are compliance issues, this treatment has been successfully applied in clinical 
settings under medical supervision (Ehrenreich and Krampe, 2004).  
There are currently no successful pharmacotherapies to treat psychostimulant 
addiction (Taylor and Gold, 1990; Gawin, 1991). The cocaine analogue, cocaethylene 
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has been tested for use in cocaine withdrawal and maintenance therapy. Cocaethylene 
was effective in decreasing behavioural effects of cocaine in humans (Baker et al., 
2007). However, due to its toxic liability, it is likely to fail as anti-cocaine agents 
(Tacker and Okorodudu, 2004). Monoamine oxidase inhibitors such as selegiline have 
shown promising anti-cocaine effects in pre-clinical studies but have failed to produce 
similar effects in humans (Elkashef et al., 2006; Gatch et al., 2006). Additionally, Negus 
and Mello, (2004) showed that methadone infusions (0.032-1.0 mg/kg/hr) produced 
non-specific decrease in operant responding without affecting cocaine reinforcements in 
rhesus monkeys.   
These reports show that most of the currently available pharmacotherapies have 
shown limited success. In some cases drug-addicts have a high incidence of relapse and 
risk fatal drug induced toxicity. Furthermore, some of these medications can themselves 
cause addiction (methadone for opioid maintenance therapy), or have safety and 
compliance issues warranting caution while being used clinically (disulfiram, 
varenicline, bupropion). The development of more effective anti-addiction 
pharmacotherapies are therefore needed to help break the addiction cycle and to reduce 
relapse. Understanding the eiteology of addiction cycle can help in designing new 
treatment strategies which will be useful to combat the progression and development of 
substance abuse (Markou et al., 1993; Le Moal and Koob, 2005).   
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1.2. The addiction cycle 
The development of addiction cycle has been extensively reviewed and has been 
studied both pre-clinically and clinically (Gawin and Kleber, 1988; Koob, 2008, Koob 
and Le Moal, 2008; Koob and Volkov, 2009). Briefly, the addiction cycle consists of 
three different stages, the initial binging stage, followed by drug abstinence and relapse 
(Fig 1.1; Koob and La Moal, 2008). The binging phase is characterized by the hedonic 
properties of the drugs of abuse (Gawin, 1991). During this stage the drug-taker 
experiences positive reinforcement (A in Fig. 1.1; Eddy et al., 1965; Gawin, 1991) and 
this leads to a gradual escalation in drug use (B in Fig. 1.1). During the abstinence from 
drug use (forced or self-imposed; shown as C in Fig 1.1), neuronal adaptations 
occurring especially in the brain reward circuits results into negative mood states such 
as dysphoria, stress and depression (Koob and Volkov, 2009; Carlezon et al., 1998; 
Nestler, 2001; D in Fig. 1.1). These negative mood states during abstinence can enhance 
drug craving (E in Fig. 1.1) and re-exposure to a drug prime or an environmental cue 
associated with drug use (such as party settings where drugs were abused) or stress can 
predispose relapse (Hunt et al., 1971; Goeders, 2002a; 2002b). Pre-clinical models of 
addiction have been shown to mimic the behavioural conditions observed in humans at 
different stages of the addiction cycle (Markau et al., 1993; Koob, 2000). The following 
section will discuss various animal models commonly applied in addiction research and 
anti-addiction drug discovery.     
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A. Initial binging (Positive 
reinforcement stage)
B. Escalation in drug use
D. Negative effects of 
Withdrawal
C. WithdrawalE. Craving
Cycle 
of 
Addiction
 
Fig 1.1 Stages in the cycle of addiction 
(Adapted from Koob and Le Moal, 2008). After initial ‘binges’ of drug exposure (A), escalation 
in the drug administration develops (B). This is due to the ‘positive reinforcing or hedonic 
effects of drugs of abuse. Later on during abstinence from the drug use (C), negative mood 
states such as depression and stress are observed (D). These negative states are due to the 
neuronal adaptations associated with drug use and can lead to craving (E). Exposure to drug, 
drug associated environmental cues and stressors can predispose the addict to relapse back to 
the drug use. This marks the establishment of the addiction cycle.    
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1.3. Animal models of addiction 
Animal models are an important tool which have been utilized to study the 
underlying pathophysiology of addiction and also to test novel therapeutic strategies 
(Spanagel, 2003; Self, 2004; Kalivas et al., 2006). The use of various animal models in 
understanding the stages of the addiction cycle has been reviewed extensively 
(Auriacombe et al, 1997; Koob et al, 1999; Stewart, 2000; Sanchis-Segura and Spanagel, 
2006; and Spanagel and Holter, 2000; Shalev et al., 2002; O’Brian and Gardner, 2005; 
Kalivas et al, 2006; Koob and Le Moal, 2008; Koob and Le Moal, 2005). Animal 
models commonly applied to study various stages in addiction cycle are shown in      
Tab. 1.1.  
The positive reinforcement stage has been studied using models which measure 
intravenous or oral drug self-administration, conditioned place preference (CPP), or 
intracranial self-stimulation (ICSS). The craving stage can be depicted by models 
measuring the reinstatement of extinguished drug-seeking and behavioural sensitization. 
The negative reinforcement stage of the addiction cycle can be depicted in models 
measuring drug self-administration, ICSS, conditioned place aversion and drug 
discrimination. (Koob and La Moal, 2005; Sanches-Segura and Spanagel, 2006). 
1.3.1. Operant conditioning in studying addictive behaviours. 
Most of these paradigms are based on the rationale of ‘Skinner’s box’ which 
applies the principle of ‘operant reinforcer induced reward’ (Skinner, 1938). Briefly, a 
reinforcer is any stimulus which is used to learn a task (operant lever pressing) and will 
lead to a response (delivery of reward such as palatable food or drugs of abuse) (Skinner, 
1938; Shalev et al., 2002). The hedonic nature of response will lead to an increased 
lever pressing, thus leading to positive reinforcement (Skinner, 1938; Dinsmoor, 2004; 
Shalev et al., 2002). Once the animal learns to obtain reward, the effect of exposure to a 
pharmacological/ external stimulus can be determined on the positive reinforcement 
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(Shaham et al., 2003). Such conditioning is called ‘instrumental conditioning’ and the 
pharmacological/external stimuli applied are known as ‘unconditioned stimulus’ 
(Thorndike, 1911; Pavlov, 1927; 1941; Dinsmoor, 2004). Drugs of abuse such as 
cocaine, amphetamine and morphine act as positive reinforcers and have been shown to 
increase operant responding in laboratory animals (Deaneu et al., 1969; Devine and 
Wise, 1994). Furthermore, the principle of instrumental conditioning has been applied 
to understand the craving for abused drug by using the reinstatement model (Stewart, 
2000; Shalev et al., 2002; Shaham et al., 2003). By using this model, presentation of 
drug primes (De Wit and Stewart, 1981; 1983), environmental cues (Wissenborn et al., 
1995; Koob et al., 1996) and stressors (Erb et al., 1996) have been shown to reinstate 
extinguished drug-seeking behaviours in rats. This paradigm has been used extensively 
to determine the pathophysiology of drug addiction as well as anti-addiction drug 
discovery (Kalivas et al., 2006; Stewart, 2000; Shalev et al., 2002; Self, 2004).       
1.3.2. Non-operant conditioning in studying aversive behaviours.   
In addition to operant conditioning, laboratory animals can also be trained using 
non-operant conditioning methods to study the aversive behaviours (Sanchez Segura 
and Spanagel, 2006). One of the paradigms based on this principle is conditioned taste 
aversion (CTA). In this test, water deprived animals are presented with a novel tasting 
saccharin solution. The novel taste of saccharin (conditioned stimuli) is paired with the 
unconditioned stimuli (x-ray irradiation or pharmacological agents; Garcia et al., 1955; 
Davis et al., 2009). A reduction in the amount of saccharin consumed when presented 
next shows the aversive properties produced by the unconditioned stimuli (Sanchez 
Segura and Spanagel, 2006; Davis and Riley, 2010).   
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Tab. 1.1. Stage of addiction and corresponding pre-clinical paradigms.  
Addiction stage Source of 
reinforcement 
Preclinical models 
Binging Positive reinforcement Increased self-administration and 
CPP, decreased ICSS thresholds 
Craving/ 
anticipation  
Conditioned positive 
reinforcement 
Drug prime, stress and cue 
induced reinstatement, 
behavioural sensitization 
Withdrawal stage Negative reinforcement Conditioned place aversion, 
increased self-administration 
(dependence stage), increased 
ICSS thresholds 
(Modified from Sanchez-Segura and Spanagel, 2006; Koob and La Moal, 2008).  
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1.4. Cocaine addiction in pre-clinical models. 
Cocaine has been widely used by the indigenous communities in South America 
for over 3000 years (Siegel, 1982; Gawin and Kleber, 1988). Its addictive potential has 
been extensively studied in pre-clinical as well as clinical settings (Shaham et al., 2000; 
Sughondhabirom et al., 2005). Cocaine acts as a positive reinforcer and has been shown 
to produce self-administration in rats, mice and monkeys (Pickins and Thompson, 1968; 
Deneau et al., 1969; Hill and Powell, 1976; Papasava et al., 1981). It also produces 
discriminative stimulus effects (Spealman et al., 1991), CPP (Shippenberg et al., 1995) 
and decreases ICSS thresholds (Markou and Koob, 1991; Kornetsky and Esposito, 1981) 
in laboratory animals. A single injection of cocaine has also been shown to enhance 
motor function (Bhattacharya and Pradhan, 1979; Kalivas and Duffy, 1990). When 
cocaine is either experimenter- (Kalivas and Duffy, 1990; Kalivas and Stewart 1991; 
Heidbreder et al., 1996; Kalivas et al., 1998) or self-administered (Hooks et al., 1994; 
Philips and Di Ciano, 1996), it produces sensitization to its motor stimulant effects. 
Cocaine has been shown to reinstate extinguished drug-seeking behaviour following 
drug primes (Downs and Woods, 1974; de Wit and Stewart, 1981; 1983; Worley et al., 
1994; Stewart, 2000; McFarland and Kalivas, 2001). Additionally, presentation of 
environmental cues associated with cocaine self-administration (Koob et al., 1995; 
Weissenborn et al., 1996) and environmental stressors have also been shown to induce 
reinstatement of cocaine seeking behaviour (Erb et al., 1996; Kupferschmidt et al., 
2011). The following sections will briefly describe the mechanism by which cocaine 
induces addictive behaviours.  
1.4.1. Effect of cocaine on DA transporter function  
Synaptic DA neurotransmission following cocaine use is shown in Fig 1.2A. On 
activation, the pre-synaptic neurons release DA which binds to DA receptors and 
depending on the receptor subtypes it activates, can produce neuronal excitation (Fig 
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1.2B). Later, the released DA from the receptors gets transported back to the pre-
synaptic neurons via the DA transporter (DAT). There it is either repackaged into 
vesicles for re-release or degraded by enzymes (Carlsson, 1969; Vogt, 1969; White, 
1990).    
The transportation of DA into the pre-synaptic neuron requires sodium and 
chloride ions to bind to DAT (Zhanisar and Dolen, 2001). This is followed by DA 
binding which leads to the structural conformation change in DAT, resulting in DA 
uptake into the neuron (Torres et al., 2003). This process requires de-phosphorylation of 
adenosine tri-phosphate to adenosine di-phosphate and is facilitated in the presence of 
the enzyme Na+/K+ ATPase (Fig 1.2C; Sonders et al., 1997). Along with DAT, cocaine 
is also a substrate for the nor-epinephrine transporter (NET) and serotonin transporter 
(SERT) (Ravna et al., 2003). Its action on the reward circuit is mediated mainly via its 
interaction with DAT (Kuhar et al., 1991). Recent studies have shown that cocaine and 
DA bind at the same site on DAT (Beuming et al., 2008). The increased binding of 
cocaine to DAT results into decreased DA uptake and increased availability of DA in 
the synapse (Fig 1.2D; Zhaniser et al., 1999). The rewarding effects of cocaine are due 
to its modulation of DA neurotransmission, thereby acting as an indirect DA receptor 
agonist (Kreek et al., 1999; Zhaniser and Dolen, 2001; Torres et al., 2003).  
Due to this, pharmacological agents which modulate DA receptors have been 
studied as anti-cocaine pharmacotherapeutics (Jupp and Lawrence, 2010; Heidbreder, 
2008). However, studies have indicated that DA receptor antagonists produce adverse 
effects such as suppression of reward reinforcements and extra-pyramidal motor effects 
which have discouraged their development as anti-cocaine agents (Woolverton et al., 
1986; Wise and Schwartz, 1981; Mello and Negus, 1996). Recent studies have shown 
that the DA 3 receptor preferring compound ropinirole has an anti-addictive effect in 
humans (Meini et al., 2008). The partial DA 2 receptor agonist, aripiprazole has also 
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been shown to decrease cocaine craving (Vorspan et al., 2008). On the other hand, the 
DA 1/DA 2 receptor agonist amantadine showed no significant effect in treating cocaine 
dependence (Kampman et al., 2006). Furthermore, recent in vitro studies have shown 
that DA 2 receptor activation has shown to increase DAT function (Bolan et al., 2007). 
Taken together, these results indicate that modulating DA 2 receptor tone could be 
useful in maintaining cocaine withdrawal effects. However, serious adverse effects such 
as potentiating other drug use (aripiprazole potentiating methamphetamine and 
amphetamine use) can be a limiting factor in developing these agents as anti-cocaine 
pharmacotherapies (Tiihonen et al., 2007). Recently, benztropane DAT inhibitors such 
as JHW 007 (Velazquez-Sanchez et al., 2010) and AHN 1055 (Velazquez-Sanchez et al., 
2009; Ferragud et al., 2009) have been tested as cocaine replacement agents in animals. 
Results from these studies showed that DAT antagonism may prevent cocaine relapse. 
This, however, needs to be tested in humans to determine its clinical application. 
Collectively taken, these results strongly suggest developing agents which indirectly 
modulate DA neurotransmission, ideally with fewer adverse effects may be an effective 
strategy to tackle cocaine addiction, (Sonders et al., 1997; Mello and Negus, 2000).          
It is well documented that KOPr activation decreases DA levels in NAc (Di 
Chiara and Imparato, 1988a; 1988b; Spanagel et al., 1992). This effect produced by 
KOPr agonists might be due to an increase in DAT function (Thompson et al., 2000) as 
both KOPr and DAT are co-localized in NAc (Svingos et al., 2001). Furthermore, pre-
clinical studies have shown that KOPr activation opposes cocaine produced behaviours 
(Heidbreder et al., 1993; Shippenberg et al., 1998). Therefore, KOPr activation can 
indirectly modulate cocaine produced behavioural and neurochemical alterations 
(Thompson et al., 2000). Thus, making them an ideal candidate to be developed as anti-
cocaine agents (Prisinzano et al., 2005; Shippenberg et al., 2001).   
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Fig.1.2 Effect of cocaine on dopamine transporter function 
 Schematic representation of the effect of cocaine on DA neurotransmission. A. Pre-synaptic 
neuron and a post- synaptic neuron. The pre-synaptic neuron has stored dopamine (DA) in the 
vesicles and DAT is present on the surface of the neuron. The DA receptors are present on the 
post-synaptic neuron. B. The activated neuron releases DA in synapse which binds to the DA 
receptors and activates it. C. DA then dissociates from the receptors and is either repackaged 
back to the neurons by DAT or is destroyed by the enzymatic degradation. The transportation of 
DA is facilitated by Na+/K+ATPase. D. Cocaine competes with DA and binds to DAT leading to 
an increase in DA levels in the synapse. The freely available DA binds to the DA receptors and 
hyper-activates the post synaptic neuron. blue dots- DA; Orange dots- sodium ions; Red dot- 
chloride ions; Dotted lines indicates decreased activity; Straight lines indicates increased 
activity; Red circle- storage vesicles for DA.       
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 1.5. The kappa opioid receptors 
The KOPr is a member of 7 transmembrane G-protein coupled receptor protein 
(Eguchi, 2004) and the endogenous neuropeptide dynorphin (DYN; Goldstein et al., 
1979) binds with high affinity to the KOPr (Corbett et al., 1982; Chavkin et al., 1982). 
High levels of KOPr’s are found in the NAc, caudate putamen (CPU), claustrum, 
amygdala, endoperiform nucleus, whereas low levels of KOPr’s were observed in the 
VTA and substantia nigra (Mansour et al., 1995; 1996; Quirion et al., 1987). 
Correspondingly, high levels of DYN were detected in the forebrain, hypothalamus and 
substantia nigra, whereas low levels of DYN have been reported in the dorsal and 
ventral striatum, amygdala and hippocampus (Goldstein and Ghazarossian, 1980; 
Webber et al., 1982). Although, pharmacological studies have indicated three subtypes 
of KOPr’s, to date only one subclass of KOPr, KOPr1, has been cloned (Connor and 
Kitchen, 2006).  
The mechanism by which the KOPr activates is shown in Fig 1.3. The inhibitory 
G-protein coupled receptors are associated with the intracellular G-protein heterodimer 
(Eguchi, 2004). The G-protein heterodimer comprises of Gα, Gβ and Gγ subunits 
(Connor et al., 1999). Upon activation of the KOPr, the G-protein trimer undergoes 
conformational changes followed by the dissociation of the Gα and Gβγ subunits 
(Salamon et al., 2002). The dissociated subunits further modulate other signal 
transduction systems for example; the Gα subunit reduces adenylyl cyclise activity 
which decreases cyclic adenosine monophosphate (cAMP) induced protein kinase A 
signalling (Watts and Neve, 2005). The Gβγ subunit directly activates the inwardly 
rectifying potassium channel and inhibits voltage gated calcium channels (Holtz et al., 
1998). Overall, this stabilizes the neuron by maintaining its resting state potential (Lu, 
2004). The following section describes the activation of the KOPr/DYN negative 
feedback loop in response to repeated exposures to cocaine.   
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Fig.1.3. Signal transduction mechanism for kappa opioid receptor 
activation  
 (Adapted from Bruchas and Chavkin, 2010). The signal transduction mechanism following 
acute and chronic KOPr activation. KOPr is an inhibitory GPCR which has Gαβγ subunits. On 
KOPr activated, these subunits dissociates into Gα and Gβγ subunits. The Gα subunit decreases 
the levels of adenylyl cyclase and the Gβγ subunit modulates intracellular potassium and 
calcium ion levels. KOPr activation also leads to activation of protein kinases ERK1/2 and p38. 
However, long term activation of KOPr leads to receptor phosphorylation and kinase activation 
via GRK3-Arrestin dependent mechanism. KOPr- kappa opioid receptor; K+- potassium ion; 
Kir3- G-protein gated inward rectifying K
+ channel; Ca2+- calcium ion; α- G protein alpha 
subunit; βγ- G protein beta-gamma subunit; GTP- Guanosine tri-phosphate; AC- adenylyl 
cyclise; cAMP- cyclic adenosine mono-phosphate; P- phosphorylation; GRK3- G-protein 
coupled receptor kinase 3; ERK1/2- extra-cellular signal-regulated kinase; p38 – p38 mitogen 
activated protein kinase.    
 
 
 
29 | P a g e  
 
1.5.1. Negative feedback loop and DYN/kappa opioid system 
The DYN/KOPr mediated negative feedback loop is presented in Fig 1.4. The 
gamma amino butyric acid - medium spiny neurons located in the NAc receives 
DAergic inputs from the VTA (Van Bockstaele and Pickel, 1995). This neuron 
expresses DA 1 receptors, which are coupled to stimulatory G-protiens (Carlezon et al., 
1998) and functions by increasing the adenylyl cyclise activity. The increased cAMP 
activity enhances the transcription of CREB resulting in release of the endogeneous 
KOPr neuropeptide, DYN (Carlezon et al., 1998; Nestler, 2001). The spiny projections 
from NAc releases DYN at the pre-synaptic DA neurons where it binds to the pre-
synaptic KOPr (Carlezon et al., 1998). The activated KOPr’s has shown to oppose the 
hedonic effects produced by the drugs of abuse. (Nestler 2001; Shippenberg et al., 2007; 
Mysels and Sullivan, 2009). An increase in KOPr expression has been observed during 
chronic cocaine administration in NAc shell, CPU, claustrum and endopiriform nucleus 
(Collins et al., 2002). This is also accompanied by an elevation in striatal DYN levels 
and pro-DYN gene expression levels (Sivam, 1989; Daunais et al., 1995; Ramouldi et 
al., 1996). Agonists at KOPr’s have shown to suppress elevation in DA levels in the 
midbrain dopaminergic systems (Di Chiara and Imparato 1988a; 1988b; Shippenberg et 
al., 1996). Therefore, activation of KOPr during the initial stages of the addiction cycle 
or prior to the drug withdrawal might help in curbing the development and progression 
of cocaine addiction (Shippenberg et al., 2007; Hasabe et al., 2004; Mysels, 2009; 
Prisinzano et al., 2005). This hypothesis has led to the idea of developing KOPr agonists 
as anti-addiction agents (Mysels and Sulliva, 2009; Shippenberg et al., 2007). The 
following section gives information on the endogeneous, synthetic and naturally derived 
KOPr agonists.  
 
30 | P a g e  
 
 
DA
ĸ
D1
GS
C
R
EB
pr
o-
D
YN
GABA
VTA
NAc
 
Fig.1.4.Negative feedback loop  
 (Adapted from Carlezon et al., 1998; Nestler, 2001). Opposing effects to the initial rewarding 
behaviours produced by drugs of abuse via the negative feedback loop. The NAc receives DA 
inputs from the VTA which activates the DA 1receptor present on the gamma amino butyric acid 
medium spiny neurons. Upon activation, these neurons activate CREB, which releases the 
neuropeptide DYN at the presynaptic neurons. DYN binds to the KOPr and opposes the hedonic 
properties of cocaine via modulating DA tone in NAc. NAc- nucleus accumbens; GABA- gamma 
amino butyric medium spiny neuron; VTA- ventral tegmental area; CREB- cAMP response 
element binding protein; pro-DYN- prodynorphin gene; DA- dopaminergic neuron commencing 
from VTA; D1- DA 1 receptor; Gs- Stimulatory G-protein coupled receptors; green dots- 
dopamine; ĸ- kappa opioid receptor; red dots- DYN. 
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1.5.2. Kappa opioid receptor agonists 
The endogeneous and synthetic KOPr agonists are shown in Fig 1.5. The KOPr 
agonists consist of endogeneous peptide DYN (1-17) (Goldstein et al., 1980; Chavkin et 
al., 1982), arylacetamide analogues (U50488H; Vonvoigtlander et al., 1982; 1983, 
U69593; Lahti et al., 1985, spiradoline; Lahti et al., 1985); benzomorphans 
(bremazocine, Romer et al., 1980; cyclazocine, pentazocine, Harris and Pierson, 1964); 
epoxymorphinans (nalfurafine; Nagase et al., 1988); iboga alkaloids (ibogaine and its 
structural derivatives; Maisonneuve and Glick, 2003) and neoclerodane diterpenes 
derived from the plant Salvia divinorum (Sal A and its structural derivatives; Roth et al., 
2002). The coming sections shall give an account of the behavioural anti-addiction as 
well as the adverse effect profile of KOPr agonists.   
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Ethylketocyclazocine
Bremazocine
Nalfurafine (TRK-820)
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Ibogaine
NEOCLERODANE 
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EPOXYMORPHINANS
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Fig. 1.5. Kappa opioid receptor agonists 
 (Modified from Eguchi, 2004; Baumann et al., 2001; Tachibana et al., 1982) Kappa opioid 
receptor agonists consist of the naturally occurring endogenous ligand DYN. Synthetic classes 
of agonists includes benzomorphans (ethylketazocine, bremazocine, cyclazocine); 
arylacetamides (U50488H, U69593, spiradoline); epoxymorphinans (nalfurafine); 
neoclerodane diterpenes (Sal A and its derivatives); Iboga alkaloids (ibogaine and its 
derivatives)    
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1.5.3. Kappa opioid agonists in pre-clinical models of addiction   
The effect of KOPr activation on cocaine produced behaviours has been studied 
extensively in laboratory animals and summarised in Tab 1.2.  
1.5.3.1. Arylacetamides  
Acute KOPr activation by the arylacetamide KOPr agonist U50488H and 
U69593 attenuated nicotine induced behaviours in rats (Hahn et al., 2000; Ismailova 
and Shoaib, 2010). U69593 has been shown to attenuate self administration of heroin 
(Xi et al., 1998), and suppress amphetamine induced behaviours (Gray et al., 1999) in 
laboratory animals. U50488H and spiradoline both dose-dependently attenuated self-
administration of cocaine and morphine in rats, which was reversed by KOPr antagonist 
pre-treatment (Glick et al., 1995; Kuzmin et al., 1997). The same study also showed that 
at a higher dose, both arylaceamides (5, 10 mg/kg) decreased water consumption in rats 
(Glick et al., 1995). Thus, suggesting a non-selective attenuation at higher dose. 
U50488H has also been shown to attenuate ethanol self-administration in rats (Lorgip et 
al., 2008). In a drug discrimination model, U50488H either had no effect (Broadbent et 
al., 2002) or attenuated rewarding effects produced by a low training dose of cocaine (3 
mg/kg vs. 10 mg/kg; Kantak et al., 1999). U50488H, U69593 and spiradoline pre-
treatment attenuated cocaine-induced hyperactivity (Vanderschuren et al., 2000) and -
behavioural sensitization (Heidbreder et al., 1996; Puig-Ramos et al., 2008) in rats. 
Additionally, spiradoline attenuated morphine induced behavioural sensitization (Smith 
et al., 2003) and cross sensitization to cocaine (Smith et al., 2009). Also, U50488H, 
U69593, and spiradoline all attenuate cocaine prime induced reinstatement in rats (See 
et al., 2010; Morani et al., 2009; Schenk et al., 2000). These findings indicate that 
arylacetamide KOPr agonists produce anti-addiction like effects in laboratory animals 
which might be non-selective (Glick et al., 1996).  
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1.5.3.2. Benzomorphans  
The benzomorphan analogue, cyclazocine has also been shown to attenuate 
cocaine self-administration without affecting water consumption in rats (Glick et al., 
1998). However, in rhesus monkeys, bremazocine but not cyclazocine attenuated 
cocaine maintained behaviours (Negus and Mello, 2000). Bremazocine also attenuated 
self-administration of cocaine and oral ethanol with decreased saccharin consumption in 
rhesus monkeys (Cosgrove and Carrol, 2002). However, in another study, bremazocine 
induced attenuation of freely available ethanol was without any effect on sucrose 
consumption in rats (Nestby et al., 1999). Also, bremazocine pre-treatment attenuated 
cocaine and amphetamine induced enhancement in motor function, and amphetamine 
behavioural sensitization in laboratory animals (Vanderschuren et al., 2000). 
Collectively, these findings imply the role of benzomorphan compounds in producing 
anti-addiction effects.  
 
1.5.3.3. Epoxymorphinans  
The epoxymorphinan analogue, nalfurafine has also been shown to attenuate 
cocaine discriminative stimulus effects in a KOPr specific manner (Mori et al., 2002). 
Furthermore, nalfurafine attenuated rewarding and locomotor effects of cocaine in mice 
(Hesebe et al., 2004). Also, low doses of nalfurafine (10, 20 µg/kg) did not produce 
place preference or aversion (Mori et al., 2002; Hesebe et al., 2004). However, at high 
dose (80 µg/kg) it induces conditioned place aversion in laboratory animals. Thus 
suggesting that place aversion produced by nalfurafine is dose related.   
 
1.5.3.4. Phytochemical KOPr agonists  
Naturally derived KOPr agonists such as iboga alkaloids and neoclerodane 
diterpenes have been tested for their anti-addiction effects using animal models. Pre-
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treatment with ibogaine, an alkaloid derived from plant Tabermanthe iboga (Family: 
Apocynaceae) led to decreased cocaine induced hyperactivity and cocaine self-
administration in laboratory animals (Cappendijk and Dzoljic, 1993; Sershen et al., 
1992). Synthetic derivatives of ibogaine have also been shown to be effective in 
suppressing cocaine produced behaviours (Maissaneuve and Glick, 2003). In addition to 
its cocaine antagonist actions, ibogaine also attenuates DA sensitization to cocaine 
treatment (Szumlnski et al., 2000), thus explaining its anti-addiction effects. 
Taken together, these results suggests that KOPr activation by arylacetamides, 
benzomorphans, epoxymorphinans and phytochemicals such as ibogaine and Sal A 
produce anti-addiction behaviours in laboratory animals. Because of the behavioural 
pharmacology of KOPr agonists, they have been proposed for development as anti-
addiction pharmacotherapeutics (Neumeyer et al., 2000; Mello and Negus, 2000; 
Shippenberg et al., 2001; Prisinzano et al., 2005; Shippenberg et al., 2007). KOPr 
agonists oppose the DA sensitizing effects produced by cocaine and this has been 
suggested as a possible mechanism by which KOPr activation produces anti-addiction 
effects. The following section briefly describes the mechanism of the anti-addiction 
effects produced by KOPr activation.  
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1.5.4. Mechanism of KOPr agonist induced anti-addiction effects  
KOPr agonist pre-treatment has been shown to attenuate extracellular DA levels 
in the reward circuits (Shippenberg et al., 1996). Direct infusion of DYN in the NAc has 
been shown to decrease DA levels in the MDS (Zhang et al., 2004). Additionally,  
intracerebroventricular (icv) or systemic injections of U50488H and U69593 decreases 
DA levels in NAc (Spanagel et al., 1992; Devine et al., 1993; Di Chiara and Imparato, 
1988a; 1988b; Maisonneuve et al., 1994; Shippenberg et al., 1996; Heidbreder et al., 
1996; Thompson et al., 2000). This effect was reversed by nor-BNI pre-treatment 
(Spanagel et al., 1990; 1992). Furthermore, when the VTA was directly pre-treated with 
KOPr agonists a decrease in DA levels in the PFC was seen (Margolis et al., 2003; 
2006). Also, pre-treatment with another arylacetamide analogue R-84760 and the novel 
KOPr agonist Sal A has been shown to dose dependently attenuate DA levels in CPU 
(Zhang et al., 2004; Zhang et al., 2005; Gherke et al., 2008). Systemic treatment with 
Sal A has also been shown to decrease DA levels in the NAc (Carlezon et al., 2006), 
and cocaine produced cFOS expression in the CPU was also reduced (Chartoff et al., 
2008). KOPr activation by U69593 has also been shown to decrease cocaine induced 
dopamine- and adenosine 3′,5′-monophosphate-regulated protein with phosphorylation, 
which seems to play an important role in cocaine produced locomotor sensitization 
(D’Addario et al., 2007). Collectively, these findings show that KOPr activation 
opposes cocaine induced behaviours by decreasing extracellular DA levels in the NAc, 
thus indirectly acting as cocaine antagonists (Shippenberg et al., 2001; Prisinzano et al., 
2005). The adverse effects however, associated with KOPr activation (depression, 
aversion, sedation) have limited their further clinical development. The following 
section describes the behavioural adverse effects associated with KOPr activation and 
the mechanisms that may mediate these behaviours.    
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Tab1.2. KOPr agonists in pre-clinical studies of addiction   
Pharmacological effect KOPr agonists tested Behaviour produced References 
Cocaine self-administration U50488H Attenuate Glick et al., 1995; Kuzmin 
et al., 1997; Negus et al., 
1997 
Spiradoline Attenuate Wadenberg, 2003, Glick et 
al., 1995 
Bremazocine Attenuate Cosgrove and Carrol, 2002;   
Iboga alkaloids Attenuate Coppendijk and Dzoljic, 
1993 
Cocaine motor sensitization U50488H, U69593 Attenuate Heidbreder et al., 1993; 
1995; Collins et al., 2001a; 
2001b; Puig-Ramos et al., 
2008 
Cocaine induced brain 
stimulation reward 
U69593 Attenuate Tomasaiwicz et al., 2008 
Cocaine induced discriminative 
stimulus effects 
U50488H No effect Broadbent et al., 2002 
U50488H, Cl-977 Attenuates at low training dose of 
cocaine (3 mg/kg)  
Kantak et al., 1999; 
Spealman and Bergman; 
1992 
Nalfurafine Attenuate Mori et al., 2002 
Cocaine induced reinstatement 
(self-administering rats) 
U50488H, U69593, 
spiradoline,  
Sal A 
Attenuate Schenk et al., 1999b; 
2000a; Morani et al., 2009 
Cocaine induced enhancement 
in CPP 
U69593, U50488H Attenuate Shippenberg et al., 1996 
 
Cocaine induced hyperactivity 
U69593 Attenuate Collins et al., 2001a, 
2001b; Vanderschuren et 
al., 2000 
U50488H Attenuate Vanderschuren et al., 2000; 
Heidbreder et al., 1995 
Nalfurafine Attenuate Hasabe et al., 2004 
Sal A Attenuate Chartoff et al., 2008 
R-84760 Attenuate Zhang et al., 2004 
Bremazocine Attenuates Vanderschuren et al., 2000 
Effect on midbrain dopamine 
release  
 
 
U50488H,  Decreases in NAc Di Chiara and Imparato, 
1988a,1988b; Maisonneuve 
et al., 1994;  
U69593 Decreases in NAc Shippenberg et al., 1996; 
Thompson et al., 2000 
R-84760 Decreases in CPU Zhang et al., 2004 
Sal A Decrease in NAc and CPU Carlezon et al., 2006; 
Gherke et al., 2008, Zhang 
et al., 2005. 
Ibogaine Decrease DA sensitization Szumlinski et al., 2000 
Amphetamine induced 
behaviours 
U69593 Attenuate Gray et al., 1999 
Morphine self-administration U50488H Attenuate Glick et al., 1995; Kuzmin 
et al., 1997 
Morphine induced rewarding 
behaviours 
Spiradoline 
 
Attenuate 
 
Glick et al., 1995; 
Smith et al.,2003;  2009 
Heroin self-administration U50488H Attenuates Xi et al., 1998 
Nicotine self-administration U69593, U50488H, CI-
977 
 Attenuate Hahn et al., 2000; 
Ismailova and Shoaib, 
2010 
Ethanol self-administration Bremazocine  Attenuate Nestby et al., 1999 
U50488H Attenuate Lorgip et al., 2008 
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1.5.5. Behavioural adverse effects of KOPr agonists 
1.5.5.1. Sedation and psychotomimic effects  
KOPr agonists U50488H, bremazocine, spiradoline and U69593 have been 
shown to decrease spontaneous open field activity in laboratory animals (Von 
Voigtlander et al., 1983; Lahti et al., 1982; 1985; Wadenberg, 2003). Furthermore, 
KOPr activation by Sal A and U69593 induces hallucinations in non-human primates 
(Butelman et al., 2007; 2009; 2010). Clinical studies showed that acute administration 
of enadoline, a selective KOPr agonist produces sedation, emesis, hallucinations, 
dizziness, excessive urination and psychotomimesis in humans (Walsh et al., 2001a). 
Moreover, KOPr activation by the benzomorphan analogue, Mr2033 also produces 
psychotomimetic actions in humans (Pfeiffer et al., 1996). These adverse behaviours 
produced by KOPr agonists have discouraged the development of KOPr agonists as 
potential anti-addiction agents (Wee and Koob, 2010). 
1.5.5.2. Depression and aversion.  
The KOPr agonists have been shown to produce depressive behaviours in 
laboratory animals. Both U69593 and Sal A dose dependently increase immobility time 
in the forced swim test (FST; Mague et al., 2003; Carlezon et al., 2006). Additionally, 
pre-treatment with U50488H, U69593 and Sal A increases the ICSS threshold in rats 
(Todtenkopff et al., 2004; Ebner et al., 2010; Dinieri et al., 2009). These data indicate 
that KOPr activation produces depressive effects in laboratory animals. In addition to its 
depressive effects, KOPr activation also produces aversive behaviours as pre-treatment 
with U50488H, bremazocine, ethylketocyclazocine or U69593 has been shown to 
induce conditioned -place and -taste aversion in laboratory animals (Shippenberg and 
Herz, 1986; Mucha and Herz, 1985).  The following section gives an account of the 
mechanisms underlying KOPr activation mediated depressive and aversive behaviours. 
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1.5.5.3. Nucleus accumbens and KOPr agonists induced depression and aversion.   
Direct or systemic injection of U69593 into the NAc has been shown to induce 
aversive behaviours in laboratory animals, which were reversed by pre-treatment with 
the selective KOPr antagonist, nor-binaltorphimine (nor-BNI; Bals Kubik et al., 1989; 
1993). The aversion induced by KOPr activation is believed to involve DA 
neurotransmission in the NAc, as direct application of the DYN peptide E2078 to the 
NAc reduces release of phasic DA. This effect was reversed by KOPr antagonist pre-
treatment (Spanagel et al., 1990). 
Another reason for the depressive effects produced by KOPr agonists might be 
due to the phosphorylation of CREB in the NAc (Carlezon et al., 1998; Nestler et al., 
2001; Hyman and Malenka, 2001; Carlezon et al., 2005; Dinieri et al., 2009). Recent 
results suggests that enhancement in levels of phosphorylated CREB in NAc is 
associated with increased immobility time in the forced swim test (FST; Plaikas et al., 
2001). KOPr agonists have shown to increase time spent immobile in FST and also 
increase CREB levels in NAc (Mague et al., 2003; Carlezon et al., 2006). On the other 
hand blocking central KOPr’s opposes depressive effects in FST and also reduces 
CREB phosphorylation in the NAc (Mague et al., 2003; Chartoff et al., 2009).  
Collectively, this data strongly suggests that NAc is one of the major sites for 
KOPr activation induced depression (Nestler et al., 2001; Carlezon et al., 2009) and  
alterations in DA neurotransmission and CREB in NAc plays a major role in the 
pathophysiology of KOPr mediated depressive behaviours (Knoll and Carlezon, 2010; 
Carlezon et al., 2009).    
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1.5.5.4. Central 5HT systems and KOPr activation induced depression and aversion.  
KOPr have been located in brain regions such as raphae nucleus, NAc, 
hippocampus which are rich in 5HT neurotransmission (Battaglia et al., 1991; Pinnock, 
1992). Depletion of 5HT by parachlorophenylalanine (a synthetic amino acid which 
depletes serotonin from cell body) attenuated the analgesic effects of U50488H 
(Nemmani and Mogil, 2003). Whereas prior treatment with selective serotonin reuptake 
inhibitor; fluoxetine (SSRI; FLX) potentiated U50488H induced analgesic effects in 
mice (Nemmani et al., 2001). Additionally, 5HT is also believed to play a key role in 
controlling DYN levels. The depletion of 5HT has also been shown to decrease pro-
DYN mRNA expression by approximately 60% in CPU, hippocampus and 
hypothalamus (Di Addario et al., 2007). These findings suggest the importance of 5HT 
systems in KOPr agonist induced behaviours. Moreover, modulation of 5HT systems by 
KOPr agonists have been implicated in cocaine induced behaviours. A recent study by 
Zakharova et al., (2008) suggested that depletion of 5HT from the brain decreased the 
ability of U69593 to attenuate cocaine induced motor stimulation. Additionally, 
selective SERT inhibitors FLX (5.6 mg/kg) and citalopram (10 mg/kg) attenuated 
cocaine induced drug-seeking behaviour in squirrel monkeys (Ruedi-Bettschen et al., 
2010). Moreover, the same study showed that this effect produced by KOPr agonist 
enadoline and FLX was reversed by the pre-treatment with 5HT 2A receptor agonist 8-
OH-DPAT (Ruedi-Bettschen et al., 2010). Thus, KOPr activation may modulate 5HT 
systems which, in turn also modulate cocaine induced behaviours (Ruedi-Bettschen et 
al., 2010). 
The 5HT systems might be implicated in the KOPr agonist’s induced adverse 
effects as KOPr activation has been shown to modulate the 5HT neurotransmission in 
various brain regions. Yilmaz and colleagues, (2006) reported that icv administration of 
U50488H significantly decreased the tissue levels of 5HT and its metabolite, 5-
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hydroxyindole acetic acid in hippocampus and hypothalamus. These effects were 
prevented by nor-BNI pre-treatment. Also, a significant reduction (approx 30%) in 5HT 
concentrations using in vivo microdialysis following local infusions of U50488H (300 
µM) was observed in the dorsal raphae nucleus (Tao and Auerbach, 2005). A, recently 
published report by Land et al., (2009) implicate 5HT projections from the dorsal 
raphae nucleus to NAc in KOPr activation and repeated stress induced aversion. These 
results strongly suggest that central KOPr activation alters 5HT neurotransmission. This 
may account for the KOPr mediated adverse effects and manipulation of 5HT systems 
might help in alleviating these adverse effects.    
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1.5.6. Effect of acute vs. chronic KOPr activation. 
Previous studies have shown that intravenous (iv) infusions (23 hr/day for 10 
consecutive days) of the KOPr agonist bremazocine (0.0032 mg/kg/hr); enadoline 
(0.001, 0.0032 mg/kg/hr); ethylketazocine (0.01, 0.0032 mg/kg/hr); Mr2033 (0.01, 
0.0032 mg/kg/hr) and U50488H (0.1 mg/kg/hr) decreased cocaine self-administration in 
rhesus monkeys (Negus et al., 1997; Mello and Negus, 1998; 2000). This attenuation 
was also accompanied by a significant reduction in food reinforcement, sedation and 
emesis, which subsided after 2-3 days of treatment (Mello and Negus, 2000). Acute 
exposure to these compounds also suppressed food reinforcement in rhesus monkeys 
(Mello and Negus, 2000). The enadoline and Mr2033 induced reduction in cocaine self-
administration reverted to baseline levels of cocaine self-administration during last 
week of treatment, when these compounds were administered for 28 subsequent days 
(Mello and Negus, 2000). This implies that chronic KOPr activation had no effect on 
cocaine’s reinforcing effects in rhesus monkeys. Another study by Negus, (2004), 
however showed that monkeys trained to discriminate between food and cocaine using 
concurrent choice paradigm, when continuously infused with U50488H (0.032 mg/kg/hr, 
iv infusion) showed cocaine preference. The same study also showd that this effect was 
KOPr dependent as nor-BNI pre-treatment reversed it (Negus, 2004). This result 
suggests that continuous KOPr activation might enhance cocaine’s reinforcing 
properties in comparison to natural reward such as food. 
On the other hand, a study by Preston and colleagues (2004) showed that acute 
oral administration of cyclazocine (0.2-0.8 mg) for 4 consecutive days significantly 
decreased the acute subjective effects of cocaine in humans. Moreover, acute 
administration of KOPr agonists attenuated cocaine self-administration and 
reinstatement in rats (Glick et al., 1995; Kuzmin et al., 1997; Schenk et al., 1999; 2000; 
Morani et al., 2009). These findings show differences in acute and chronic KOPr 
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treatment on cocaine induced behaviour and support the short term use of KOPr 
agonists in attenuating the effects of cocaine.  
The effects produced by KOPr agonists on DA levels in the NAc may depend 
upon the frequency of KOPr activation, as acute administration of U69593 inhibits the 
potassium ion evoked DA release from rat striatal synaptosomes which was reversed by 
nor-BNI pre-treatment (Ronken et al., 1993). In contrast, repeated administration of 
U69593 significantly increased potassium ion evoked DA levels in the NAc (Fuentelaba 
et al., 2006) and in cultured mesencephalonic DA neurons (Ronken et al., 1993). 
Moreover, acute administration of U69593 directly into the NAc of mice has been 
shown to attenuate DA release (Chefer et al., 2005). Whereas, repeated administration 
of U69593 decreases DA uptake without affecting extracellular DA levels in the NAc 
(Thompson et al., 2000). These data further strengthen the role of acute KOPr activation 
in producing desired anti-addiction effects at cell and tissue levels.    
Chronic KOPr activation leads to receptor deactivation via KOPr 
phosphorylation and may cause KOPr internalization as decreased KOPr binding was 
observed after chronic treatment with U50488H in vitro (Bhargava et al., 1989). Also, 
chronic KOPr treatment activate protein kinase (p38 mitogen activated protein kinase 
and extracellular signal-regulated kinases 1 and 2; Bruchas et al., 2006; Belcheva et al., 
2005). However, differences in acute and chronic KOPr activation mediated 
phosphorylation of protein kinases have been reported (McLennan et al., 2009; Fig 1.3). 
The KOPr mediated signal transduction mechanism has been extensively reviewed by 
Carr and Mague, (2008); Bruchas and Chavkin, (2010) and is shown in Fig 1.3. Taken 
together, these findings suggest that acute but not chronic KOPr activation might be 
beneficial in producing anti-addiction effects.  
A study by Walsh and colleagues, (2001b) showed that, acute administration of 
selective KOPr agonist enadoline attenuated subjective effects of cocaine without 
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having any effect on cocaine self-administration in humans. Moreover, enadoline 
produced compliance problems and psychotomimesis when tested in healthy subjects 
(Walsh et al., 2001a). Thus, despite having anti-addiction properties, these adverse 
effects have limited the development of KOPr agonists as anti-addiction 
pharmacotherpies. Recently, Sal A, was reported to be a novel, naturally occurring, 
potent and selective KOPr agonist. One of the aims of this thesis was to determine 
behavioural anti-addiction and side effect profile of Sal A. The following section gives a 
detailed account on the behavioural pharmacology of Sal A.    
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1.6. Salvinorin A 
Sal A is the selective KOPr agonist found in the plant Salvia divinorum (family:- 
Lamiaceae; Roth et al., 2002). This plant has been used for spiritual and divination 
purposes by the Mazatecs from Oaxaca, Mexico for centuries (Ott, 1995; Siebert, 1994; 
Valdez et al., 1984; Valdez, 94). Smoking dried Salvia divinorum leaves is associated 
with intense hallucinations of short duration (Valdez, 1994; Siebert, 1994). Sal A has a 
novel neoclerodane diterpene structure and has been shown to bind to the inhibitory Gαi 
protein coupled KOPr (Roth et al., 2002). Sal A is selective in binding and activating 
KOPr expressing in the human embryonic kidney (HEK -293) cells and at native KOPr 
expressed in guinea pig brain (Roth et al., 2002). Furthermore, Sal A has no affinity for 
MOPr or DOPr (Roth et al., 2002; Yan and Roth 2004; Chavkin et al., 2004: 
Vorthermes and Roth 2006). Also, Sal A showed no affinity for DA, serotonin (5HT), 
muscarinic acetylcholine, adrenergic, cannabinoid or sigma receptors, which was 
measured using functional binding assays (Roth et al., 2002). Thus, Sal A is a unique 
hallucinogen without any affinity for 5HT 2A receptors, which are the primary target 
for classic hallucinogens (Roth et al., 2002; Vorthermes and Roth, 2006). Taken 
together, this data suggests that hallucinations produced by Sal A are via KOPr 
activation (Roth et al., 2002; Killinger et al., 2010).  
In vitro binding studies have shown that Sal A binds with greater affinity to 
KOPr than the arylacetamide KOPr agonists U50588H and U69593, and with equal 
affinity to the endogeneous KOPr ligand DYN (Chavkin et al., 2004). The incubation of 
Chinese hamster ovary cells stably expressing human KOPr with Sal A for 4 hr induced 
a receptor down-regulation which was similar to other KOPr agonists tested (Wang et 
al., 2005). However, another study by Wang and colleagues (2008) showed that Sal A 
pre-treatment had no effect, whereas U50488H pre-treatment induced 40 times more 
KOPr internalization in vitro. As Sal A has a different structure compared to 
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arylacetamides (Fig 1.5), these observed differences might, at least be related to the 
structural dissimilarities noted between these two class of KOPr agonists.   
 
1.6.1. Behavioural pharmacology of Sal A 
The behavioural pharmacology of Sal A is summarised in Tab 1.3.  
1.6.1.1. Sedation, hallucinations and motor suppression. 
Sal A has shown to produce hallucinations in humans (Siebert et al., 1994; 
Valdes et al., 1983; Johnson et al., 2010) and induce sedative effects in non-human 
primates (Butelman et al., 2009; 2010). At doses of 1 and 3.2 mg/kg it produces a KOPr 
mediated, nor-BNI reversible decrease in locomotor activity in mice (Zhang et al., 
2005). Furthermore, Sal A decreases climbing behaviour in mice in an inverted screen 
model (Fantagrossi et al., 2005). However, another study indicated that Sal A pre-
treatment (1 mg/kg, 0.25 – 2 mg/kg) had no effect on locomotor activity in rats (Hooker 
et al., 2008; Carlezon et al., 2006). Additionally, 2-methoxy-methyl salvinorin B (MOM 
Sal B), a more potent and longer acting Sal A analogue, produced a rapid, long lasting 
(about 3 hr) immobility in mice which was dose dependent and nor-BNI reversible 
(Wang et al., 2008). However, the same study showed that MOM Sal B increased 
locomotion in the Y-maze test in rats. Thus, indicating an effect which might be species 
specific.  
 
1.6.1.2. Antinociception  
 Sal A has been shown to produce rapid anti-nociception (commencing within 
10 min) with short duration of effects (30 min) in laboratory animals (McCurdy et al., 
2006; John et al., 2006). This effect produced by Sal A was KOPr mediated, as nor-BNI 
pre-treatment completely reversed it (McCurdy et al., 2006; Ansonoff et al., 2006). 
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Furthermore, 2-propionate Sal A and MOM Sal B have been shown to produce anti-
nociception in laboratory animals (Ansonoff et al., 2006; Wang et al., 2008).  
 
1.6.1.3. Drug Discrimination 
In drug discrimination studies, Sal A pre-treatment completely substituted for 
U69593 in rats paired with U69593 and conditioned to obtain food reinforcements 
(Willmore-Fordham et al., 2007). This effect was reversed by nor-BNI pre-treatment 
(Willmore-Fordham et al., 2007). Furthermore, the Sal A induced discriminative 
stimulus effects of U69593 in rats were also observed in non-human primates 
(Butelman et al., 2004). A recent study by Baker and colleagues, (2009) showed that 
the longer acting, more potent, Sal A analogues, 2-ethoxymethyl salvinorin B (EOM 
Sal B) and MOM Sal B also substituted for U69593 at doses lower than Sal A. These 
findings indicates a similar pharmacological effects induced by U69593, Sal A and its 
analogues in activating central KOPr’s.  
 
1.6.1.4. Anti-cocaine effects   
Acute intraperitoneal (ip) administration of Sal A (2 mg/kg) has been shown to 
decrease cocaine induced hyperactivity in rats (Chartoff et al., 2008). This effect was 
dependent on context learning as Sal A, when injected in the activity boxes potentiated 
locomotor activity; whereas, administration of Sal A in the home cages did not 
potentiate motor function induced by the cocaine challenge (Chartoff et al., 2008). 
Furthermore, acute administration of Sal A, dose dependently (0.3, 1.0 mg/kg) 
attenuated cocaine prime induced reinstatement of cocaine seeking without suppressing 
sucrose reinforcements or causing sedation in rats (Morani et al., 2009). These findings 
indicate that anti-cocaine behaviours are produced by Sal A, just like traditional KOPr 
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agonists in laboratory animals. More work is necessary to characterize the therapeutic 
anti-addiction potential of Sal A-like compounds. 
 
1.6.1.5. Depression and Aversion 
Recent studies have shown that Sal A (2 mg/kg) dose dependently increases 
ICSS thresholds, decreases swimming time and increases immobility time in the FST 
paradigm in rats (0.25- 2 mg/kg; Carlezon et al., 2006). Furthermore, Sal A (2 mg/kg) 
has been shown to suppress sucrose reinforcement in laboratory animals (Ebner et al., 
2010). Sal A (1.0, 3.2 mg/kg) pre-treatment has also been shown to induce conditioned 
place aversion in mice (Zhang et al., 2005). Additionally, the N-methylacetamide 
derivative of Sal A has also shown to produce long lasting increases in ICSS thresholds 
in rats (Beguin et al., 2008). However, in zebrafish, Sal A at high doses (80 µg/kg) 
induces place aversion, whereas at lower doses (1 µg/kg) induces place preference 
(Braida et al., 2007). Recent reports by Braida et al., (2009) suggests that Sal A pre-
treatment produces anti-depressant and anxiolytic effects using FST, tail suspension and 
elevated plus maze tests in laboratory animals. Also, lower dose of Sal A (0.25, 0.3 
mg/kg) did not suppress sucrose reinforcements in rats (Ebnar et al., 2010; Morani et al., 
2010). Thus the aversive effects induced by Sal A are likely to be dose related.     
 
1.6.1.6. Toxicity studies 
Pre-clinical toxicological studies with Sal A show that Sal A does not produce 
any toxicity in mice, even at high dose (1000 mg/kg) (Mowry et al., 2003). These 
findings also show that chronic treatment (once every 14 days) of Sal A (dose range 0.4 
– 6.4 mg/kg) did not significantly alter the histology of  liver, spleen, kidney, brain and 
bone marrow, or change cardiac function, heart rate or pulse pressure in laboratory 
animals (Mowry et al., 2003). Recent studies have also shown that Sal A administration 
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in healthy volunteers did not produce any cardiovascular adverse effects, however, 
hallucinations were observed (Johnson et al., 2010; Siebert, 1994). Also, some 
incidences of Sal A induced psychosis have been reported clinically (Singh, 2007; 
Przekop and Lee, 2009; Paulzen and Grunder, 2008). Therefore, further detailed studies 
are warranted to establish the psychological safety profile for Sal A at pharmacological 
doses.  
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Tab.1.3. Salvinorin A: Pre-clinical studies 
Pharmacological effect Reference 
Anti-nociception John et al., 2006; McCurdy et al., 2006; 
Ansenoff et al., 2006. 
Hallucination Butelman et al., 2007; 2009; 2010. 
Sedation Zhang et al., 2005; Fantagrossi et al., 2005; 
Butelman et al., 2009; 2010. 
Discriminative stimulus Willmore-Fordham et al., 2007; Butelman et al., 
2004; Baker et al., 2009. 
Depression Carlezon et al., 2006; Ebnar et al., 2010. 
Conditioned place aversion Zhang et al., 2005. 
Anti-depression/ Anti-
anxiety 
Braida et al., 2009; Braida et al., 2008. 
Attenuate cocaine induced 
behaviours 
Chartoff et al., 2008; Morani et al., 2009. 
Decreased dopamine levels 
in MDS 
Carlezon et al., 2006; Gherke et al., 2008, 
Zhang et al., 2005. 
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1.6.2. C-2 derived Sal A analogues 
Sal A has a quick onset of action which is attributed to its rapid crossing of the 
blood brain barrier (approximately 1 min; Butelman et al., 2007; Schmidt et al., 2005; 
Hooker et al., 2008). Furthermore, Sal A has an elimination half life of 56.6 ± 24.8 min 
in non-human primates (Schmidt et al., 2005). Sal A gets hydrolysed at C-2 position 
via enzyme esterases to Sal B, which is pharmacologically inactive (Chavkin et al., 
2004 Ansenoff et al., 2006; Wang et al., 2008; Fig 1.6). The position C-2 is considered 
as an important site for the binding and activation of KOPr by Sal A (Bikbulatov et al., 
2007; Yan and Roth, 2004). Additionally, this position is also implicated in improving 
the pharmacokinetic profile of Sal A (Prisinzano and Rothman, 2008; Munro et al., 
2008). Substitution of methoxymethyl and ethoxymethyl groups at C-2 position yields 
compounds with increased duration of effect and greater affinity for KOPr as compared 
to Sal A (MOM Sal B, EOM Sal B; Munro et al., 2005; Beguin et al., 2008; Fig 1.6). 
Additionally, aromatic substitution at the C-2 position produces compounds with a 
greater affinity for MOPr than KOPr (Herkinorin; Harding et al., 2005; Tidgewell et al., 
2006; Fig 1.6). The substitution of a mesylate group at this position yielded a 
compound which had a similar affinity but slightly higher potency for KOPr as 
compared to Sal A (DS1; Harding et al., 2005, Fig 1.6). One of the aims of this study 
was to determine behavioural anti-addiction and side-effect profiles of novel Sal A 
analogues. The following section describes the pharmacological profile of Sal A and 
selected analogues..    
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-R Compound Binding 
affinity 
at KOPr 
Ki (nM) 
Binding 
affinity at 
MOPr Ki 
(nM) 
Potency 
 at KOPr 
EC50 
(nM)  
 
Potency 
at 
MOPr 
(nM)  
 
Reference 
-CO-
CH3 
Salvinorin A 1.9 ± 0.2a >10000 1.8 ± 0.5c 
40 ± 10d 
 Harding et al., 
2005; 
Tidgewell et 
al., 2008; 
Munro et al., 
2008 
-H Salvinorin B >10000 >10000 -  Chavkin et al., 
2004 
-CH2-
O-CH3 
2-methoxymethyl 
Salvinorin B 
0.6 ± 
0.07b 
ND 0.40 ± 0.04c  Munro et al., 
2008 
-CH2-
O-
C2H5 
2-ethoxymethyl 
Salvinorin B 
0.32 ± 
0.02b 
ND 0.14 ± 0.01c  Munro et al., 
2008 
-SO2-
CH3 
DS-1 2.3 ± 0.1 a 6820 ± 660a 30 ± 5d  Harding et al., 
2005 
-CO-
C6H5 
Herkinorin 90 ± 2 a 12.1 ± 1a 1320±150d  Harding et al., 
2005; 
Tidgewell et 
al., 2008 
 Nalmefene 0.083 ± 
0.0008 b  
 
0.24±0.006b  
 
EC50 = 
4.2±1.6c 
IC50 = 
18±1.0c   
 
IC50 = 
13±2.3c  
 
Bart et al., 
2005 
  
Fig.1.6. Salvinorin A, its structural analogues and nalmefene 
 (Adapted from Prisinzano and Rothman, 2008) Binding affinity of Sal A, C-2 derived 
analogues of Sal A and nalmefene for KOPr and MOPr.aData expressed as ± SD; bData 
expressed as ± SEM; ND= not defined.cEnhancement of [35S]GTPcS binding to CHO-hKOPr; 
EC50 ± SEM  (nM). d[35S]GTP-γS functional assay carried out in stably transfected CHO cells 
containing DNA for hKOPr;EC50 ± SD nM. ND= not defined. 
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1.7. Mixed opioid compounds as anti-cocaine agents.  
MOPr and KOPr activation have been shown to produce opposite reward related 
behaviours (Pan, 1998; Smith et al., 2003; Glick et al., 1995). MOPr activation produces 
self-administration (Bozarth and Wise, 1981; Devine and Wise, 1994), decreases ICSS 
thresholds (Esposito and Kornetsky, 1977), enhances motor function (Oka and Hosoya, 
1976), produces sensitization (Smith et al., 2003) and cross sensitization to the 
rewarding effects of cocaine (Kim et al., 2004; Smith et al., 2009). Thus, activation of 
MOPr produces reward related behaviours with the potential to cause addiction (Wang 
et al., 2004). Moreover, MOPr agonists have shown to produce place and taste 
preference in laboratory animals (Mucha and Herz, 1985; 1986). Activation of MOPr 
increases DA levels in the mesolimbic brain regions when measured using microdialysis 
techniques (Di Chiara and Imperato, 1988a; 1988b: Spanagel et al., 1992; Devine et al., 
1993). On the other hand, KOPr activation produces opposite reward related effects 
(Mucha and Herz, 1985; Shippenberg and Herz, 1986; Di Chiara and Imperato, 1988a; 
Spanagel et al., 1992). Rats produced aversive behaviour when either MOPr was 
inhibited or KOPr was activated in the dorsal periaquiductal grey region (Nobre et al., 
2000; Sante et al., 2000). Moreover, morphine induced place preference was blocked by 
KOPr agonists (Funada et al., 1993; Liang et al., 2006). Additionally, KOPr activation 
attenuated morphine self-administration in rats (Glick et al., 1995; Kuzmin et al., 1997). 
Taken together, these findings suggest the opposing role of KOPr and MOPr activation 
in reward related behaviours.  
Nalmefene (REVEX; Ohmeda Pharmaceutical Products, Liberty Corner, NJ) is a 
longer acting structural analogue of the non-selective opioid receptor antagonist 
naloxone and naltrexone (June et al., 1999; Barson et al., 1989). It has a slow onset of 
action and has prolonged effects on morphine induced behaviours such as 
antinociception, locomotion and withdrawal effects in mice (Osborn et al., 2010). 
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Clinical studies with nalmefene indicate that it is effective in reducing symptoms of 
pathological gambling (Grant et al., 2006; 2010), attenuate ethanol self-administration 
in laboratory animals (June et al., 1998; 2002; 2004) and humans (Mason et al., 1999; 
Karhuvara et al., 2007). Because of these reasons, it has been proposed for clinical use 
in ethanol abuse (Jupp and Lawrence 2010; Soyka and Rosner, 2010). Moreover, 
nalmefene is used clinically in opioid overdose (Wang et al., 1998; Barson et al., 1989). 
Recent opioid receptor affinity and selectivity studies show that nalmefene has a greater 
affinity for KOPr and MOPr than delta opioid receptors (Bart et al., 2005). The same 
study showed that nalmefene is a MOPr antagonist and partial KOPr agonist (Bart et al., 
2005).  
The reported anti-addiction properties of nalmefene (Kreek et al., 2002; 2005;  
Bart et al., 2005) on cocaine are required to be evaluated before any conclusions can be 
made on its therapeutic potential. Therefore, one of the aims of this thesis was to study 
the anti-cocaine effects and behavioural adverse effect profile of nalmefene in rats.   
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1.8. Aims 
KOPr agonists have been implicated in anti-addiction behaviours but have not 
been developed clinically because of the adverse effects associated with them (Walsh et 
al., 2001a; Mello and Negus, 2000). The emergence of Sal A as a novel KOPr ligand 
has opened a new avenue in kappa opioid research. Sal A is structurally dissimilar to the 
traditional KOPr agonists, yet it produces similar pharmacology at KOPr. Therefore, if 
Sal A produces anti-addiction behaviour like traditional KOPr agonists with fewer  
adverse effects, then Sal A (and its structural derivatives) could open a novel class of 
KOPr agonists with potential anti-addiction effects (Prisinzano and Rothman, 2008; 
Munro et al., 2008; Beguin et al., 2008; Wee and Koob, 2010; Prisinzano, 2008; 
Prevatt-Smith and Prisinzano, 2010).  
With this as the central hypothesis of this thesis, Sal A, its novel analogues 
(MOM Sal B, EOM Sal B, herkinorin, DS1) and MOPr antagonist/ partial KOPr agonist 
nalmefene were pharmacologically screened for their anti-addiction effects using the 
cocaine prime induced reinstatement model. Furthermore, the anti-cocaine profile of 
those KOPr compounds were determined which attenuated drug-seeking in a selective 
manner without producing motor suppression by themselves. This was performed by 
using cocaine induced enhancement and sensitization to motor function in rats.  
The next aim of this thesis was to test for the selectivity of the attenuation of 
cocaine induced reinstatement. This was done by measuring sucrose reinforcement 
(attenuation in operant reinforcement) and cocaine induced hyperactivity in self-
administering animals (motor suppression during reinstatement test). Another aim of 
this thesis was to evaluate the behavioural adverse effects of the KOPr agonists which 
were successful at attenuating cocaine reinstatement. This was achieved by using 
spontaneous open field activity (motor suppression), conditioned taste aversion 
(aversion) and forced swim test (depression) in rats.  
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The last part of this thesis applies behavioural and in vitro models to better 
understand the mechanism of KOPr mediated depression. This was achieved by 
investigating the effects of serotonin transporter (SERT) blockade on KOPr agonists 
induced depression and effect of KOPr activation on in vitro SERT function.   
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Chapter 2. Anti-addiction profile of KOPr agonists. 
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2.1. Introduction 
2.1.1. Cocaine prime induced reinstatement model 
The phenomenon of reinstatement of drug seeking in animals has been shown to 
mimic human conditions (Sinha et al., 1999; Littleton, 2000; Shalev et al., 2002; 
Shaham et al., 2003). Presentation of stimuli such as drug primes, environmental cues 
and stressors have all been shown to initiate drug-seeking in both animals and humans 
(Ludwig et al., 1974; De Wit and Stewart, 1981; 1983; Jaffe et al., 1989; Koob et al., 
1996; McFarland and Ettenberg, 1997; Erb et al., 1996; Sinha et al., 1999; 2001; Weiss 
et al., 2001). Due to these reasons, pre-clinical models have been extensively used to 
study the neurobiology of drug addiction (Markau et al., 1993; Koob and La Moal, 2001, 
2005; Koob, 2006; Olmstead, 2006). The reinstatement of cocaine self-administration 
model mimics the potential to relapse back to drug use following a period of extinction 
in laboratory animals (Stewart, 2000; Epstein et al., 2006; Shalev et al., 2002; Fuchs et 
al., 1998; Shaham et al., 2003). Therefore, this paradigm has been used extensively for 
the pharmacological evaluation of potential anti-addiction compounds (Schenk et al., 
1999a; 1999b; Beardsley et al., 2005; 2010).  
Reinstatement of drug-seeking via self-administration training has been 
performed pre-clinically using between session (Stretch et al., 1971), within session (de 
Wit and Stewart, 1981; 1983) and between-within session models (Tran-Nguyen et al., 
1998). In between session reinstatement, animals undergo self-administration, 
extinction training sessions and reinstatement test on separate days (Stretch et al., 1971; 
Stewart, 2000). The within session reinstatement model animals self-administer cocaine 
for 1-2 hr followed by the extinction training (for 3-4 hr) and then testing for 
reinstatement with all the procedures performed in a single day (de Wit and Stewart, 
1981; 1984). In between-within reinstatement test, animals are trained to self-administer 
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cocaine on different days, whereas extinction and reinstatement tests are performed on 
the same day (Tran-Nguyen et al., 1998; Shaham et al., 2003). 
In the current study, the within session reinstatement paradigm was used 
(Worley et al., 1994; Schenk et al., 1999b; 2000a). This paradigm mimics the potential 
of priming injection of cocaine to reinstate cocaine self-administration in rats which 
were previously self-administering cocaine and were subjected to short period of 
extinction training (Stewart, 2000; Epstein et al., 2006). An advantage of this model is 
that it can be used to screen the effects of acute pharmacological exposure on cocaine 
seeking behaviour (Schenk et al., 1999b; 2000a; 2001b; Schenk, 2000; Schenk and 
Partridge, 2001; Morani et al., 2009). Furthermore, traditional KOPr agonists, U69593, 
U50488H and spiradoline have all been shown to attenuate reinstatement of drug-
seeking using this paradigm (Schenk et al. 1999b, 2000a; Morani et al., 2009). 
Therefore, in order to characterize the effects of KOPr compounds on cocaine seeking 
behaviour, we performed an initial preliminary screening using the within session 
reinstatement paradigm in rats.       
2.1.2. Cocaine induced enhancement in motor activity 
Experimenter administered cocaine has been shown to produce increases in 
motor function in laboratory animals (Post and Contel, 1983; Kalivas and Stewart, 
1991). A robust enhancement in motor function is also observed in animals with prior 
cocaine experience in which an acute challenge of injected cocaine reveals motor 
sensitization (Post and Contel, 1983; Pierce and Kalivas, 1997; Vanderschuren and 
Kalivas, 2000). This sensitized response persists even after a period of prolonged 
abstinence (Robinson and Berridge, 1993; 2001; 2003), thus indicating the long lasting 
alterations in central neuronal circuits following intermittent cocaine exposures 
(Robinson and Berridge, 1993; 2000; 2003; 2008; Pierce and Kalivas, 1997). 
Expression and development of behavioral sensitization is a paradigm that highlights 
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cocaine’s ability to alter neural circuits underlying its psychomotor effects (Robinson 
and Berridge, 1993; 2001; 2003; 2008; Kalivas et al., 1998; O’Brian et al., 1992; 
Todtenkopff et al., 2002; Lambert et al., 2006). Therefore, increasing our understanding 
of the factors which attenuate the expression and development of cocaine induced 
behavioural sensitization could prove useful in designing therapeutics for cocaine 
addiction (Pierce and Kalivas, 1997; Robinson and Berridge, 2003). Recently, Chartoff 
and colleagues (2008) showed that acute exposure to Sal A attenuates hyperactivity to a 
single injection of cocaine in a similar way to traditional KOPr agonists. In order to 
extend the findings of Chartoff et al. (2008), this study characterizes the anti-cocaine 
profile of Sal A and another novel KOPr agonist (DS1) on cocaine induced 
hyperactivity and expression of behavioural sensitization in rats. As forward locomotion 
during sensitization experiments does not augment with cocaine produced stereotypy 
(Ushijima et al., 1995; Post et al., 1987), we further analysed the effect of Sal A and 
DS1 on cocaine produced stereotypic counts in sensitized rats.    
2.1.3. Aims 
The novel non-nitrogenous structure of Sal A has led to the synthesis of many 
KOPr agonists with unknown pharmacology (Prisinzano and Rothman, 2008; Munro et 
al., 2008; Section 1.6; Chapter 1). This chapter aims to determine if these novel 
compounds have anti-addiction pharmacology. To do this we will: 
1. Screen the effect of novel KOPr compounds Sal A, DS1, MOM Sal B, EOM 
Sal B, herkinorin and MOPr antagonist/partial KOPr agonist, nalmefene on cocaine 
prime induced drug-seeking in rats. 
2.  Determine if the effects seen are in fact KOPr mediated. This will be 
performed by measuring the behavioural effect of pre-treatment with selective KOPr 
antagonist (nor-BNI; Portoghese et al., 1987) on KOPr agonist mediated attenuation in 
drug-seeking.   
61 | P a g e  
 
3. Compounds shown to attenuate drug-seeking in a specific manner without 
suppressing motor function by themselves (Chapter 3) will be further characterized 
behaviourally to determine their effects on cocaine induced enhancement in motor 
function (Heidbreder et al., 1993; Collins et al., 2001a; 2001b). This will be determined 
experimentally by measuring changes in cocaine induced hyperactivity, expression of 
behavioural sensitization and cocaine produced stereotypy in rats.  
 
2.2. Methods 
2.2.1. Subjects  
Male Sprague-Dawley rats weighing 325-350 g (for reinstatement test; one per 
cage) and 200-250 g (for cocaine induced hyperactivity and behavioural sensitization 
tests; two per cage) were housed in a temperature (19-21°C) and humidity (55% relative 
humidity) controlled room at the animal facility in the School of Psychology, Victoria 
University of Wellington. Lights were maintained on a 12:12 hr cycle with lights on at 
0700. Animals had free access to food and water except during experimental sessions. 
All rats were housed in the animal facility five days prior the commencement of 
experiments and were handled daily to reduce handling stress. All experimental 
procedures were reviewed and approved by the Animal Ethics Committee of Victoria 
University of Wellington.  
 
2.2.2 Drugs 
Cocaine HCl (Merck Pharmaceuticals, Palmerston North, New Zealand), nor-
BNI and nalmefene (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in 
physiological saline. Sal A, MOM Sal B, EOM Sal B, DS1 and herkinorin (gifts from 
Dr. Thomas E. Prisinzano, University of Kansas) were suspended in 75% DMSO. 
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Subcutaneous (sc) or intraperitoneal (ip) injections were in a volume of 1 ml/kg. IV 
infusions were given in the volume of 100 µl. All drug weights refer to the salt. 
 
2.2.3. Cocaine prime induced reinstatement test  
2.2.3.1. Surgery   
The surgery was performed by Mr. Caleb Carati, Mr. Alex Howard and Mr. 
Alex Crowther. Under deep anaesthesia produced by ketamine/xylazine (90/9 mg/kg, ip; 
Provet, Palmerston North, New Zealand), the right jugular vein was isolated and the 
catheter was inserted. The distal end (22 gauge stainless steel tubing) was passed sc to 
an exposed portion of the skull where it was fixed to embedded jeweller’s screws with 
dental acrylic. The catheters were infused daily with 0.1 mL of a sterile saline solution 
containing heparin (30.0 U/mL; Provet, Palmerston North), penicillin G Potassium 
(250,000 U/mL; Provet, Palmerston North) and streptokinase (8000 U/mL; Health Care 
Logistics, Auckland) to prevent infection and the formation of clots and fibroids. The 
rats were allowed five days post surgery to recover.  
2.2.3.2. Apparatus 
Self-administration training and reinstatement testing were carried out in 
humidity (55%) and temperature (19-21°C) controlled environment in standard operant 
chambers (Med Associates, ENV-001) equipped with 2 levers. Depression of one lever 
(the active lever) resulted in a 0.l mL iv infusion of cocaine HCl dissolved in sterile 
physiological saline containing heparin (3.0 U/mL). Infusions were of 12 sec duration. 
Coincident with drug delivery was the illumination of a stimulus light located directly 
above the active lever. This stimulus light remained illuminated throughout each 12 sec 
infusion. Depression of the other lever (the inactive lever) was without programmed 
consequence. 
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Rats were maintained in the animal colony except during testing. Immediately 
prior to each daily self-administration session, the catheter lines were infused with 0.1 
mL of heparin-penicillin-streptokinase solution. The stainless steel catheter was 
connected to a length of microbore tubing and connected to the syringe. At the end of 
each session, the lines were again infused with 0.1 mL of the heparin-penicillin-
streptokinase solution, the stainless steel tubing was plugged and the animal was 
returned to its home cage. Drug delivery and data acquisition were controlled using Med 
Associates software (St. Albans, VA, USA). Cocaine deliveries were made via 
mechanical pumps (Razel, Model A with 1.0 rpm motor equipped with 20 mL syringe).  
2.2.3.3. Cocaine self-administration training 
The cocaine self-administration protocols we followed have been described by 
Worley et al, (1994), Schenk et al, (1999b) and Morani et al., (2009). Rats were initially 
trained to self-administer cocaine using a FR-1 schedule of reinforcement (pressing the 
active lever once delivered a single infusion of cocaine, 0.5 mg/kg/infusion) for 2 hr. 
The self-administration training was performed in the dark using light proof boxes. 
Once stable responding was achieved (at least 20 infusions per 2 hr session for 3 
consecutive days), they were upgraded to FR-5 schedule of reinforcement, where in 
pressing the active lever five times resulted in a single infusion of cocaine (0.5 
mg/kg/infusion). Self-administration was considered to be acquired when there was less 
than 20% variation in responding for three consecutive days.  
2.2.3.4. Cocaine prime induced reinstatement test. 
Once responding on the FR-5 schedule was stable, the effect of KOPr agonist 
(Sal A, MOM Sal B, EOM Sal B, DS1, herkinorin and nalmefene) administration on 
drug-seeking produced by a priming injection of cocaine was measured. This test was 
conducted in a single day and consisted of three phases. The first phase comprised a one 
hr period of cocaine self-administration (0.5 mg/kg/infusion, FR-5 schedule of 
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reinforcement) in which the light stimulus was paired with cocaine infusions. After the 
one hr self-administration period, the cocaine solution was replaced with heparinised 
saline and responding was reinforced with the vehicle infusion (FR-5 schedule of 
reinforcement) coupled with illumination of the light stimulus. Saline reinforced 
responding was measured during the second phase which was of 3 hr duration. By the 
end of the 3rd hr, animals which showed less than 20% of responding as compared to 
phase 1 were subjected to the reinstatement test. At the beginning of this third phase, 
separate groups of rats (n=5-10) received an injection of either vehicle (0.9% saline or 
75% DMSO) or KOPr agonists Sal A (0.1, 0.3 and 1.0 mg/kg, ip); MOM Sal B (0.03, 
0.1 and 0.3 mg/kg, ip); EOM Sal B (0.03, 0.1 and 0.3 mg/kg, ip); DS1 (0.1, 0.3 and 1.0 
mg/kg, ip); herkinorin (0.1, 0.3 and 1.0 mg/kg, ip) or nalmefene (0.1, 0.3 and 1.0 mg/kg, 
sc). These injections were administered either 5 (Sal A, MOM Sal B, EOM Sal B, 
herkinorin), 15 (nalmefene) or 45 (DS1) min prior to an injection of cocaine (20 mg/kg, 
ip). This was followed by measuring saline reinforced responding at FR-5 schedule of 
reinforcement with an infusion of vehicle solution (heparinised saline) and illumination 
of the light stimulus. Responding was measured for 1 hr following the cocaine injection. 
Operant lever press responding observed during the three phases of the reinstatement 
test is shown in Fig 2.1.  
The vehicle used to suspend Sal A and its derivatives was selected based on 
previous studies showing that 75% DMSO was well tolerated by rats (Willmore-
Fordham et al., 2007; Baker et al., 2009; Chartoff et al., 2008; Morani et al., 2009).  Sal 
A, MOM Sal B and EOM Sal B have a quick onset of action via the ip route of 
administration (Hooker et al., 2009a; Baker et al., 2009; Wang et al., 2008). Also, 
previous studies with herkinorin suggest a quick onset of action in vivo (Butelman et al., 
2008). Therefore, the pre-treatment time was chosen as 5 min for Sal A, MOM Sal B, 
EOM Sal B and herkinorin. The route of administration (sc) and pre-treatment time (15 
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min) for nalmefene was selected based on previously published reports (June et al., 
1998).   
2.2.3.5. KOPr antagonist reversal experiment 
The effect of 30 min pre-treatment with selective KOPr antagonist, nor-BNI (2 
mg/kg, ip) on attenuation of cocaine prime induced drug-seeking by the KOPr agonists 
was also performed. This experiment was performed in order to verify that attenuation 
of reinstatement behaviour by the novel KOPr compounds was mediated via KOPr 
activation. Also, this experiment was performed on KOPr compounds using a minimum 
effective dose (0.3 mg/kg) at which they attenuated drug-seeking behaviour in a specific 
manner (Sal A, DS1, nalmefene; Chapter 3). The experimental conditions were similar 
to the reinstatement test, except that rats (n = 5-10 for each group) received an injection 
of nor-BNI (0, 2 mg/kg, ip) 30 min prior to the exposure to Sal A (0.3 mg/kg, ip), DS1 
(0.3 mg/kg, ip) or nalmefene (0.3 mg/kg, sc). Saline-reinforced responding was 
recorded following the priming injection of cocaine (20 mg/kg, ip). The dose (2 mg/kg), 
route of administration (ip) and pre-treatment time (30 min) for nor-BNI was also 
selected based on previous reports (Xu et al., 2006). 
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Fig 2.1. Cocaine prime induced reinstatement test.  
 Animals previously self-administering cocaine stably at a FR-5 schedule of reinforcement were 
subjected to the reinstatement test. During the first phase, rats were allowed to self administer 
cocaine (0.5 mg/ml/infusion) for 1 hr. Corresponding active lever presses were observed to be 
high. During the second phase, cocaine was replaced by saline in the infusion pump. This 
resulted in extinguished lever press responding by the end of the 3rd hr. Prior to the beginning 
of the third phase, animals received either KOPr agonist or corresponding vehicle and a single 
priming injection of cocaine (20 mg/kg, ip) and saline reinforced active lever responding was 
measured for 1 hr. In the above figure, the high rate of responding during the third phase is due 
to the priming injection of cocaine (20 mg/kg) as the infusion pump contained only heparinised 
saline. Therefore, this reinstatement is called cocaine prime induced reinstatement of cocaine 
seeking following a short period of extinction (n=8).  
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2.2.4. Cocaine induced hyperactivity and behavioural sensitization 
Cocaine induced hyperactivity and behavioural sensitization tests were 
performed to further explore the anti-cocaine effects of novel KOPr agonists which 
showed attenuation of drug-seeking behaviour in a specific manner without suppressing 
motor function (Chapter 3).   
2.2.4.1. Apparatus 
Eight open field chambers (Med Associates, ENV-520) equipped with two 
banks of sixteen photocells on each wall were used to measure horizontal and vertical 
locomotion. The open field boxes were interfaced with an adjacent microcomputer. 
Stereotypic counts during the sensitization experiments were determined by measuring 
repetitive beam breaks obtained from the activity monitoring software (Med 
Associates). Testing was conducted in the dark between 1000 and 1600 hr.  White noise 
was continually present to mask extraneous disturbances. The floor and the sides of the 
test chamber were cleaned before and after testing each animal using Virkon “S” 
disinfectant (Southern Veterinary Supplies, Palmerston North, New Zealand).  
 
2.2.4.2. Procedure 
A. Cocaine induced hyperactivity in drug naive rats. 
For this study we modified the methods of Frankowska et al., (2009) and Xu et 
al., (2010). On the test day, drug naive rats received an injection of either vehicle (75% 
DMSO) or KOPr compound (Sal A, 0.3 mg/kg; DS1, 0.3 mg/kg). Five minutes later (or 
45 min following DS1 injection) this was followed by an injection of either 0.9% saline 
(1 mL/kg) or cocaine (20 mg/kg, ip). Immediately following the second injection, total 
activity, a compilation of horizontal and vertical activity was measured every 5 min for 
60 min. 
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B. Expression of cocaine sensitization and stereotypy. 
  For this study we modified the methods described by Frankowska et al., (2009) 
and Xu et al., (2010). Rats received a single injection of either 0.9% saline (1 mL/kg) or 
cocaine (20 mg/kg, ip) for 5 consecutive days (day 1-5) in their home cages. On days 6-
9 the animals remained drug-free in their home cages. On the test day (day 10), animals 
first received KOPr compounds (Sal A, DS1) or vehicle (75% DMSO) followed by a 
single injection of cocaine (20 mg/kg, ip). Locomotor activity (total ambulatory counts) 
and cocaine produced stereotypy was measured at 5 min intervals for 60 min.  
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Tab 2.1  Experimental groups for cocaine induced hyperactivity.  
Acute Pre-treatment (ip) Challenge injection (ip) 
Vehicle  Saline (1 mL/kg) 
Sal A Saline (1 mL/kg) 
DS1 Saline (1 mL/kg) 
Vehicle Cocaine (20 mg/kg) 
Sal A Cocaine (20 mg/kg) 
DS1 Cocaine (20 mg/kg) 
 Vehicle (75% DMSO; 1 mL/kg); Sal A (0.3 mg/kg), DS1 (0.3 mg/kg) 
Tab 2.2 Experimental groups for cocaine behavioural sensitization.  
Pre-treatment  
(day 1-5; ip) 
Acute treatment  
(day 10; ip) 
Challenge injection 
 (day 10; ip) 
Saline (1 mL/kg) Vehicle  Cocaine (20 mg/kg) 
Saline (1 mL/kg) Sal A Cocaine (20 mg/kg) 
Saline (1 mL/kg) DS1 Cocaine (20 mg/kg) 
Cocaine (20 mg/kg) Vehicle Cocaine (20 mg/kg) 
Cocaine (20 mg/kg) Sal A Cocaine (20 mg/kg) 
Cocaine (20 mg/kg) DS1 Cocaine (20 mg/kg) 
Vehicle (75% DMSO; 1 mL/kg); Sal A (0.3 mg/kg), DS1 (0.3 mg/kg) 
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2.2.5. Statistical analysis  
 Data analyses were performed by using Prism Graphpad software (Version 5.0, 
San Diego, CA). Statistical analysis for cocaine induced locomotion and cocaine 
sensitization studies (for total ambulatory counts) were performed using one-way 
ANOVA followed by Tukey post-hoc tests. Further statistical analysis was performed 
using two-way ANOVA (treatment x time) with repeated measures on time for cocaine 
induced hyperactivity, expression of sensitization and cocaine induced stereotypic 
counts. A Bonferroni post hoc test was also performed. The number of active lever 
responses during phase 3 of the reinstatement phase is shown as mean +SEM. For 
cocaine induced reinstatement tests separate one-way ANOVA was performed followed 
by Tukey post-hoc test (Morani et al., 2009). Student t-tests were performed on the data 
from nor-BNI reversal experiments.  
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2.3. Results 
2.3.1. Effect of Sal A on cocaine prime induced reinstatement. 
The effect of Sal A (0, 0.1, 0.3, 1.0 mg/kg, ip) pre-treatment on cocaine prime 
(20 mg/kg, ip) induced reinstatement in rats is shown in Fig 2.2. Statistical analysis 
showed that pre-treatment with Sal A (0.3, 1.0 mg/kg) significantly attenuated cocaine 
prime induced reinstatement [F (3,23) = 79.33, p<0.0001; Fig 2.2a] in a dose dependent 
manner. This attenuation was not seen in animals pre-treated with the KOPr antagonist 
nor-BNI (0, 2.0 mg/kg, ip) (p<0.001; Fig. 2.2b).  
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Fig. 2.2 Effect of Sal A on cocaine prime induced reinstatement  
Symbols indicate active lever press responses +SEM produced during phase 3 of the 
reinstatement test. (a) Rats which had shown extinguished saline reinforcement during the 
extinction phase were initially treated with different doses of Sal A (0, 0.1, 0.3 and 1.0 mg/kg) 
followed by a priming injection of cocaine (20 mg/kg) and saline reinforced responses were 
recorded for a period of 60 min. ***p<0.001, data were compared with vehicle treated group 
(0 mg/kg). One-way ANOVA followed by Tukey post hoc test. n=6-7 for each group (b) For nor-
BNI reversal experiments, animals were first treated with nor-BNI (0, 2.0 mg/kg) followed by 
Sal A (0.3 mg/kg) and cocaine (20 mg/kg) injections.***p<0.001, Student t-tests. n=5-7 for 
each group.  
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2.3.2. Effect of Sal A on cocaine induced hyperactivity (drug naïve animals) 
The effect of Sal A (0, 0.3 mg/kg, ip) pre-treatment on cocaine (0, 20 mg/kg, ip) 
induced hyperactivity in rats is shown in Fig 2.3. A significant increase in the 
locomotion activity was observed in animals pre-treated with vehicle/cocaine as 
compared to those which were treated with vehicle/saline (p<0.01) demonstrating 
cocaine induced hyperactivity in rats [F (3, 22) = 22.2, P < 0.0001; Fig. 2.3a]. Post hoc 
analysis indicated no significant difference between Sal A and vehicle pre-treatment on 
the locomotor activity produced following the saline (P > 0.05) or cocaine (P > 0.05) 
injection (Fig 2.3). A non-significant trend towards an increase in total activity was 
observed in Sal A/cocaine treated rats as compared to vehicle/cocaine treated rats (P > 
0.05). Further time course comparison revealed a significant treatment [F (3, 364) = 
101.4, P < 0.0001] and interaction [F (33,364) = 3.28, P < 0.0001] effect (Fig 2.3b). 
Post-hoc tests showed a significant increase in activity for Sal A/Coc treated group vs. 
Veh/Coc treated group of animals 5, 10 and 15 min following cocaine injection (P < 
0.05). 
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Fig. 2.3 Effect of Sal A on cocaine induced hyperactivity (drug naive 
animals).  
Drug naive rats were initially injected with either vehicle (75% DMSO) or Sal A (0.3 mg/kg) 
followed by saline (1 mL/kg) or cocaine (Coc; 20 mg/kg) and locomotion activity was measured 
for 60 min. (a) Figures represents mean total activity +SEM. **p<0.01, data compared with 
Vehicle/Saline treated group, #p<0.01, data compared with Sal A/Saline treated group. One-
way ANOVA followed by Tukey post hoc test. (b) Activity counts (± SEM) measured after 5 min 
interval. *p<0.05, data compared with Veh/Coc treated group. Repeated measures two-way 
ANOVA followed by Bonferroni post-hoc test. n= 6-7 for each group. 
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2.3.3. Effect of Sal A on expression of cocaine sensitization and stereotypy. 
The effect of Sal A (0, 0.3 mg/kg, ip) pre-treatment on expression of cocaine 
behavioural sensitization in rats is shown in Fig 2.4. Animals were pre-treated with 
cocaine on days 1-5 and then on day 10 exposed to vehicle followed by a cocaine 
injection, showed a significant increase in locomotion as compared to the group of 
animals which received saline from day 1-5, demonstrating the expression of cocaine-
induced sensitization [F (3,23) = 4.45, P = 0.013; Fig. 2.4a]. Post-hoc tests revealed no 
measurable difference in activity between animals exposed to Sal A (0.3 mg/kg) on the 
test day than those receiving either saline or cocaine from day 1-5 (P > 0.05; Fig. 2.4a). 
However, a further time course analysis showed a significant treatment [F (3,276) = 
23.18, P < 0.0001] and interaction [F (33,276) = 3.61, P < 0.0001] effect (Fig. 2.4b). 
Post hoc tests showed a significant reduction in locomotion activity in Sal A pre-treated 
rats vs. vehicle treated rats at 5, 10, 15 and 20 min following a single cocaine injection 
(P<0.05; Fig.2.4b). Time course analysis on cocaine induced stereotypic counts showed 
significant treatment effect [F (3, 276) = 3.99, P < 0.01] but no interaction effect [F (33, 
276) = 1.2, P = 0.24]. Bonferroni post-hoc tests showed no significant effect on cocaine 
induced stereotypic counts following Sal A pre-treatment in cocaine sensitized animals 
(P > 0.05; Fig 2.4c). Sal A pre-treatment however showed a trend towards an increase in 
cocaine produced stereotypic counts in sensitized animals 5, 10 and 15 min post cocaine 
treatment compared to vehicle treated animals (P > 0.05; Fig 2.4c). 
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Fig. 2.4 Effect of Sal A on expression of cocaine sensitization and 
stereotypy. 
Rats were injected with saline (1 mL/kg) or cocaine (20 mg/kg) for 5 consecutive days. Animals 
remained drug free from day 6-9. On day 10, rats were injected with either vehicle (Veh, 75% 
DMSO) or Sal A (0.3 mg/kg) and 5 min later were injected with cocaine (Coc, 20 mg/kg) and 
activity was measured for 60 min. (a) Data expressed as mean total ambulations 
(+SEM).**p<0.01, data compared with Saline/Veh/Coc treated group. One-way ANOVA 
followed by Tukey test. (b) Time course measurement of mean (±SEM) of locomotion activity 
over a period of 5 min interval. *p<0.05, vs. Cocaine/Sal A/Coc treated group. Repeated 
measures two-way ANOVA followed by Bonferroni post hoc test. (c) Time course measurement 
of mean (±SEM) stereotypic counts every 5 min for 60 min. Repeated measures two-way 
ANOVA followed by Bonferroni post hoc test. n= 6-8 for each group. 
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2.3.4. Preliminary study to determine pre-treatment time for DS1 
Initial studies were carried out to determine the time taken for DS1 to have an 
effect on laboratory rat behaviour. This was ascertained by measuring the effect of DS1 
on cocaine induced hyperactivity. Three separate groups of drug naive rats were pre-
treated with DS1 (0.3 mg/kg, ip) for 5, 30 or 45 min prior to the injection of cocaine (20 
mg/kg) and total ambulatory counts as well as activity after every 5 min interval was 
measured for 1 hr (Fig. 2.5). The results indicate that DS1, when injected 5 min or 30 
min prior to cocaine, had no significant effect on total activity compared to the vehicle 
controls (75% DMSO; 1 mL/kg, ip). However, a significant suppression in cocaine 
induced hyperactivity was observed when DS1 was injected 45 min prior to cocaine 
exposure [F (3,14) = 5.28, p<0.012; Fig. 2.5a]. A further time course analysis showed 
that DS1 (administered 45 min prior to cocaine) significantly attenuated locomotor 
activity at 5, 10 and 20 min following cocaine (p<0.05) when compared to vehicle pre-
treated controls [F (3,168) = 23.64, P < 0.0001; Fig.2.5b].  
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Fig. 2.5. Preliminary study to determine pre-treatment time for DS1.  
Rats initially received vehicle (75% DMSO) or DS1 (0.3 mg/kg) 5 min, 30 min or 45 min prior 
to an injection of cocaine (20 mg/kg) and locomotion was monitored for 60 min. a) Data are 
expressed as mean total activity (+SEM). *p<0.05, data compared with Vehicle/Cocaine 
treated group, One-way ANOVA followed by Tukey test. b) Data expressed as mean (± SEM) for 
locomotor activity measured at 5 min intervals. *p<0.05, for Vehicle/Cocaine vs. DS1/Cocaine 
(45 min) treated groups. Repeated measures Two-way ANOVA followed by Bonferroni post hoc 
test. n= 4-6 for each group. 
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2.3.5. Effect of DS1 on cocaine prime induced reinstatement. 
The effect of various dose of DS1 (0, 0.1, 0.3 and 1.0 mg/kg, ip) on cocaine (20 
mg/kg, ip) induced drug-seeking is shown in Fig 2.6. Statistical analysis showed that 
pre-treatment with DS1 (0.3, 1.0 mg/kg) attenuated cocaine prime induced 
reinstatement in a dose dependent manner [F (3,26) = 36.82, p<0.0001; Fig 2.6a]. 
However, a trend towards increased active lever press responses was noted in animals 
treated with low dose DS1 (0.1 mg/kg), which was non-significant. The KOPr 
antagonist pre-treatment significantly reversed DS1 induced attenuation of cocaine 
reinstatement (p<0.001; Fig. 2.6b).  
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Fig. 2.6. Effect of DS1 on cocaine prime induced reinstatement. 
Bars indicate active lever press responses +SEM produced during phase 3 of the reinstatement 
test. (a) Rats which had shown extinguished responding during the extinction phase were 
initially treated with different doses of DS1 (0, 0.1, 0.3 and 1.0 mg/kg) followed by a priming 
injection of cocaine (20 mg/kg) and saline reinforced responses were recorded for a period of 
60 min. ***p<0.001, data compared with vehicle treated group (0 mg/kg). One-way ANOVA 
followed by Tukey post hoc test. n=6-10 for each group. (b) For nor-BNI reversal experiments, 
animals were first treated with nor-BNI (0, 2.0 mg/kg) followed by DS1 (0.3 mg/kg) and cocaine 
(20 mg/kg) injections. ***p<0.001, Student t-tests. n=6-10 for each group.  
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2.3.6. Effect of DS1 on cocaine induced hyperactivity (drug naïve animals) 
The effect of acute exposure to DS1 (0, 0.3 mg/kg) on cocaine (0, 20 mg/kg) 
induced hyperactivity is shown in Fig 2.7. A significant increase in the locomotion 
activity was observed in animals pre-treated with vehicle/cocaine as compared to those 
which were treated with vehicle/saline (p<0.001) indicating cocaine induced 
hyperactivity in rats [F (3,26) = 14.68, P<0.0001; Fig. 2.7a]. Post hoc analysis indicated 
no significant difference between DS1 and vehicle pre-treatment on the locomotor 
activity produced following saline treatment (P>0.05; Fig 2.7a). However, an increase 
in total activity was observed in rats pre-treated with vehicle followed by an injection of 
cocaine (20 mg/kg) which was significantly attenuated by DS1 pre-treatment (p<0.01; 
Fig 2.9a). Also, a further time course comparison between DS1 and vehicle treated 
groups showed that DS1 pre-treatment significantly suppressed locomotion 10, 20, 25, 
30, 35 and 40 min (p<0.05) following cocaine injection vs. vehicle treated group 
[treatment effect: F (3,276) = 88.3, P<0.0001; interaction effect: F (33,276) = 2.2, P = 
0.0003; Fig. 2.7b).  
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Fig. 2.7. Effect of DS1 on cocaine induced hyperactivity (drug naïve rats).  
Drug naive rats were initially injected with either vehicle (Veh; 75% DMSO) or DS1 (0.3 mg/kg) 
followed by saline (1 mL/kg) or cocaine (Coc; 20 mg/kg) and total locomotion activity was 
monitored for 60 min. a) Figures represents mean total activity +SEM. ***p<0.001, Veh/Saline 
vs. Veh/Coc treated group, **p<0.01, Veh/Coc vs. DS1/Coc treated group. One-way ANOVA 
followed by Tukey post hoc test. b) Data expressed as mean ±SEM for locomotor activity 
measured at 5 min intervals. *p<0.05, for Veh/Coc vs. DS1/Coc treated groups. Repeated 
measures Two-way ANOVA followed by Bonferroni post hoc test. n= 6-8 for each group. 
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2.3.7. Effect of DS1 on expression of cocaine sensitization. 
The effect of DS1 (0, 0.3 mg/kg, ip) exposure on the expression of cocaine 
sensitization in rats is shown in Fig 2.8. Animals that were pre-treated with cocaine on 
days 1-5 and exposed to vehicle followed by a cocaine injection on day 10, showed a 
significant increase in locomotion compared to the group of animals which received 
saline from day 1-5, indicating the expression of cocaine sensitization [F (3,26) = 6.2, 
P=0.0031; Fig 2.8a]. Post-hoc tests showed no measurable difference in activity 
between animals exposed to DS1 on the test day after recieving either saline or cocaine 
on days 1-5 (P>0.05; Fig. 2.8a). However, a significant reduction in cocaine induced 
hyperactivity was observed in DS1 pre-treated animals vs. vehicle treated animals, all of  
which received cocaine on days 1-5 (p<0.05; Fig 2.8a). Analysis of time course data 
also showed a significant treatment [F (3,276) = 25.39, P < 0.0001] and interaction [F 
(33,276) = 3.84, P < 0.0001] effect (Fig. 2.8b). Post hoc tests showed a significant 
reduction in locomotion activity in DS1 pre-treated rats vs. the vehicle treated group at 
5, 10, 15 and 20 min following a single cocaine injection (P < 0.05). Statistical analysis 
for cocaine induced stereotypy showed significant treatment effect [F (3, 276) = 3.6, P < 
0.05] but no interaction effect [F (33, 276) = 1.37, P = 0.24]. Post-hoc tests showed no 
significant effect on cocaine induced stereotypic counts following DS1 pre-treatment vs. 
vehicle pre-treatment in cocaine sensitized animals (P > 0.05; Fig 2.8c). However, DS1 
pre-treatment showed a trend towards an increase in cocaine produced stereotypic 
counts in sensitized animals 5, 10 and 15 min post cocaine treatment (Fig 2.8c). 
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Fig. 2.8. Effect of DS1 on expression of cocaine sensitization.  
Rats were injected with saline (1 mL/kg) or cocaine (20 mg/kg) for 5 consecutive days. Animals 
remained drug free from day 6-9. On day 10, rats were injected with either vehicle (Veh, 75% 
DMSO) or DS1 (0.3 mg/kg) and 45 min later were injected with cocaine (Coc, 20 mg/kg) and 
activity was measured for 60 min. a) Data are expressed as mean total activity +SEM. 
**p<0.01 Saline/Veh/Coc vs. Cocaine/Veh/Coc treated group, *p<0.05 Cocaine/Veh/Coc vs. 
Cocaine/DS1/Coc treated group. One-way ANOVA followed by Tukey post hoc test. b) Time 
course measurement of mean ±SEM of locomotion activity over 5 min intervals. *p<0.05 
Cocaine/Veh/Coc vs. Cocaine/DS1/Coc treated group. Two-way ANOVA followed by 
Bonferroni post hoc test.  n= 6-8 for each group. (c) Time course measurement of mean (±SEM) 
stereotypic counts for a period of 60 min. Repeated measures two-way ANOVA followed by 
Bonferroni post hoc test. n= 6-8 for each group. 
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2.3.8. Effect of MOM Sal B and EOM Sal B on cocaine prime induced reinstatement 
Effect of MOM Sal B and EOM Sal B on cocaine prime induced drug-seeking is 
shown in Fig 2.9. Statistical analysis showed that MOM Sal B (0.3 mg/kg) significantly 
attenuated cocaine prime induced reinstatement [F (3,17) = 4.71, p<0.05; Fig 2.9a]. 
However, no significant decrease in cocaine prime induced lever press responding was 
noted following EOM Sal B exposure [F (3,17) = 2.427, p = 0.989; Fig 2.9b]. A non-
significant trend towards increased active lever press responding was noted with MOM 
Sal B (0.03, 0.1 mg/kg) and EOM Sal B (0.1, 0.3 mg/kg).    
 
 
 
 
 
86 | P a g e  
 
Cocaine (20 mg/kg, ip)
0 0.03 0.1 0.3
0
100
200
300
 * 
Dose MOM Sal B (mg/kg, ip)
R
es
po
ns
es
Cocaine (20 mg/kg, ip)
0 0.03 0.1 0.3
0
100
200
300
Dose: EOM Sal B (mg/kg, ip)
R
es
po
ns
es
 (a) 
 (b) 
 
Fig.2.9. Effect of MOM Sal B and EOM Sal B on cocaine prime induced 
reinstatement.  
Symbols indicate active lever press responses +SEM produced during phase 3 of the 
reinstatement test. Rats which had shown extinguished saline reinforcements during the 
extinction phase were initially treated with different doses of (a) MOM Sal B (0, 0.03, 0.1 and 
0.3 mg/kg) and (b) EOM Sal B (0, 0.03, 0.1 and 0.3 mg/kg) followed by a priming injection of 
cocaine (20 mg/kg) and saline reinforced responses were recorded for a period of 60 min. 
*p<0.05, data compared with vehicle treated group (0 mg/kg). One-way ANOVA followed by 
Tukey post hoc test. n=5-7 for each group.  
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2.3.9. Effect of herkinorin on cocaine prime induced reinstatement. 
The effect of herkinorin pre-treatment on cocaine prime induced reinstatement is 
shown in Fig. 2.10. No significant change in responding was observed in rats pre-
treated with a high dose of herkinorin [0.3, 1.0 mg/kg; F (3,24) = 1.48, p=0.245]. 
However, a non-significant (p>0.05) trend towards an increase in lever press responding 
was observed in animals treated with a low dose of herkinorin (0.1 mg/kg). Also, a 
trend in decreasing responses was noted in rats treated with the higher dose of 
herkinorin (0.3, 1.0 mg/kg), which was non-significant.   
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Fig.2.10. Effect of herkinorin on cocaine prime induced reinstatement.  
Symbols indicate active lever press responses +SEM produced during phase 3 of the 
reinstatement test. Rats which had shown extinguished saline reinforcements during the 
extinction phase were initially treated with different doses of herkinorin (0, 0.1, 0.3 and 1.0 
mg/kg) followed by a priming injection of cocaine (20 mg/kg) and saline reinforced responses 
were recorded for a period of 60 min. One-way ANOVA followed by Tukey post hoc test. n= 5-
10 for each group.  
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2.3.10. Effect of nalmefene on cocaine prime induced reinstatement. 
The effect of a single injection of nalmefene (0, 0.1, 0.3 and 1.0 mg/kg) on 
cocaine prime-induced reinstatement is shown in Fig. 2.11. Statistical analysis showed a 
significant attenuation in cocaine prime-induced drug-seeking in nalmefene pre-treated 
groups when compared to the vehicle treated group of rats [F(3,17) = 6.48, p<0.01]. 
This effect produced by nalmefene (0.3, 1.0 mg/kg) was reversed by nor-BNI (0, 2.0 
mg/kg) pre-treatment (p<0.001; Fig 2.11b).   
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Fig. 2.11. Effect of nalmefene on cocaine prime induced reinstatement.  
Symbols indicate active lever press responses +SEM produced during phase 3 of the 
reinstatement test. (a) Rats which had shown extinguished saline responding during the 
extinction phase were initially treated with different doses of nalmefene (0, 0.1, 0.3 and 1.0 
mg/kg) followed by a priming injection of cocaine (20 mg/kg) and saline reinforced responses 
were recorded for a period of 60 min. **p<0.01, data compared with vehicle treated group (0 
mg/kg). One-way ANOVA followed by Tukey post hoc test. n=5-6 for each group. (b) For nor-
BNI reversal experiments, animals were first treated with nor-BNI (0, 2.0 mg/kg) followed by 
nalmefene (0.3 mg/kg) and cocaine (20 mg/kg) treatment. ***p<0.001, Student t-tests. n=5-6 
for each group. 
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2.4. Summary of results 
 
 
Tab. 2.3. Effect of KOPr agonists on cocaine prime induced drug-seeking 
Compound tested Cocaine prime induced 
reinstatement 
KOPr antagonist 
induced reversal 
Sal A Attenuated (selective) Reversed 
DS1 Attenuated (selective) Reversed 
MOM Sal B Attenuated (non-selective) - 
EOM Sal B No effect - 
Herkinorin No effect - 
Nalmefene Attenuated (selective) Reversed 
 
 
 
Tab 2.4. Effect of KOPr agonists on cocaine induced motor activity 
Compound tested Cocaine induced 
hyperactivity 
Expression of cocaine 
behavioural sensitization 
Motor 
sensitization 
Stereotypic 
counts 
Sal A Potentiated Attenuated No effect 
DS1 Attenuated Attenuated No effect 
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2.5. Discussion 
In the present study, the novel neoclerodane diterpene KOPr agonist Sal A and 
its structural analogues DS1, MOM Sal B, EOM Sal B, herkinorin and partial KOPr 
agonist/MOPr antagonist, nalmefene, were tested for their anti-addiction behaviours 
using cocaine prime induced reinstatement in rats. To determine if their behavioural 
effects were mediated via KOPr activation, self-administration animals were also pre-
treated with the selective KOPr antagonist nor-BNI. The anti-cocaine reinstatement 
effects produced by novel KOPr agonists that attenuated cocaine seeking behaviours 
selectively without producing sedation by themselves (Chapter 3) were subjected to 
further behavioural tests. These tests included the measurement of cocaine induced 
behavioural sensitization and stereotypic counts. Effect of acute cocaine induced 
hyperactivity was also measured in rats.  
Previous studies have shown that a single systemic injection of cocaine (20 
mg/kg, ip) reinstates extinguished cocaine reinforced responding behaviour (Worley et 
al., 1994; Schenk and Partridge, 1999a; Schenk et al., 2000a). Injecting 20 mg/kg 
cocaine for 5 consecutive days has been shown to produce a sensitized response to 
cocaine. This has been shown by a decreased latency in self-administration acquisition 
(Schenk and Partridge, 2000b). Furthermore, cocaine (20 mg/kg, ip) when injected for 5 
consecutive days also produces sensitization to cocaine’s motor stimulating effects 
(Heidbreder et al., 1995; 1996). The results from this study support these previous 
findings as shown by cocaine (20 mg/kg, ip) initiated prime induced reinstatement (Fig 
2.1) and expression of motor sensitization in rats (Fig 2.4; Fig 2.8).     
Previous studies have shown that conditioning stimuli can play an important role 
in the expression of motor sensitized responses in laboratory animals (Post et al., 1981; 
Beninger and Herz, 1986). In the present study, rats which received cocaine or saline 
injections for 5 consecutive days were returned to their home cage after drug/vehicle 
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exposures. Therefore, the difference in ambulation which was measured in the 
locomotion chamber after cocaine was administered on the test day (day 10) was 
specifically due to cocaine exposures during pre-treatment days 1-5 (Fig 2.3; Fig 2.8). 
The presence of the house light above the active lever has been considered to be 
conditioned stimuli and has been used for training animals to self-administer cocaine 
(Schenk and Partridge, 2001a). Therefore, a light stimulus was presented just above the 
active lever and was lit whenever the animal pressed the active lever during this cocaine 
self-administration study. Consistent with this, presentation of such drug associated 
cues have been shown to initiate the reinstatement of extinguished drug-seeking 
(Stewart et al., 1984). In order to avoid any cue-induced effects while testing during the 
reinstatement phase, the light stimulus was presented to the animals above the active 
lever throughout all the phases of the reinstatement test. Thus, increase in the lever press 
responses observed during the self-administration phase followed by a decrease in lever 
press responding during the extinction phase may be attributed only to the presence of 
cocaine and saline in the infusion pump during phase 1 and 2 respectively (Fig. 2.1). 
No previous in vivo work has been reported on the Sal A analogue, DS1. 
Therefore the onset of action time for DS1 (0.3 mg/kg) on cocaine induced 
hyperactivity was performed at various pre-treatment times. DS1 showed a significant 
suppression in hyperactivity produced when injected 45 min, but not 5 or 30 min prior 
to receiving cocaine injections (Fig. 2.5). This finding suggests that DS1 has a slower, 
more prolonged onset of action in vivo compared to Sal A (2-5 min; Schmidt et al., 
2005). Behavioural tests measuring KOPr agonist induced analgesia have been 
previously used to determine the duration of action of the compound tested (Wang et al., 
2008; John et al., 2005). Such tests apply the hot plate, tail flick and acetic acid induced 
writhing assays in laboratory animals (John et al., 2005; McCurdy et al., 2005; Wang et 
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al., 2008). As the duration of action of DS1 still remains unanswered, detailed studies 
using these behavioural paradigms are therefore warranted.  
Results from this study indicate that Sal A and DS1 both attenuated cocaine 
prime induced drug-seeking behaviour (0.3, 1.0 mg/kg; Fig 2.2a; Morani et al., 2009; 
Fig 2.6a; Tab 2.3). In order to further characterise their anti-addiction potential, the 
effect of acute exposure to Sal A and DS1 (0.3 mg/kg) was tested on cocaine induced 
stimulation of motor function. Sal A and DS1, at the minimum effective dose which 
attenuated drug-seeking behaviour (0.3 mg/kg), significantly suppressed the expression 
of cocaine behavioural sensitization in rats (Fig 2.4; 2.8; Tab 2.4). In addition to its 
effect on cocaine sensitization, DS1 (0.3 mg/kg) pre-treatment significantly suppressed 
cocaine induced hyperactivity (Fig 2.7; Tab 2.4). In contrast, Sal A (0.3 mg/kg) 
exposure significantly increased motor function produced by a single cocaine injection 
(Fig. 2.3; Tab 2.4). Contrary to this present finding, a recent report by Chartoff and 
colleagues (2008) suggested that Sal A (2.0 mg/kg) pre-treatment decreases cocaine 
induced hyperactivity in rats (Chartoff et al., 2008). One of the reasons for the 
differences observed might be due to the relatively low dose of Sal A (0.3 mg/kg vs. 2.0 
mg/kg; Chartoff et al., 2008) and relatively high dose of cocaine (20 mg/kg vs. 10 
mg/kg; Chartoff et al., 2008) used in this study. In contrast to its effect on behavioural 
sensitization, Sal A and DS1 pre-treatment produced opposite effects on acute cocaine 
induced activity. Sal A significantly enhanced whereas DS1 significantly suppressed 
cocaine motor function. This observed discrepancy might reflect the difference in the 
pharmacokinetic properties of these compounds as Sal A has a quick onset of action (5 
min; Schmidt et al., 2005b) compared to DS1 (45 min; Fig 2.5).      
An increase in total activity was noted in animals treated with cocaine on the test 
day following no- (Fig 2.3, 2.5, 2.7) or prior-cocaine exposures (Fig 2.4, 2.8) when 
compared to saline injections. Thus indicating the presence of cocaine induced 
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hyperactivity and expression of cocaine sensitization. On close observation, a greater 
enhancement in motor function was noted in animals receiving vehicle followed by acute 
cocaine challenge (Fig 2.3, 2.7) compared to animals pre-treated with saline for 5 days 
followed by cocaine treatment on test day Fig 2.4, 2.8). Additionally, the sensitized 
animals (i.e. those receiving 5 days of cocaine pre-treatment; Fig 2.4, 2.8) had a 
cocaine response that  was similar to that observed in naïve animals treated with 
acute cocaine (Fig 2.3, 2.7). A possible explanation for these discrepancies may include 
batch differences as both of these experiments were performed at different times.  
An increase in stereotypy behaviour is generally not favoured by forward 
locomotion (Post et al., 1987). Repeated cocaine treatment or high dose of cocaine (20 
mg/kg) has been shown to initially enhance locomotion activity followed by an increase 
in stereotypy behaviours in laboratory rats (Post et al., 1987; Ushijima et al., 1995). 
Therefore, we analyzed the number of stereotypic counts in cocaine sensitized animals 
treated with either Sal A or DS1. There was no significant effect on cocaine produced 
stereotypy with Sal A or DS1 pre-treatment (Fig 2.4; 2.8). However, a non-significant 
enhancement in cocaine produced stereotypy was noted in both Sal A and DS1 treated 
animals which coincided with the suppression of motor sensitization (5-15 min post 
cocaine treatment; Fig 2.4, 2.8). Thus, the decrease in cocaine-induced behavioural 
sensitization produced by both the KOPr compounds might reflect either a decrease in 
the ability of cocaine to produce horizontal activity or an increase in the ability of 
cocaine to produce the competing behaviour of stereotypy following the administration 
of higher doses of psychostimulants (Ushijima et al., 1995; Post et al., 1987). Further 
studies are warranted to define the effects of Sal A and DS1 on cocaine induced 
stereotypic behaviours. Such experiments have been described in details in Chapter 4.  
Ultrastructural studies by Svingos and colleagues (2001) have shown that KOPr 
and DAT are co-localized in the NAc and therefore activation of KOPr can modulate 
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cocaine induced behaviours via DAT. Because of the interaction between KOPr and 
dopaminergic mechanisms, a focus on the effects of Sal A on dopamine-mediated 
behaviours has been of interest (Gherke et al., 2008; Chartoff et al., 2008). In drug 
discrimination tests, Sal A and its synthetic derivatives, MOM Sal B and EOM Sal B, 
substituted completely for U69593 (Baker et al., 2009), suggesting they share effects 
mediated via the KOPr. Cocaine-seeking has been attributed to dopaminergic 
mechanisms (Schmidt et al., 2005a; Section 1.4; Chapter 1), which is supported by data 
showing that Sal A modulates the effects of cocaine through interactions with D1 
receptor mediated signalling pathways in the dorsal striatum (Chartoff et al., 2008). 
Also, Sal A pre-treatment has been shown to decrease DA levels in the NAc (Carlezon 
et al., 2006) and CPU (Zhang et al., 2005; Gherke et al., 2008). However, the effects 
produced by Sal A might be bi-phasic as a lower dose of Sal A (40 µg/kg) increased DA 
levels in NAc (Braida et al., 2008) whereas higher doses (1.0 – 3.2 mg/kg) decreased 
DA levels in dorsal (Zhang et. al., 2005) and ventral (Carlezon et al., 2006) striatum. 
Therefore, the ability of moderate to high doses of Sal A to decrease cocaine-produced 
drug-seeking might be due to its effect on the dopaminergic system. However, further 
work is required to link the role of Sal A in modulating DA neurotransmission with its 
attenuation of cocaine seeking behaviour.   
Sal A analogues, MOM Sal B (Wang et al., 2008) and EOM Sal B (Hooker et al., 
2009), have a longer duration of action than Sal A. These compounds were tested for 
their effects on cocaine prime-induced drug-seeking behaviour. EOM Sal B, which is 10 
times more potent than Sal A at KOPr (Beguin et al., 2005; Munro et al., 2008), had no 
effect on cocaine prime induced drug-seeking behaviour. However, a trend in 
enhancement of active lever press responding was observed when rats were pre-treated 
with the higher doses of EOM Sal B (0.1, 0.3 mg/kg; Fig 2.9b; Tab 2.3). On the other 
hand, Sal A at the same dose (0.3 mg/kg) significantly attenuated cocaine-seeking (Fig 
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2.2; Tab 2.3). A recent study by Hooker et al., (2009) showed that EOM Sal B was 
metabolically more stable than Sal A. Additionally, EOM Sal B when injected ip 
showed a gradual decline in the whole brain concentrations in the rats (Hooker et al., 
2009). Also, EOM Sal B showed less affinity for plasma proteins in baboons reflecting 
more bioavailability (Hooker et al., 2009). These data are suggestive that differences 
between EOM Sal B and Sal A with respect to cocaine seeking might reflect their 
different pharmacokinetic profiles. MOM Sal B, is approximately 7 times more potent 
than Sal A at KOPr (Beguin et al., 2005; Munro et al., 2008), at low doses (0.03, 0.1 
mg/kg) MOM Sal B also showed a non-significant trend towards an increase in active 
lever press responding. However at a higher dose (0.3 mg/kg), MOM Sal B significantly 
attenuated drug-seeking behaviour (Fig 2.9a; Tab 2.3). It was interesting to observe that 
although EOM Sal B and MOM Sal B are both potent and long acting Sal Aanalogues, 
they produce dissimilar effects on cocaine-seeking behaviour at the high dose tested 
(0.3 mg/kg; Fig 2.9). Further studies are required to explain these dissimilarities. As, 
KOPr activation has been shown to decrease natural reward seeking behaviour (Mello 
and Negus, 2000), it would be interesting to observe the effect of MOM Sal B (0.3 
mg/kg) pre-treatment in animals trained to obtain natural reward related reinforcements, 
like sucrose. This would help in determining the degree of selectivity of MOM Sal B in 
attenuation of cocaine-seeking behaviour. The results from such tests have been 
discussed in the following chapter (Chapter 3).    
Herkinorin has a higher affinity for MOPr than KOPr (Harding et al., 2005; 
Tidgewell et al., 2006; Prisinzano and Rothman, 2008), and was tested for its capacity 
to reinstate cocaine induced behaviour. Herkinorin pre-treatment had no significant 
effect on cocaine prime induced drug-seeking (Fig 2.10; Tab 2.3). However, it was 
interesting to observe that there was a slight trend towards a decrease in lever press 
responding in rats pre-treated with high doses (0.3, 1.0 mg/kg) of herkinorin.  
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MOPr agonists such as methadone and its derivatives have been used clinically 
for opioid maintenance therapy (Paulus and Halliday, 1967; Section 1.1, Chapter 1). 
However, one of the problems associated with methadone is that it is itself addictive and 
in some cases might also lead to fatal overdosing (Reingardiene et al., 2009). It is well 
known that KOPr activation opposes MOPr activation related behaviours (Pan, 1998; 
Section 1.7; Chapter 1). Therefore, developing Sal A analogues which activates MOPr 
as well as KOPr may have the potential to be developed into pharmacotherapies to 
manage opioid withdrawal effects. A recent study by Groer and colleagues, (2007) also 
showed that herkinorin, unlike other MOPr agonists, did not promote beta-arrestin 
recruitment to MOPr or cause receptor internalization. Further detailed behavioural and 
neurochemical studies with herkinorin are required to explore its usefulness in drug 
withdrawal. Future studies with herkinorin as maintenance therapy has been discussed 
in Chapter 4. Since herkinorin is the only Sal A analogue with MOPr affinity, a sense of 
interest has been generated in developing herkinorin analogues possessing analgesic 
effects with fewer adverse effects compared to selective MOPr agonists (Harding et al., 
2005; Tidgewell et al., 2006; 2008; Prisinzano and Rothman, 2008).   
KOPr ligands having affinities for other opioid receptors have previously been 
suggested to attenuate cocaine induced behaviours with safer adverse effect profile than 
selective KOPr agonists (Archer et al., 1996; Bowen et al., 2003; Stevenson et al., 2004; 
Kreek et al., 2005; Bart et al., 2005). Additionally, bremazocine and cyclazocine (KOPr 
agonists with MOPr antagonist actions) have been shown to modulate cocaine induced 
behaviours in laboratory animals (Archer et al., 1996; Vanderschuren et al., 2000; Glick 
et al., 1998; Section 1.7; Chapter 1). The present study showed that nalmefene, which is 
a MOPr antagonist having partial agonist activity at KOPr attenuated cocaine prime 
induced drug-seeking behaviour (0.3, 1.0 mg/kg; Fig 2.11a). This study is the first to 
present pre-clinical evidence suggesting that nalmefene attenuates cocaine induced 
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behaviour (Tab 2.3). Ligands activating KOPr and antagonising MOPr functions have 
been proposed as anti-addiction agents with possibly less adverse effects as compared to 
selective KOPr agonists (Mello and Negus, 2000; Bowen et al., 2003; Wang et al., 
2009). Since nalmefene has been shown to attenuate cocaine induced drug-seeking in 
rats, it would be interesting to note the extent to which a single exposure to nalmefene 
produces KOPr related adverse effects. Further work in this regard was undertaken and 
is described in the following chapter (Chapter 3).  
In order to determine if KOPr activation by Sal A, DS1 and nalmefene was in 
fact due to selective KOPr activation cocaine-seeking behaviour in the presence of 
KOPr antagonist nor-BNI was also determined.  Animals pretreated with Nor-BNI 30 
min before injection of KOPr agonists (Sal A, DS1 and nalmefene) completely reversed 
the attenuation in drug-seeking behaviour, thus confirming a KOPr mediated effect (Fig. 
2.2b; 2.6b; 2.11b; Tab 2.3). Nalmefene is also an antagonist at MOPr (Bart et al., 2005; 
Ingman et al., 2005), therefore, the role of MOPr antagonism in the nalmefene induced 
anti-cocaine effects needs to be further characterised. KOPr activation has been shown 
to reduce extracellular DA levels in the NAc, an effect reversed with nor-BNI pre-
treatment (Spanagel et al., 1990). Thus, a reduction in extracellular DA levels in the 
NAc by KOPr activating compounds might reflect its ability to attenuate cocaine-
seeking behaviour. To validate this hypothesis future studies are required and have been 
discussed in Chapter 4. 
It was interesting to note an enhancement in active lever-pressing in animals pre-
treated with nor-BNI (181.8 ± 39.38, Fig 2.2b; 251.2 ± 37.21, Fig 2.11b) compared to 
control (0 mg/kg) animals (107.1 ± 7.3, Fig 2.2a; 166.2 ± 42.39, Fig 2.11a). Similarly, 
Beardsley and colleagues (2005) also reported a non-significant potentiation of cocaine 
prime induced reinstatement in rats pre-treated with JDTic, a selective KOPr antagonist. 
Thus, enhancement in the cocaine’s reinforcing effects by KOPr antagonists might be 
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via the blockade of endogenous KOPr tone. This also shows that opposite effects are 
produced by KOPr antagonists’ vs KOPr agonists on cocaine seeking (Fig 2.2, 2.11).  
As explained in Section 2.1, the cocaine induced reinstatement paradigm has 
been extensively used to determine the effectiveness of pharmacological agents in 
producing anti-addiction effects. The within-session reinstatement paradigm however 
has its limitations. This model does not take into account the neuroadaptations 
associated with long term withdrawal from the drug self-administration. Such 
neuroadaptations are considered critical for the emergence of negative reinforcement 
and for expression of craving and relapse (Self, 2004; Self et al., 2004; Wolf, 2010; 
Koob & Volkow, 2010; Feltenstein & See, 2008). Therefore, the effect of modulating 
KOPr system on long term withdrawal from cocaine self-administration needs further 
assessment and can be performed using a between session reinstatement test. Such 
studies have the potential to determine the effect of KOPr activation on 
neuroadaptations associated with withdrawal and relate them to relapse.  
The within-reinstatement model exhibits low predictive power by itself and 
results obtained using this paradigm fail to discriminate between false positives and 
compounds producing anti-addiction behaviour. This can be illustrated by considering 
the possible effects of dopamine agonists and antagonists on this model. The 
neuroleptic haloperidol or the D1 antagonist SCH23390, at doses that do not induce 
catalepsy or motor inhibition by themselves, may block cocaine-induced reinstatement 
of drug seeking. However, we might not think of them as potential or safe therapeutics 
for cocaine abuse. These probable results would, at least, imply the role of DA 
receptors in cocaine-induced reinstatement (Self, 2004). Additionally, it would be 
interesting to consider the effect of DA agonist on measuring cocaine-seeking 
behaviour in this model. One example is apomorphine, a classical mixed D1/D2 
receptor agonist which, at low doses, produces sedative, yawning and motor inhibition 
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effects (Ernst, 1967). If apomorphine attenuates cocaine-seeking at this dose, it might 
reflect a false positive effect. Furthermore, low doses of apomorphine via D2 auto-
receptors have been shown to inhibit the synthesis and release of DA (Anderson and 
Gazzara, 1993), an effect similar to that elicited by KOPr activation (Shippenberg et 
al., 2007). Apomorphine suppresses cocaine-induced reinstatement of drug-seeking 
(De Vries et al., 1999), however, it is ineffective at treating cocaine addiction. Also 
the D3 receptor agonist’ quinpirole and 7- OH-DPAT have been shown to produce 
similar inhibitory profiles in attenuating cocaine self-administration (Caine and Koob, 
1993), but are unlikely to be used as an anti-addiction pharmacotherapies. Taken 
together, these data suggest that the within-session reinstatement model could be 
applied as a preliminary screening tool to identify the effectiveness of neoclerodane 
diterpenes as anti-addiction compounds. Further screening is therefore required to 
coin the effectiveness of KOPr compounds in modulating addictive behaviours and 
such experiments are described in detail in chapter 4.  
KOPr compounds that attenuate cocaine-seeking using the within-session 
reinstatement model will need further evaluation to discriminate them from false 
positives. To do so, we have applied control experiments which were aimed to 
measure motor suppression during reinstatement test and effect of KOPr compounds 
on natural reward related behaviour in rats. Data from these experiments have been 
described in the following chapter (Chapter 3).    
 
2.6. Summary and conclusions 
The results from this chapter indicate that Sal A and its analogues MOM Sal B, 
DS1 and partial KOPr agonist/ MOPr antagonist, nalmefene attenuated cocaine prime-
induced drug seeking behaviour in rats in a similar way to traditional KOPr agonists. 
Sal A and DS1 also attenuated expression of cocaine behavioural sensitization, with 
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DS1 also attenuating cocaine induced hyperactivity in rats. Thus given the anti-cocaine 
profile for these novel KOPr analogues, it will be interesting to note if they produce 
KOPr agonist related adverse effects such as anhedonia, depression, aversion and motor 
suppression. The next chapter deals with the adverse effect profiles of these novel KOPr 
agonists.    
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Chapter.3. Side effect profile of novel KOPr agonists 
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3.1. Introduction 
3.1.1 Adverse effects of traditional KOPr agonists  
Although, KOPr agonists attenuate cocaine induced behaviours, they are also 
associated with producing adverse effects such as conditioned place and taste aversion, 
depression, hallucination, sedation, emesis and decreased responding for food 
reinforcements in laboratory animals (Todtenkopff et al., 2004; Butelman et al., 2010; 
Mello and Negus, 2000; Section 1.5, Chapter 1). Also, clinically, KOPr activation has 
been shown to induce depersonalization, confusion, visual distortions and hallucinations 
(Pfeiffer et al., 1986; Walsh et al., 2001a; Johnson et al., 2011; Section 1.5, Chapter 1). 
These adverse effects associated with KOPr agonists have limited their development as 
anti-addiction therapeutics (Walsh et al., 2001a). Due to the undesirable effects 
associated with KOPr agonists, we performed behavioural adverse effect screening on 
the compounds which successfully attenuated cocaine-seeking behaviour (Chapter 2).  
3.1.2. Pre-clinical models to screen side effect profile of KOPr agonists 
The following section gives a brief account on the behavioural models used to 
screen the adverse effect profile for novel KOPr agonists. The spontaneous open field 
activity test has been used to determine the motor suppressant effects of traditional 
KOPr agonists (U50488H, U69593, spiradoline) pre-clinically (Sction 1.5, Chapter 1; 
Wadenberg, 2003; Lahti et al., 1982; 1985). The principle for sucrose reinforcement test 
and CTA has been described in Section 1.3, of Chapter 1. A recent study by Davis and 
colleagues (2009) has shown that a single pairing of U50488H with novel tasting 
saccharin solution produces taste aversion. Also, a previous study by Mucha and Herz, 
(1985) showed that traditional KOPr agonists (U50488H, bremazocine, ethylketazocine, 
trifluadom) produced taste and place aversion in a dose dependent manner. Therefore, in 
this present study, CTA was applied to measure the aversive behaviour produced by a 
single KOPr agonist exposure in rats.  
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The FST (Porsolt et al., 1979) has been used extensively as an animal model of 
depressive like behaviours (Porsolt et al., 1979; Carlezon et al., 2006) and to screen 
pharmacological anti-depressants in laboratory animals (Detke et al., 1995). In the FST, 
the animals are habituated to force swimming in a cylindrical chamber for 15 min. The 
next day, animals having been pharmacologically treated during the intervening period, 
are again placed in the cylindrical chamber and the frequency of these behaviours 
(climbing, swimming and immobility) is noted for 5 min. If the treated animal spends 
more time immobile and relatively less time swimming or climbing, it then indicates 
possible depressive effects induced by the pharmacological agent (Porsolt et al., 1979; 
Carlezon et al., 2006). On the other hand, more time spent either climbing or swimming 
(active behaviours) and less time spent immobile, indicates potential anti-depressant 
like effect of the administered pharmacological agent (Detke et al., 1995).  
3.1.3. KOPr mediated SERT modulation  
SERT belongs to the sodium-chloride symporter protein family and plays a 
prominent role in 5HT neurotransmission by clearing 5HT from the synaptic cleft 
(Blakely et al., 1994; Saier, 1999; Zahniser and Doolen, 2001; Rudnick, 2006). 
Alteration of5HT neurotransmission has been implicated in numerous psychiatric 
disorders such as depression (Owens and Nemeroff, 1994), anxiety (Suranyi-Cadotte et 
al., 1990), bipolar disorder (Bellivier et al., 1997; Velayudhan et al., 1999) and 
addiction to psychostimulants (Heinz et al., 2001; Bauman and Rothman, 1998). It is 
well documented that KOPr’s are co-localized with DAT in the NAc (Svignos et al., 
2001) and KOPr agonists modulate DA neurotransmission by increasing DAT function 
in the NAc (Thompson et al., 2000). However, little is known about their effects on 
modulating the function of other monoamine transporters. Therefore, it would be 
interesting to understand whether KOPr activation by both established and novel KOPr 
agonists modulates 5HT systems.  
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3.1.4. Live cell ASP+ uptake accumulation model   
4-(4-(dimethylamino)-styryl)-N-methylpyridinium (ASP+), an analogue of the 
neurotoxin 1-methyl-4-phenylpyridinium (Javitch et al., 1985) is a monoamine 
transporter substrate which fluoresces in a lipid environment (Schwartz et al., 2003; 
2005; Blakely and DeFelice, 2007). ASP+ has been used to measure real-time function 
of DAT (Bolan et al., 2007; Zapata et al., 2007), NET (Schwartz et al., 2003) and SERT 
(Oz et al., 2010) in single cells. The transport of ASP+ can be classified into two stages. 
Initially, ASP+ binds rapidly to the monoamine transporter which is followed by its 
linear uptake into the cell. This can be visualized as accumulation of ASP+ fluorescence 
within the cell (Schwartz et al., 2005; Fig. 3.1). Recent reports have shown that ASP+ 
binds to SERT at micromolar concentrations and accumulates in cells expressing SERT 
(Schwartz et al., 2003; Oz et al., 2010). Additionally, the uptake of ASP+ is saturable, 
temperature dependent, and is dependent on sodium and chloride ions (Schwartz et al., 
2003; Oz et al., 2010). Radio-ligand uptake assays are usually employed to measure 
SERT function (Owens et al., 2001). The advantage of using the ASP+ uptake technique 
is that modulation of SERT function can be observed in real-time, whereas this cannot 
be done by using the radio-ligand uptake assays (Oz et al., 2010). This technique can 
also determine alterations in transporter functional kinetics using single cells over a 
period of time, whereas radio-ligand assays require addition of ligands followed by 
washout periods (Bylund and Toews, 1993) which limits the collection of rapid kinetic 
data. Within cell- and between cell- ASP+ uptake protocols can be used to determine 
monoamine transporter function immediately or after incubating cells with drug 
treatment (Oz et al., 2010; Bolan et al., 2007; Zapata et al., 2007; Schwartz et al., 2003). 
The rationale behind this study was to determine if U50488H, Sal A and DS1 had the 
ability to directly modulate SERT function in vitro in cells transiently expressing both 
SERT and KOPr. Development of an in vitro cell model will help to determine the 
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mechanism by which KOPr agonists modulate addictive behaviours. Overall, this may 
aid in the development of more effective and better tolerated anti-addiction 
pharmacotherapies. 
Results from the previous chapter (Chapter 2) indicate that Sal A, DS1, MOM 
Sal B and nalmefene attenuate cocaine prime induced drug-seeking, an effect similar to 
what has been reported using the traditional KOPr agonists. Therefore, this chapter 
deals with studying the adverse behavioural effect profile of these compounds with 
respect to motor function, CTA and FST in rats. The 5HT system is implicated in the 
aetiology and treatment of depression (Pare, 1971; Pare et al., 1974). It is therefore 
possible that KOPr agonists induced depressive like symptoms might improve via 
modulating the serotonin systems. In order to test this, the effect of antagonising SERT 
function prior to novel KOPr agonist exposure on depressive like behaviours were 
measured using FST in rats. Additionally, we tested the effect of pre-treatment with 
established as well as novel KOPr agonists on modulating SERT function using live cell 
ASP+ accumulation assay in vitro.     
 
3.1.5. Aims 
KOPr compounds (Sal A, DS1, MOM Sal B, nalmefene) with demonstrated 
efficacy for attenuating cocaine seeking behaviours as identified in Chapter 2, were 
tested for undesirable behavioural side-effects. The aims of the experiments described in 
this chapter were:-  
1. To determine if selected KOPr compounds (Sal A, DS1, MOM Sal B, 
nalmefene) alter cocaine induced hyperactivity in cocaine self-administering rats (motor 
suppression during reinstatement tests).  
2. To determine if single exposure to KOPr agonists (Sal A, DS1, MOM Sal B 
and nalmefene) alters the rats natural reward-seeking behaviour. This will be done by 
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measuring weather KOPr agonists disrupt operant responding to obtain 10% sucrose 
solution.       
3. To determine if acute exposure to Sal A, DS1, MOM Sal B and nalmefene 
causes motor suppression (sedation) during recording of spontaneous open field activity.  
4. To determine if acute exposure to Sal A, DS1 and nalmefene produces 
aversion using CTA in rats.  
5. To determine if acute exposure to Sal A, DS1 and nalmefene produces 
depressive symptoms using the FST in rats. 
6. To identify if SERT blockade improves KOPr agonist induced depressive like 
behaviour. In order to determine this, the effect of sub-chronic treatment with FLX on 
Sal A and DS1 induced depressive like behaviours will be determined by using the FST 
paradigm in rats. 
7. To study the effect of classical KOPr (U50488H) and novel neoclerodane 
diterpenes (Sal A, DS1) KOPr agonists on modulating SERT function using live cell 
ASP+ uptake assay in vitro. 
3.2 Methods 
3.2.1. Subjects 
 Animals previously self-administering cocaine and used in cocaine 
reinstatement tests were also used to measure cocaine induced hyperactivity. These 
were male Sprague Dawley rats, weighing 350-400 g. Drug naive male Sprague Dawley 
rats weighing 200-300 g were used for the spontaneous open field activity, CTA, FST 
and sucrose reinforcement tests. In addition rats (Male Sprague Dawley; 350-400 g) 
which were self-administering and tested for reinstatement but no longer had patent iv 
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cannulae were used for preliminary experiments with the KOPr compounds for the FST 
(Tab. 3.1).  
Animals were housed individually (cocaine induced hyperactivity in self-
administering rats, preliminary experiments with FST, sucrose reinforcements, CTA) or 
two per cage (spontaneous locomotion, FST in drug naive rats) in hanging 
polycarbonate cages. All rats were housed at least 5 days prior to the test in the animal 
facility in a temperature (19-21°C) and humidity controlled (55% relative humidity) 
room. Animals were handled for at least 5 days before the experiments to avoid 
handling stress. Lights in the room were maintained at 12:12 h, with lights on from 
0700 h. All experimental procedures were approved by the Animal Ethics Committee of 
Victoria University of Wellington.   
For locomotion tests, rats were placed in the activity chambers and were 
acclimatized for 30 min before they received drug treatment. For sucrose reinforcement 
tests, animals were maintained at approximately 85% of their initial feeding weights 
with free access to water throughout the experiment. For conditioned taste aversion, rats 
had free access to food but were water deprived for 23 hr (water habituation session) or 
23 hr 20 min (saccharin sessions) per day for the entire duration of study. During 
habituation sessions, rats received water, whereas, on the pairing and test days, animals 
received a 0.1% novel tasting saccharin solution. Doses used to test the undesirable 
effects for each KOPr agonist (Sal A, DS1, MOM Sal B, nalmefene) were the minimal 
effective dose which attenuated cocaine reinstatement (0.3 mg/kg; Chapter 2). 
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Tab 3.1. Amount of cocaine consumed by rats used for preliminary FST 
experiments.  
Sr. 
No. 
Days exposed to 
cocaine (days) 
Days abstinent from 
cocaine before FST 
(days) 
Amount of cocaine 
consumed (mg/kg) 
1 82 26 564 
2 76 22 392 
3 81 18 393 
4 77 26 380 
5 77 30 510 
6 76 32 547 
7 74 27 601 
8 78 32 487 
9 78 34 568 
10 61 33 649 
11 59 33 359 
Avg 75  29  496  
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3.2.2. Cell culture maintenance for live cell ASP+ uptake experiments.  
HEK-293 (American type culture collection, USA) cells were maintained in 
culture in Dulbecco’s Modified Eagle Medium (Gibco, Invitrogen) containing 10% 
foetal bovine serum (Gibco, Invitrogen) and 1 % penstrap (5,000 units of penicillin G 
sodium salt and 5,000 µg streptomycin sulphate/ml in 0.85% saline; Invitrogen). The 
cells were grown in a T75 tissue culture flask (BD Bioscience) and were maintained in a 
humidified atmosphere in an incubator at 37°C with 5% CO2.  
3.2.3. Drugs 
Sal A, DS1 and MOM Sal B (from Dr. Thomas E. Prisinzano, University of 
Kansas) were suspended in 75% DMSO. Cocaine hydrochloride (Merck, Palmerston 
North, New Zealand), nalmefene (Sigma Aldrich, MO) and fluoxetine (Tocris, UK) 
were dissolved in 0.9% saline and ip and sc injections were administered in the volume 
of 1 mL/kg. For live cell confocal microscopy experiments, 4-(4-(dimethylamino)-
styryl)-N-methylpyridinium (ASP+; Sigma Aldrich, St Louis MO) was dissolved in 
Krebs Ringer Herpes buffer (KRH; pH 7.4). U50488H (Sigma Aldrich, St. Louis, MO), 
Sal A and DS1 were initially suspended in 100% DMSO followed by further dilution 
into KRH (pH 7.4).      
 
3.2.4. Apparatus 
3.2.4.1. Locomotion tests  
As described in Section 2.2.4.1, Chapter 2. 
3.2.4.2. Sucrose reinforcement 
Training and testing procedures were conducted in eight modular test chambers 
(Med Associates, ENV-008) equipped with two retractable levers (Med Associates 
ENV-112CM) situated at the front of the chamber to either side. 10% sucrose solution 
was delivered by a liquid dipper (Med-Associates ENV-202M). The dipper was situated 
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in the centre, at the front of the chamber 2 cm from the chamber floor.  The two 
retractable levers were positioned to the left and right 8 cm from the liquid dipper and 3 
cm from the sides of the chamber. These chambers were located in an unlit, sound 
attenuated room. Sucrose delivery and data acquisition were controlled by Med 
Associates software (St Albans, VA, USA). Experiments were conducted between 0900 
and 1600 hr.  
3.2.4.3. Forced swim test 
The FST apparatus consisted of a cylinder which was 44 cm high and 20 cm in 
diameter. The cylinder was filled with water maintained at 25 ± 1 °C. The water was 
filled up to 35 cm and the animal was placed in the water and behaviour was recorded 
by a camera connected to a nearby computer. The forced swimming behaviours 
(climbing, swimming or immobile) were recorded for a period of 5 min and later 
analysed by a blinded to treatment observer.    
3.2.5. Procedure 
3.2.5.1. Cocaine induced hyperactivity (in self-administering rats) 
This test was conducted to measure weather KOPr agonists caused any disruption in 
motor function during the reinstatement test. Methods described by Morani et al., (2009) 
were followed. The conditions for this test were maintained similar to the reinstatement 
test. On the test day, rats previously self-administering cocaine received an injection of 
either Sal A (0.3 mg/kg, ip) 5 min, MOM Sal B (0.3 mg/kg, ip) 5 min, nalmefene (0.3 
mg/kg, sc) 15 min and DS1 (0.3 mg/kg, ip) 45 min prior to an injection of cocaine (20 
mg/kg, ip). Immediately following the cocaine injection, the rats were placed in the 
activity chambers and total activity, a compilation of horizontal and vertical activity, 
and ambulation at 5 min intervals was measured for a period of 1 hr. All injections were 
administered in the open field chamber. The experimenter remained outside the test 
room while the activity test was in progress. 
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3.2.5.2. Spontaneous open field activity (drug naive rats) 
This test was performed to detect any sedative or motor suppression effects 
produced by an acute exposure to the KOPr agonists. For this study, we modified the 
methods of Frankowska et al, (2009) and Xu et al, (2010). On the test day, drug naive 
rats were injected with either vehicle (75% DMSO or 0.9% saline) or KOPr compounds 
5 min (Sal A, 0.3 mg/kg, ip; MOM Sal B, 0.3 mg/kg, ip), 15 min (nalmefene, 0.3 mg/kg, 
sc) or 45 min (DS1, 0.3 mg/kg, ip) prior to measuring their spontaneous open field 
activity. Total activity, a compilation of horizontal and vertical activity, and ambulation 
at 5 min intervals was measured for a period of 1 hr. All injections were administered in 
the activity chamber with the experimenter remaining outside the test room while the 
activity test was in progress.  
3.2.5.3. Sucrose reinforcement training and test  
 This test was performed to determine the effect of acute exposure to KOPr 
agonists on operant lever press responding to a palatable reward (10% sucrose solution). 
Methods described by Morani et al., (2009) were followed. Animals were maintained at 
approximately 85% of their initial feeding weights throughout the experiment. Initially 
rats were trained to obtain sucrose reinforcements using an auto-shaping procedure for 
45 min daily for ten consecutive days. Once they were stably responding, the animals 
were trained to self-administer sucrose orally on a FR1 schedule of reinforcement. 
Following acquisition, the response requirement was increased to a FR-5 schedule. 
Daily 1 hr sessions were conducted until there was less than 20% variation in 
responding for three consecutive days. Once responding on the FR-5 schedule was 
stable, the effects of prior administration of Sal A (0.3, 1.0 mg/kg, ip), DS1 (0.3, 1.0 
mg/kg, ip), MOM Sal B (0.3 mg/kg, ip), nalmefene (0.3 mg/kg, sc) and vehicle (75% 
DMSO; 0.9% saline) on sucrose-reinforced responding were noted. The injections were 
administered 5 min (Sal A, MOM Sal B), 15 min (nalmefene) and 45 min (DS1) prior to 
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the experiment and responding was measured for 60 min following drug/vehicle 
treatment.  
3.2.5.4. Conditioned taste aversion  
This test was performed to determine the aversive effects produced by a single 
injection of each of the KOPr agonists. To do this we measured the amount of novel 
tasting saccharin solution (which had been paired with KOPr agonist) consumed on test 
day. For this experiment, we modified methods described by Fenu et al., (2005) and 
Schenk et al., (1987).    
Habituation: On day 1 of the experiment the rats were placed on a water deprivation 
schedule for 23 h. The following day, animals were given access to water for 1 h. The 
amount of water consumed was measured on a daily basis, to the nearest mL. This 
process was repeated untill the variation in water consumption was ≤ 2 mL for three 
consecutive days.  
Pairing: The day after rats attained stable water consumption, they were subjected to 
pairing session. During these sessions, rats were presented with a novel 0.1% saccharin 
solution instead of water, and the amount of saccharin consumed (mL) was noted for 40 
min. The animals were divided evenly into two groups (Vehicle or KOPr agonist 
treated), matched on saccharin intake and were immediately injected with either vehicle 
(75% DMSO or 0.9% saline) or KOPr compound (Sal A, DS1 or nalmefene) and were 
returned to their home cage. The following day (24 h post pairing sessions), rats were 
provided with drinking water for 60 min and were tested for the saccharin aversion the 
next day (24 h later).    
Test day: 48 hr after the pairing session, rats were again presented with the saccharin 
solution and the amount of saccharin consumed was measured for 40 min (to the nearest 
mL). In order to determine any taste aversion produced by the novel KOPr compound, 
the amount of saccharin consumed on the pairing day and test day by the KOPr agonist 
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treated groups was compared to the corresponding vehicle treated group. All 
experiments were performed between 1100 – 1300 hr. 
3.2.5.5. FST in drug naïve rats and preliminary experiments.   
To initially screen the depressive effect of novel KOPr agonists, FST was 
carried out using animals which were previously subjected to self-administration 
training and reinstatement tests (Tab 3.1). These rats were withdrawn from the self-
administration experiments due to the failure of their jugular cannulae. The average 
total amount of cocaine consumed by these rats was 496 mg/kg (range: 359-649 mg/kg). 
The average number of days these rats were exposed to cocaine was 75 days (range: 59-
82 days). The average number of days they were abstained from cocaine was 29 (range: 
18-34 days). Depressive effects produced by KOPr agonists in preliminary tests were 
later determined in drug naive animals. For this experiment, we modified methods of 
Carlezon et al., (2006).     
Habituation day: Animals were habituated in the test room for 60 min prior to the 
commencement of experiments. Rats were singly placed in the FST chamber and 
habituated to forced swimming for 15 min. Rats initially tried to escape from the FST 
chamber but later they habituated to the swimming conditions which was observed as 
maintaining immobility. After the 15 min session, animals were removed from the 
chamber, dried using cloth towels and were placed under a heating lamp for at least 30 
min. Water in the cylinder was changed every 1-2 rats (to remove  animal litter). After 
the habituation sessions were completed, the rats were returned to their home cages. 
Test day: Rats were injected with KOPr compounds 5 min (Sal A), 15 min (nalmefene) 
and 45 min (DS1) prior to the experiments. This second FST was carried out for a 
period of 5 min. The climbing, swimming and immobility behaviours were recorded 
using a camera connected to a nearby computer via Ethernet. To avoid any bias in 
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analysis, treatments were masked from the experimenter during subsequent video 
analysis. The incidence of each FST behaviour was analysed in bins of 5 sec interval.   
3.2.5.6. Effect of serotonin transporter blockade by FLX on KOPr agonist induced 
depression in FST: 
The habituation and test sessions were carried out as previously described 
(section 3.2.4.5). In between the habituation and test sessions, rats were treated with 
saline (1 mL/kg, sc) or FLX (5 mg/kg, sc; Detke et al., 1995; Estrada-Camarena et al., 
2003), 30 min, 19 hr and 23 hr post habituation. The next day (24 hr after habituation), 
animals received the KOPr agonists (Sal A, DS1) and were subjected to FST for 5 min. 
The data obtained from these experiments were analysed as described in section 3.2.5.5.    
 
3.2.5.7. Transfections and live-cell imaging to determine SERT function modulation 
by KOPr agonists (between cell designs). 
Transfections:- For ASP+ uptake experiments, HEK-293 cells were trypinised 
(TrypLETM express stable Trypsin-like enzyme with Phenol red, Invitrogen, New 
Zealand), washed and cultured in fresh antibiotic-free media (Dulbecco’s modified 
Eagle medium (Gibco, Invitrogen) containing 10% fetal bovine serum) and were seeded 
in 35 mm sterile glass bottomed Delta T culture dishes (MatTek MA, USA) at 1.25 X 
105 cells/mL, using 1 mL/dish. Transient transfections were performed with plasmids 
containing green fluorescence protein tagged human SERT (GFP-hSERT; a gift from 
Dr. Samanda Ramamoorthy, Medical University of South Carolina, USA; 
Ramamoorthy et al., 1993) and myc-tagged rat KOPr (myc-rKOPr; a gift from Dr. 
Lakshmi Devi, Mount Sinai School of Medicine, NY, USA; Li et al., 1993; Meng et al., 
1993) using Lipofectamine 2000 (Invitrogen) and OptiMEM media (Invitrogen). The 
transfections were carried out according to the manufacturer’s instructions (Appendix 3). 
The transfection solution contained 3 µL Lipofectamine and 1 µg plasmid DNA (GFP-
117 | P a g e  
 
hSERT: 0.4 µg ; myc-rKOPr: 0.6 µg) and the volume made up to 100 µl using  
OptiMEM. Each 35 mm culture dish was treated with 100 µL of the transfection 
solution. The cells were transfected 24 hr post-seeding. Drug treatment and imaging 
experiments were performed 36-48 hr post transfection when cells were found confluent 
between 70-90%.  
 
Live-cell ASP+ uptake experiments:- On the day of the experiment, cells were treated 
with either drug (10 µM U50488H, 10 µM Sal A, 10 µM DS1) or vehicle (0.1% DMSO 
diluted in Krebs Ringer Herpes buffer; KRH, pH: 7.4, Appendix 4) and placed into the 
incubator for 30 min. Just before image capture, the media from the dish was replaced 
with KRH and the dish was mounted on a temperature (37°C) and humidity controlled 
stage (Tokai Hit; INU-ZILCS-Fl; Shizuoka-ken; Japan) and attached to an Olympus 
FV1000 laser scanning confocal microscope (Olympus, Wellington, New Zealand). 
Initially cells were visualized using a 40X water immersion objective (Olympus) and a 
monolayer of cells selected. The KRH was then removed without disturbing the dish 
and an initial image showing GFP-hSERT fluorescence was captured (Fig. 3.1A). 
Immediately after this, 1 ml of 10 µM ASP+ solution in KRH (Sigma, MO; 1 mL/dish) 
was added, and live-cell ASP+ uptake recorded for 5 min with images taken every 5 sec 
(Fig. 3.1B). The GFP-hSERT and ASP+ were excited to fluoresce by using the solid 
state lasers (Olympus, Wellington, New Zealand). GFP-hSERT was excited at 473 nm, 
(485-545 filter) and ASP+ was excited at 559 nm (570-670 filter). 
 
Data analysis for live-cell ASP+ uptake experiments:- Individual cells were selected in 
a region of interest using both differential interference contrast and GFP-hSERT images 
to localise the cell boundaries (Fig. 3.1C). The GFP-hSERT and ASP+ fluorescence 
were quantified for each cell using Fluoview FV1000 software (Olympus; Fig. 3.1D). 
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Non-transfected cells had shown some non-specific ASP+ accumulation. This non-
specific accumulation was subtracted from the accumulation measured in the transfected 
cells. In order for ASP+ accumulation to be directly correlated to the amount of GFP-
hSERT expressed on the cell surface, we expressed ASP+ uptake as a percentage of  
SERT expression using the following formula:-  
 
All experiments were performed in duplicate from at least three separate transfections.  
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Fig. 3.1 ASP+ accumulation and fluorescence analysis. 
A. After incubating the cells with KOPr agonists (10 µM U50488H, Sal A, DS1) or vehicle 
(DMSO), each culture dish was placed on the inverted confocal microscope stage which 
focussed on the monolayer of cells visualised using differential interference contrast and GFP-
hSERT fluorescence (green colour) to identify and locate cells. The GFP-hSERT fluorescence 
was captured just before adding ASP+. B. ASP+ was then added to the dish and uptake was 
measured every 5 sec for 5 min. C. After 5 min uptake, cells were circled and the amount of 
ASP+ uptake accumulated (red colour) over 5 min was determined using Fluoview software 
(Version 2.0c). D. The binding to and uptake pattern of ASP+ in a representative GFP-hSERT 
and myc-rKOPr transfected cell. Scale bar represents 10 µm.   
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3.2.6. Statistical analysis 
Data analysis was performed using Prism Graphpad software (Version 5.0; San 
Diego, CA). Statistical analysis for cocaine induced hyperactivity; spontaneous open 
field activity; sucrose reinforcements (for MOM Sal B, nalmefene) were performed 
using separate Student t-tests. The sucrose reinforcement tests for Sal A, DS1 and CTA 
(for Sal A, DS1 and nalmefene) were analysed using one way ANOVA followed by 
Tukey post-hoc tests. The effect of 5HT system modulation via SERT blockade using 
FLX on Sal A and DS1 induced immobility were analysed using a separate two-way 
ANOVA for each FST behaviour’. For comparing FST results in cocaine exposed and 
drug naïve rats, each forced swimming behaviour’ was analysed using the Mann-
Whitney test. Data for correlation experiments measuring ASP+ uptake and GFP-
hSERT expression levels were analysed using linear regression. ASP+ accumulation 
experiments in non-transfected vs. transfected cells were analysed from the 5 min 
uptake values using student t-test. Changes in ASP+ uptake in KOPr treated cells were 
analysed using one-way ANOVA followed by Dunnets multiple comparison tests (Oz et 
al., 2010). For analysing GFP-hSERT expression levels in cells selected for ASP+ 
accumulation experiments, one-way ANOVA followed by Dunnets multiple 
comparison tests were performed.  
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3.3. Results 
3.3.1. Effect of KOPr compounds on cocaine induced hyperactivity (cocaine self-
administering rats). 
The effect of Sal A (0, 0.3 mg/kg, ip), DS1 (0, 0.3 mg/kg, ip), MOM Sal B(0, 
0.3 mg/kg, ip) and nalmefene (0, 0.3 mg/kg, sc) pre-treatment on cocaine induced 
hyperactivity in rats previously self-administering cocaine and subjected to 
reinstatement tests is shown in Fig 3.2. No significant reduction in cocaine produced 
hyperactivity was observed in either Sal A (p = 0.46; Fig 3.2a) and MOM Sal B pre-
treated animals (p = 0.43; Fig 3.2c). A non-significant trend to increase total activity 
was noted in animals treated with nalmefene (p = 0.216; Fig 3.2d). However, rats that 
were pre-treated with DS1 showed a non-significant trend towards a decrease in cocaine 
produced hyperactivity (p = 0.09; Fig 3.2b).  
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Fig 3.2. Effect of KOPr compounds on cocaine induced hyperactivity 
(cocaine self-administering rats).  
Rats previously self-administering cocaine were initially treated with either (a) Sal A (0, 0.3 
mg/kg; n= 6), (b) DS1 (0, 0.3 mg/kg; n= 9, 10), (c) MOM Sal B (0, 0.3 mg/kg; n=5, 6), (d) 
nalmefene (0, 0.3 mg/kg; n= 5). This was followed by a priming injection of cocaine (20 mg/kg) 
and total locomotion was measured for 60 min. Symbols in the left panel represent total 
ambulatory counts (+SEM) and in right panel indicates mean (± SEM) of ambulation measured 
every 5 min interval. Student t-test.     
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3.3.2. Effect of KOPr compounds on natural reward reinforcements  
The effect of Sal A (0, 0.3, 1.0 mg/kg, ip); DS1 (0, 0.3, 1.0 mg/kg, ip); MOM 
Sal B (0, 0.3 mg/kg, ip) and nalmefene (0, 0.3 mg/kg, sc) on sucrose reinforced 
responding is shown in Fig. 3.3. Statistical analysis indicated no significant alteration in 
sucrose reinforcement observed in rats which were pre-treated with either Sal A [F (2,27) 
= 0.058, p=0.944; Fig. 3.3a]; DS1 [F (2,18) = 1.11, p=0.35; Fig. 3.3b] and nalmefene 
(p>0.05; Fig. 3.3d). However, a significant reduction in sucrose reinforcement was 
observed in rats pre-treated with MOM Sal B (p=0.0073; Fig. 3.3c).  
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Fig. 3.3. Effect of KOPr compounds on natural reward reinforcements.  
Animals which were stably responding for sucrose reinforcements at a FR-5 schedule of 
reinforcement were injected with KOPr compounds prior to measuring sucrose reinforced lever 
press responding for 60 min. Bars indicate average number of “active” lever press responses 
(+SEM) for 10% sucrose solution following (a) Sal A (0, 0.3, 1.0 mg/kg; n=10), (b) DS1 (0, 0.3, 
1.0 mg/kg, n=7), (c) MOM Sal B (0, 0.3 mg/kg, n=7), (d) nalmefene (0, 0.3 mg/kg, n=6) 
treatment. One way ANOVA followed by Tukey post-hoc tests was used for (a) and (b) and 
Student t-test for (c) and (d). **p<0.01 compared to 0 mg/kg.  
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3.3.3. Effect of KOPr compounds on motor function. 
Effect of an acute exposure to Sal A (0, 0.3 mg/kg, ip); DS1 (0, 0.3 mg/kg, ip); 
MOM Sal B (0, 0.3 mg/kg, ip) and nalmefene (0, 0.3 mg/kg, sc) on spontaneous open 
field locomotion activity in rats is shown in Fig. 3.4. Statistical analysis indicated no 
significant change in total locomotion activity observed for Sal A (p=0.78; Fig. 3.4a); 
DS1 (p=0.54; Fig. 3.4b) and MOM Sal B (p=0.43; Fig. 3.4c) pre-treated animals. 
However, rats pre-treated with nalmefene (p=0.023; Fig. 3.4d) significantly suppressed 
spontaneous open field activity. 
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Fig. 3.4. Effect of KOPr compounds on motor function. 
Drug naïve rats were treated with  (a) Sal A (0, 0.3 mg/kg; n= 7), (b) DS1 (0, 0.3 mg/kg; n= 7) 
and  (c) MOM Sal B (0, 0.3 mg/kg; n= 5,7), (d) nalmefene (0, 0.3 mg/kg, n= 5,7) and 
spontaneous open field activity was measured for 60 min. Symbols in the left panel represent 
total ambulatory counts (+SEM) and in right panel indicates mean (± SEM) of ambulation 
measured every 5 min interval. *p<0.05, data compared with 0 mg/kg, Student t-test.    
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3.3.4. Effect of KOPr compounds on conditioned taste aversion.  
The amount of saccharin consumed by rats paired with novel tasting saccharin 
solution and Sal A (0, 0.3 mg/kg, ip); DS1 (0, 0.3 mg/kg, ip) and nalmefene (0, 0.3 
mg/kg, sc), on pairing day and test day is shown in Fig 3.5. Statistical analysis showed 
no significant difference in saccharin drinking patterns observed for Sal A (F (3,22) = 
2.7; p > 0.05;  Fig 3.5a) and nalmefene (F (3, 20) = 0.3; p = 0.8; Fig 3.5c) pre-treated 
rats. However, DS1 pre-treated rats, showed a significant increase in saccharin drinking 
pattern on test day when compared with pairing day (F (3, 22) = 7.3; p <0.01; Fig 3.5b).    
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Fig. 3.5. Effect of KOPr compounds on conditioned taste aversion. 
Animals experienced a pairing of a novel tasting saccharin solution and KOPr compounds [(a) 
Sal A (0, 0.3 mg/kg; n= 6-7), (b) DS1 (0, 0.3 mg/kg; n= 6-7) and (c) nalmefene (0, 0.3 mg/kg; 
n= 6)]. They were again presented with the saccharin solution, 48 hr post pairing session, and 
the amount of saccharin consumed on pairing day and test day was measured for 40 min. Bars 
indicate average (+SEM) amount of 0.1% saccharin solution consumed by rats (mL) treated 
with vehicle or KOPr compounds on pairing and test day. **p<0.01, one way ANOVA followed 
by Tukey post-hoc test. 
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3.3.5. Effect of KOPr compounds on FST in rats with previous history of cocaine self-
administration. 
The effect of acute exposure to Sal A (0, 0.3 mg/kg, ip); DS1 (0, 0.3 mg/kg, ip) 
or nalmefene (0, 0.3 mg/kg, sc) in rats with a prior history of cocaine self-administration 
on forced swimming behaviours are shown in Fig. 3.6.  
For Sal A pre-treated animals, statistical analysis indicated no significant 
difference in time spent climbing (p=0.9) or swimming (p=0.15). However, a significant 
increase in immobility (p=0.04) time was observed for Sal A pre-treated rats vs. vehicle 
treated rats (Fig. 3.6a). 
For DS1 pre-treated rats, no significant difference in time spent climbing 
(p=0.83) was noted. However, a significant decrease in time spent swimming (p=0.01) 
and an increase in immobility (p=0.01) time were noted for DS1 pre-treated rats vs. 
vehicle treated rats (Fig. 3.6b).   
For nalmefene pre-treated rats, no significant difference in climbing time (p=1.0) 
was noted. However, a significant reduction in swimming time (p=0.03) and a 
significant increase in time spent immobile (p=0.02) were observed for nalmefene pre-
treated rats vs. vehicle treated rats (Fig. 3.6c). 
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Fig. 3.6. Effect of KOPr compounds on FST in rats with previous history 
of cocaine self-administration. 
Animals previously self-administering cocaine and subjected to reinstatement testing were 
habituated to the forced swimming sessions on day 1. The following day, animals received (a). 
Sal A (0, 0.3 mg/kg; n=4), (b). DS1 (0, 0.3 mg/kg; n=5) or (c) nalmefene (0, 0.3 mg/kg; n=4-5) 
and were subjected to FST. The forced swimming behaviours were recorded for a period of 5 
min and analysed in bins of 5 sec. Data are expressed as mean time in sec (+SEM) for climbing, 
swimming or immobility during FST. *p<0.05. Data for 0.3 mg/kg compared with 0 mg/kg for 
corresponding climbing, swimming and immobile behaviours using Mann Whitney tests.   
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3.3.6. Effect of KOPr compounds on FST in drug naive rats. 
The effect of single injections of Sal A (0, 0.3 mg/kg, ip); DS1 (0, 0.3 mg/kg, ip) 
and nalmefene (0, 0.3 mg/kg, sc) on forced swimming behaviours in drug naive rats is 
shown in Fig. 3.7.   
Significant reductions in climbing (p=0.044) and swimming (p=0.005) times 
were observed in rats pre-treated with Sal A. A significant increase in time spent 
immobile (p=0.005) was also noted for Sal A vs. vehicle pre-treated animals (Fig. 3.7a).  
For DS1 pre-treated animals, a non-significant trend to decrease time spent as 
climbing was noted (p=0.09). However, a significant decrease in swimming time 
(p=0.006) and a significant increase in time spent immobile (p=0.006) was observed for 
DS1 vs. vehicle pre-treated animals (Fig. 3.7b). 
For nalmefene pre-treated rats, statistical analysis indicated no significant 
difference in time spent as climbing (p=0.48). However, a significant decrease in 
swimming time (p=0.025) and a significant increase in immobility time (p=0.034) were 
observed for nalmefene vs. vehicle pre-treated animals (Fig. 3.7c).  
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Fig. 3.7. Effect of KOPr compounds on FST in drug naive rats. 
Drug naive animals were habituated to the forced swimming sessions on day 1. The following 
day, animals received (a). Sal A (0, 0.3 mg/kg; n=6), (b). DS1 (0, 0.3 mg/kg; n=5-7) and (c). 
nalmefene (0, 0.3 mg/kg; n=6) and were subjected to FST. The forced swimming behaviours 
were recorded for a period of 5 min and analysed in a bin of 5 sec intervals. Data expressed as 
mean time in sec (+SEM) spent by animals for climbing, swimming and immobile behaviours 
during FST. *p<0.05, **p<0.01. Data for 0.3 mg/kg compared with 0 mg/kg for corresponding 
climbing, swimming and immobile behaviours. Mann Whitney test.   
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3.3.7. Effect of SERT blockade by FLX on KOPr agonists induced immobility in FST.  
The purpose of this test was to determine the role of SERT blockade via sub-
chronic FLX pre-treatment on different forced swimming behaviours produced by Sal A 
and DS1 exposure in rats. Statistical analysis shows that FLX pre-treatment 
significantly reduced the amount of time spent immobile in animals pre-treated with Sal 
A [F (1,17) = 4.95, P < 0.05; Fig 3.8a] or DS1 [F (1, 17) = 7.25, P = 0.015; Fig 3.8b]. A 
significant increase in the amount of time spent climbing was also noted in Sal A [F 
(1,17) = 8.01, P = 0.012; Fig 3.8a] and DS1 [F (1,17) = 5.44, P < 0.05; Fig 3.8b] pre-
treated animals, following  FLX pre-treatment. No effect of FLX pre-treatment on 
swimming time was observed in Sal A [F (1, 17) = 0.15, P = 0.7; Fig 3.8a] or DS1 [F (1, 
17) = 1.75, P = 0.2; Fig 3.8b] treated rats.  
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Fig. 3.8. Effect of SERT blockade by FLX pre-treatment on KOPr agonist induced 
immobility in FST.  
Drug naive rats were habituated to the forced swimming test on day 1. Rats received injections of 
FLX (0, 0.3 mg/kg, sc), 30 min, 19 hr and 23 hr post habituation sessions. The next day (24 hr 
following habituation sessions), animals received an injection of a) Sal A (0, 0.3 mg/kg) or b) DS1 (0, 
0.3 mg/kg) and were subjected to FST. The forced swimming behaviours were recorded for a period 
of 5 min and analysed in a bin of 5 sec intervals. Data expressed as mean time in sec (+SEM) for 
climbing, swimming or immobile during FST. *p<0.05, two-way ANOVA for each FST behaviours. 
n= 5-6 for each group.  
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3.3.8. Control experiments for ASP+ uptake 
Control experiments were performed to show a correlation between the level of 
ASP+ accumulation and GFP-hSERT expression levels. An image of GFP-hSERT 
fluorescence was captured, followed by the addition of ASP+ at time 0. The ASP+ 
accumulation was measured every 5 sec for 5 min. Statistical analysis showed a linear 
correlation between GFP-hSERT expression and ASP+ accumulation in transfected cells 
(r2 = 0.82; Goodness of fit, p<0.0001; Spearman coefficient, n = 80; Fig. 3.9a).   
The amount of ASP+ accumulation in cells not expressing GFP-hSERT (non-
transfected cells) was compared with those cells expressing GFP-hSERT (transfected 
cells). Our results showed a significant increase in ASP+ accumulation in transfected 
cells vs. non-transfected cells (p<0.0001; Fig. 3.9b), thus indicating increased ASP+ 
uptake in cells expressing GFP-hSERT.  
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Fig. 3.9. Control experiments for ASP+ uptake.  
a) ASP+ uptake and GFP-hSERT expression levels. GFP-hSERT levels for each cell are shown 
at time 0 (x axis). The accumulation of ASP+ after 5 min is shown for each cell on the y axis. 
ASP+ and GFP-hSERT fluorescence are measured as arbitrary fluorescence units (AFU). Each 
dot indicates GFP-hSERT expression levels and corresponding ASP+ accumulated at 5  min by 
that particular cell. Data were analysed using linear regression. n=80. b) ASP+ accumulation 
in transfected vs. non-transfected cells. Bars indicate the amount of ASP+ accumulated in 
transfected and non-transfected cells and measured as AFU. ***p<0.0001, data compared with 
a non-transfected group of cells using student t-test. Number of non-transfected cells = 24, 
transfected cells = 80.  
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3.3.9. Effect of KOPr agonists pre-treatment on ASP+ uptake  
The effect of KOPr agonist pre-treatment on GFP-hSERT function in GFP-
hSERT and myc-rKOPr co-transfected HEK-293 cells using the ASP+ uptake method is 
shown in Fig. 3.10a. Cultures were pre-treated with 10 µM U50488H, Sal A or DS1 and 
following a 30 min incubation, SERT function was measured. Pre-treatment with the 
traditional KOPr agonist U50488H significantly decreased ASP+ uptake (p<0.001) [F 
(3,261) = 106.1, p<0.0001]. However, there was no significant difference in ASP+ 
accumulation in cells pre-treated with either Sal A or its structural analogue DS1 
(p>0.05), thus indicating a potential difference in modulation of SERT function by 
novel and traditional KOPr agonists.   
In order to verify that changes seen in ASP+ uptake were specifically due to 
KOPr agonist treatment and not due to selection of cells with lower levels of GFP-
hSERT expression levels, GFP-hSERT fluorescence intensity for cells pre-treated with 
KOPr agonists and selected for ASP+ accumulation analysis were compared with 
vehicle treated cells. Statistical analysis revealed no significant difference in GFP-
hSERT expression levels in cells analysed for ASP+ uptake [F (3,261) = 2, p = 0.11; Fig. 
3.10b].  
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Fig. 3.10. Effect of KOPr agonists pre-treatment on ASP+ uptake  
a) HEK-293 cells co-transfected with GFP-hSERT and myc-rKOPr were pre-treated 
with KOPr agonists (U50488H, Sal A and DS1; 10 µM each) for 30 min and ASP+ 
accumulation was recorded for 5 min. The quantification of ASP+ fluorescence was 
measured as arbitrary fluorescence units (AFU). Figures indicates Mean (+SEM) 
AFU’s. ***P<0.001, one-way ANOVA followed by Dunnet multiple comparison test. b) 
Symbols indicate the amount of GFP-hSERT expression measured in AFU’s for cells 
selected for ASP+ uptake analysis. One-way ANOVA followed by Dunnet multiple 
comparison tests. Numbers in parentheses indicate sample size.  
 
 
 
139 | P a g e  
 
3.4. Summary of results.  
Tab. 3.2. Control experiments to determine selectivity of KOPr agonists in 
attenuating reinstatement  
Compounds 
tested 
Cocaine induced hyperactivity in 
self-administering rats (motor 
suppression during reinstatement 
test) 
Sucrose reinforcement 
test (effect on operant 
responding for natural 
reward) 
Sal A No effect No effect 
DS1 Non-significant trend to decrease  No effect 
MOM Sal B No effect Significant attenuation 
Nalmefene Non-significant trend to increase No effect 
 
Tab. 3.3. Adverse effect profile of novel KOPr agonists 
Compounds 
 tested 
Motor function 
(spontaneous open field 
activity) 
Aversion 
(CTA) 
Depressive 
behaviours (FST) 
(Cocaine exposed and 
drug naive rats) 
Sal A  No effect No effect Inceased immobility 
DS1  No effect No effect Inceased immobility 
MOM Sal B No effect - - 
Nalmefene Significant suppression No effect Inceased immobility 
 
Tab. 3.4. Effect of FLX pre-treatment on KOPr agonist induced 
enhanced immobility in FST 
Compound tested Effect on depressive behaviour 
Sal A Improved  
DS1 Improved 
 
Tab. 3.5. Effect on  SERT modulation by traditional and novel KOPr 
agonists by using live cell ASP+ uptake.   
Compound tested Effect on ASP+ uptake 
U50488H Decreased 
Sal A No effect 
DS1 No effect 
 
 
140 | P a g e  
 
3.5. Discussion 
In Chapter 2 we showed that a single injection of either Sal A, DS1, MOM Sal B 
or nalmefene attenuated cocaine prime induced reinstatement. In the present chapter we 
evaluated whether this attenuation in cocaine seeking behaviour was selective to 
reinstatement. We tested this by measuring cocaine induced hyperactivity (in cocaine 
self-administering rats) and disruption of responding for palatable reinforcements 
(sucrose reinforcement). We also performed studies to determine if side effects such as 
sedation, aversion and depressive like behaviour resulted following acute administration 
of novel KOPr agonists. Initially FST experiments were performed using animals with 
history of cocaine self-administration (Tab. 3.1). These pilot studies were necessary to 
develop this paradigm in our laboratory and to obtain permission from the Animal 
Ethics Committee to test the effect of KOPr compounds (Sal A, DS1, nalmefene) in 
drug naive rats. In order to determine a possible mechanism for the depressive like 
effects of KOPr agonist treatment, the effect of blocking SERT on KOPr agonists 
induced depressive behaviours was tested using FLX in rats. Additionally, the effect of 
SERT modulation by KOPr agonists was tested in vitro by using live cell ASP+ uptake 
assay.   
The results from the present study indicate that acute exposure to Sal A (0.3 
mg/kg), DS1 (0.3 mg/kg; Fig 3.2a), MOM Sal B (0.3 mg/kg; Fig 3.2c) or nalmefene 
(0.3 mg/kg; Fig. 3.2d) did not produce any statistically significant motor suppression 
during the reinstatement test. However, on closer inspection, DS1 (0.3 mg/kg) exposure 
showed a non-significant trend towards a decrease in motor function (Fig 3.2b). Results 
from Chapter 2 indicate that DS1 pre-treatment significantly attenuated acute cocaine-
induced hyperactivity in rats (Tab 2.4). The observed difference in DS1’s ability to 
modulate cocaine-induced locomotion might be attributed to the multiple cocaine 
exposures as animals used in this study previously self-administered cocaine (Section 
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3.2.5.1). Drug naive animals were used for experiments outlined in Chapter 2 (Section 
2.2.4.2 A). Acute nalmefene injections, on the other hand, showed a non-significant 
trend towards an increase in motor function (Fig 3.2d). Acute exposure to Sal A, DS1 or 
nalmefene, at doses that successfully attenuated cocaine seeking, did not suppress 
sucrose reinforcement (Fig. 3.3). In contrast, MOM Sal B significantly suppressed 
sucrose reinforcements (Fig. 3.3c). These results indicate that Sal A (Morani et al., 2009) 
and an analogue with similar potency at KOPr (DS1), attenuated cocaine prime induced 
drug-seeking behaviour without reducing sucrose reinforcements. This however cannot 
be said for the more potent and longer acting Sal A analogue, MOM Sal B (Tab 3.2).   
Previous studies by June and colleagues (1998), showed that nalmefene pre-
treatment attenuated ethanol-maintained operant lever press responding without 
affecting saccharin reinforcement. Their study also showed that the efficacy of 
nalmefene was dependent on the route of administration (sc > oral route) and pre-
treatment time (15 min prior to the commencement of tests). Injections of nalmefene 
bilaterally into the NAc (1.0, 10 µg) and VTA (10 µg) also attenuated ethanol induced 
responding without affecting saccharin reinforcement (June et al., 2003). However, 
infusing a higher dose (40 µg) of nalmefene bilaterally into both the VTA and NAc 
suppressed ethanol and saccharin reinforcement. These findings indicate a dose related 
effect produced by nalmefene in selectively attenuating alcohol self-administration 
(June et al., 2003). Since the dose of nalmefene tested in this current study (0.3 mg/kg) 
attenuated cocaine induced reinstatement without suppressing sucrose reinforcements, 
this effect produced by nalmefene on cocaine seeking behaviour (Chapter 2) was 
deemed to be selective for cocaine (Tab 3.2).   
The effects of a single injection of Sal A (0.3 mg/kg), DS1 (0.3 mg/kg), MOM 
Sal B (0.3 mg/kg) and nalmefene (0.3 mg/kg) on spontaneous open field activity in rats 
were determined. Our results indicate that acute injections of Sal A, MOM Sal B and 
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DS1 did not suppress spontaneous open field activity in rats (Fig. 3.4). These results 
show that attenuation of both cocaine induced behavioural sensitization by Sal A and 
DS1 (Chapter 2) and cocaine induced hyperactivity by DS1 in drug naive rats (Chapter 
2) was a not due to motor suppression caused by Sal A and DS1 pre-treatment. 
Furthermore, previous reports have shown that acute exposure to Sal A did not suppress 
open field activity in rats (Hooker et al., 2009a; Carlezon et al., 2006). Similarly, MOM 
Sal B exposure did not produce motor suppression in rats (Wang et al., 2008).These 
published reports support our findings in the current study.  
A single injection of nalmefene, however significantly suppressed motor 
function in the drug naive rats (Fig. 3.4d). Since, nalmefene pre-treatment did not 
decrease cocaine induced hyperactivity during reinstatement tests, an observable 
difference in motor function induced by nalmefene exposure might be attributed to the 
prior cocaine exposure in self-administering rats (Tab. 3.3). Additionally, as all 
compounds tested having selective affinity for KOPr (Sal A, DS1, MOM Sal B) did not 
produce locomotor suppression; a possible role of MOPr antagonism might be 
implicated in nalmefene produced motor suppression in drug naive rats. Further studies 
are required to explain this. On close observation, animals treated with 75% DMSO (Fig 
3.4a, 3.4b, 3.4c) showed less locomotor activity compared to rats treated with 0.9% 
saline (Fig 3.4d). As nalmefene treated animals produced approximately similar 
ambulatory counts compared to the other KOPr compounds tested (Sal A, DS1, MOM 
Sal B, Fig 3.4); the suppression in motor function produced by nalmefene in the 
spontaneous locomotion test may reflect a floor effect.          
In order to evaluate the aversive behaviours produced by acute exposure to novel 
KOPr agonists, a conditioned taste aversion model was used. Our results indicated that 
Sal A (0.3 mg/kg) and nalmefene (0.3 mg/kg) when paired with the novel tasting 
saccharin solution, did not induce aversive effects in rats (Fig. 3.5a, 3.5c; Tab. 3.3). 
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However, Sal A treated rats showed a non-significant trend to increase saccharin 
drinking on the test day compared to pairing day (Fig 3.5a). Rats paired with DS1 
showed a significant increase in saccharin consumption on test day when compared to 
pairing day (Fig 3.5b; Tab 3.3). Previous reports suggest that Sal A at low doses 
produce a preference for conditioned behaviours in rats and zebrafish (Braida et al., 
2007; 2008). The preference for a novel tasting saccharin solution produced by low 
dose of Sal A (0.3 mg/kg) and DS1 (0.3 mg/kg) may be a dose related effect. One aim 
of this study was to determine if the dose of KOPr agonist that successfuly attenuated 
drug-seeking had aversive properties. We measured this by using a taste aversion model 
and showed that acute exposure to all three KOPr compounds did not produce CTA 
(Tab 3.3). However, detailed studies are required to compare and contrast the aversive 
properties of different dose of Sal A, DS1 and nalmefene with standard aversive agent 
such as lithium chloride (Taraschenko et al., 2010). Such studies have the potential to 
further characterize the aversive properties of these KOPr compounds.    
Recent studies have shown that systemic administration of Sal A (2.0 mg/kg) 
increases ICSS threshold in rats and decreases phasic DA release in the NAc (Ebnar et 
al., 2010). This same study also showed that Sal A (2 mg/kg) also significantly 
decreased sucrose reinforcements using both FR-5 schedule and progressive ratios 
schedule of reinforcement (Ebnar et al., 2010). In contrast, a lower dose of Sal A (0.25 
mg/kg) did not modulate ICSS thresholds, alter sucrose reinforcement or decrease 
phasic DA release in NAc (Ebnar et al., 2010). Moreover, results from our current study 
indicate that Sal A at comparatively lower doses (0.3 and 1.0 mg/kg) did not suppress 
sucrose reinforcement using a FR-5 schedule of reinforcement (Morani et al., 2009). 
The ip route of administration for Sal A and the vehicle control (75% DMSO) in this 
study were comparable to those used by Ebnar et al, (2010), indicating that Sal A 
induced aversive effects might be dose related. Similarly, Sal A at higher dose produced 
144 | P a g e  
 
place aversion in C57BL/6J mice (1.0, 3.2 mg/kg; Zhang et al., 2005), zebrafish (80 
µg/kg; Braida et al., 2007) and Wistar rats (160 µg/kg; Braida et al., 2008). Therefore, 
Sal A (0.3 mg/kg) produces anti-cocaine effects without producing aversion, motor 
suppression or anhedonia in rats (Morani et al., 2009).   
Our initial studies investigating the depressive like effects produced by KOPr 
compounds were performed on rats with a previous history of cocaine self-
administration. These results showed that Sal A (0.3 mg/kg), DS1 (0.3 mg/kg) and 
nalmefene (0.3 mg/kg) significantly increased immobility time in the FST (Fig. 3.6). 
These preliminary findings led to the subsequent FST studies in drug naive rats, which 
showed that all the KOPr compounds tested also produced pro-depressive behaviours 
(Fig. 3.7; Tab. 3.3).  
Depression induced by Sal A and DS1 might not be due to suppression in motor 
function, as single exposure to either compound (0.3 mg/kg) had no effect on 
spontaneous open field activity (Tab 3.3). However, treatment with nalmefene (0.3 
mg/kg) induced sedation, as shown by the results from spontaneous locomotion test (Fig 
3.4d). Therefore, the depressive effects produced by nalmefene in drug naive rats might 
not be specific. However, nalmefene has been shown to stimulate the hypothalamic 
pituitary adrenal axis, which might explain the depressive effects observed in this 
current study (Geer et al., 2005). Since depression is one of the limiting factors in 
developing selective KOPr agonists as anti-addiction pharmacotherapies, future studies 
with nalmefene may help to address wether this behavioural profile is more likely 
induced by mixed KOPr ligands compared to selective KOPr agonists.          
Previous reports have shown that Sal A produces both anti-depressant (Braida et 
al., 2008; 2009) and pro-depressive effects (Carlezon et al., 2006) in rats using the FST 
paradigm. The present study determined whether an acute injection of Sal A (0.3 mg/kg) 
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at a dose which attenuated cocaine seeking (Chapter 2) produced depressive effects or 
not. The results from this study suggest that acute exposure to Sal A (0.3 mg/kg) 
produces pro-depressive behaviour without suppressing spontaneous locomotion (Fig. 
3.7a; Fig. 3.3a). These results are in agreement with the findings of Carlezon et al., 
(2006) which showed that pre-treating rats with Sal A, dose dependently (0.25 – 2.0 
mg/kg) produced pro-depressive effects without suppressing their open field locomotion 
activity. The difference in the experimental design of this study was that Carlezon and 
colleagues, (2006) had pre-treated rats with Sal A, thrice, at 30 min, 19 hr and 23 hr 
post habituation, whereas, in our study, animals received a single injection of Sal A, 5 
min prior to the FST. In contrast to these findings, Braida et al., (2009) showed that 
acute Sal A up to 1 mg/kg produced anti-depressant effects in rats using FST paradigm. 
The observable dissimilarities may be attributed to the difference in; route of 
administration for Sal A (i.p. current study, Carlezon et al., 2006 vs. s.c. Braida et al., 
2009); time of Sal A pre-treatment (5 min, current study vs. 20 min Braida et al., 2009), 
and vehicle used to suspend Sal A (75% DMSO, current study, Carlezon et al., 2006 vs. 
1:1:8, Ethanol: Tween 80: Water, Braida et al., 2009).  
  From the present findings, it was interesting to note that in drug naive rats, Sal A 
significantly decreased climbing time and swimming time, whereas DS1 significantly 
reduced time spent swimming, although a trend to decrease climbing behaviour was 
also noted (Fig 3.7a, 3.7b). In contrast nalmefene only decreased swimming time 
without any effect on climbing behaviour. Carlezon et al. (2006) also showed that Sal A 
decreased swimming time during the FST. A decrease in climbing time is believed to 
relate to NET modulation, whereas SERT is implicated in a reduction in swimming time 
(Detke et al., 1995). Taken together, these findings implicate a possible involvement of 
SERT and NET in depressive-like behaviours induced by Sal A and DS1 in the FST and 
only SERT in nalmefene induced depression. Further studies are required to clarify this.    
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In order to determine if Sal A and DS1 modulate depressive behaviour via SERT 
modulation, we measured depressive behaviours following SERT antagonist (FLX) pre-
treatment followed by Sal A, DS1 or vehicle. Previous studies have shown that pre-
treating rats with FLX (5, 10, 20 mg/kg, sc), 30 min, 19 hr and 23 hr post FST 
habituation induces anti-depressant effects using the FST model (Detke et al., 1995). In 
this present study, a low dose of FLX (5 mg/kg) that has been shown previously to have 
anti-depressant effects in the FST was used (Detke et al., 1995). The results from our 
study show that pre-treating rats with the minimum effective dose of FLX significantly 
improved Sal A (Fig 3.8a) and DS1 (Fig 3.8b) induced depressive behaviours. This was 
noted by a reduction in immobility times and enhancement in time spent climbing with 
both Sal A and DS1. Additionally, a non-significant increase in swimming time was 
observed for saline/Sal A vs. FLX/Sal A and saline/DS1 vs FLX/DS1 treated animals 
(Fig 3.8). Thus sub-chronic FLX treatment reduced depressive behaviours produced by 
KOPr agonists (Tab. 3.4).  
Exposure to FLX (1- 20 mg/kg) dose dependently increases 5HT levels in 
raphae nucleus, ventral hippocampus and frontal cortex when measured using in vivo 
microdialysis (Malagie et al., 1995). As mentioned earlier, KOPr activation has been 
shown to decrease 5HT levels in brain regions implicated in depressive behaviours (Tao 
and Auerbach, 2005; Yilmaz et al., 2006). Therefore, modulating 5HT levels by FLX 
pre-exposure might be responsible for the observable improvement in KOPr agonist 
induced depression in FST. An increase in phosphorylated CREB levels in the NAc 
shell has been implicated in depressive like behaviours in the FST (Plaikas et al., 2001). 
Moreover, KOPr activation increases CREB phosphorylation in NAc, which is 
antagonised by FLX, desimipramine (NET inhibitor) and KOPr antagonists (Carlezon et 
al., 1998; Mague et al., 2003; Chartoff et al., 2009). Therefore, decreased CREB 
activation by FLX pre-treatment may be responsible for diminishing KOPr agonists’ 
147 | P a g e  
 
induced depressive-like behaviours. Detailed studies on this will help us to better 
understand the mechanisms underlying depressive effects produced by novel KOPr 
agonists. 
The model of FST described by Porsolt et al., (1979) has been used to 
pharmacologically evaluate anti-depressants (Castagne et al., 2010). In 1995, Detke and 
colleagues modified the FST apparatus and analysis of the forced swimming behaviours 
to enhance the efficiency of the paradigm to evaluate anti-depressants (see Detke et al., 
1995). As FST has been previously been applied to measure depressive effects produced 
by KOPr agonists (Pliakas et al., 2001; Mague et al., 2003; Carlezon et al., 2006), we 
also used this model to measure KOPr agonist induced behavioural despair in this 
current study. However, the use of FST as a model to evaluate behavioural despair has 
its limitations (Borsini and Meli, 1988; Castagne et al., 2010). The major limitation with 
FST is that the immobility behaviour might be due to the animal getting adjusted to the 
swimming conditions rather than actual behavioural despair, which might lead to false 
result interpretation (Borsini and Meli, 1988; Castagne et al., 2010). Therefore future 
studies with Sal A, DS1 and nalmefene are needed to evaluate their effects in inducing 
anhedonia and behavioural despair. Such experiments have been mentioned in detail in 
Chapter 4.  
Due to the behavioural results with FLX to improve Sal A and DS1 induced 
depressive behaviours in FST, we conducted preliminary experiments to determine if 
KOPr directly modulates SERT protein. To do this we used an in vitro cell model. Cells 
were treated to transiently express GFP-hSERT and myc-rKOPr, followed by treatment 
with traditional (U50488H) and novel (Sal A and DS1) KOPr agonist’s, and SERT 
function was measured in real-time.   
Control experiments were performed to validate that ASP+ uptake is dependent 
on the level of GFP-hSERT expression in single cells (Fig. 3.9a). The amount of ASP+ 
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accumulated by non-transfected cells was significantly lower than the uptake shown by 
transfected cells (Fig. 3.9b). These findings are in accordance with the recently 
published findings by Oz et al., (2010). The results from the current study also indicate 
that a 30 min pre-incubation with the novel KOPr agonists Sal A (10 µM) and DS1 (10 
µM) did not have any significant effect on modulating SERT function using the ASP+ 
accumulation assay in single cells (Fig. 3.10a). However, pre-incubating cells with the 
classic KOPr agonist, U50488H (10 µM for 30 min) significantly attenuated ASP+ 
uptake (Fig. 3.10a). This effect produced by the KOPr agonist was a SERT-selective 
effect as ASP+ accumulation was dependent on SERT expression levels (Fig. 3.9a) and 
no significant difference in GFP-hSERT expression levels were observed in cells 
selected from each treatment group (Fig. 3.10b). This, to the best of our knowledge, is 
the first study to determine the effect of KOPr agonist in modulating SERT function in 
vitro. However, as acute KOPr agonists show anti-addiction properties (Chapter 2) with 
depression as an adverse effect (Chapter 3), understanding the effect of acute exposure 
to KOPr agonists on modulating SERT function is necessary to confirm and quantify 
the findings from the present study. Also, such study has the potential to flesh out the 
role of SERT modulation in KOPr agonists produced depression.      
In this study, we captured the image of the whole cell SERT which included the 
amount of SERT expressed on the cell surface and within the cell. Also, the initial 
SERT measurements were recorded after KOPr compounds/vehicle incubations. The 
ASP+ uptake has been shown to be mediated by the SERT expression levels on the cell 
surface (Oz et al., 2010; Schwartz et al., 2003). Thus, in this present experiment we 
cannot measure the effect on ASP+ accumulation due to transporter internalization 
which might have occurred due to KOPr agonist pre-treatment. In order to quantify the 
amount of ASP+ accumulation due to SERT internalization, further imaging 
experiments are required. Such studies can help in differentiating the effect of chronic 
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vs. acute KOPr activation on modulating cell surface SERT expression and transporter 
internalization.  
Previous studies have shown that Sal A has a greater affinity for KOPr than 
U50488H and U69593 and equal affinity compared to DYN (Chavkin et al., 2004). 
Furthermore, Sal A pre-treatment has been shown to produce 40 times less KOPr 
internalization than U50488H (Wang et al., 2005), whereas, another study indicated Sal 
A and U50488H produced internalization to a similar extent (Wang et al., 2008). Since, 
in this experiment, the KOPr agonists were pre-incubated for 30 min, KOPr may have 
been internalised after treatment with U50488H which may not have occurred with Sal 
A or DS1. Therefore, further studies are required to compare and contrast the effect of 
traditional and novel Sal A like KOPr agonists on KOPr internalization. Since acute 
KOPr activation has been shown to produce anti-addiction behaviours in pre-clinical 
models, it would be interesting to note the effects of acute activation of KOPr on SERT 
function and kinetics. This model (ASP+ uptake) can be used in future to study the effect 
of SERT modulation following acute exposure to novel and classical KOPr agonists. 
Such experiments may aid in the development of KOPr analogues that vary in their 
effects on SERT function. 
3.6. Summary and Conclusion 
 The results from sucrose-reinforced responding showed that Sal A, DS1 and 
nalmefene attenuated cocaine seeking behaviour in a selective manner (Chapter 2), 
whereas MOM Sal B attenuated cocaine seeking in a non-selective manner. Sal A and 
DS1 did not affect motor function or produce aversion, while nalmefene suppressed 
motor function without producing aversion in cocaine naive rats. All three KOPr 
agonists induced depressive behaviours. Furthermore, we provide preliminary evidence 
to suggest that the Sal A and DS1 induced depressive behaviours may involve negative 
modulation of 5HT systems which was attenuated by SERT antagonist. Further in vitro 
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studies exploring SERT modulation by KOPr agonists indicated a potential difference in 
modulation of SERT function by classical KOPr agonist U50488H and novel 
neoclerodane diterpenes Sal A and DS1.   
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Chapter 4. General Discussion 
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4.1. Endogenous KOPr systems and cocaine addiction 
As mentioned earlier (Chapter 1, Section 1.5), central KOPr are up-regulated by 
repeated cocaine exposures (Collins et al., 2002). During this initial hedonic stage of 
cocaine use, there is an increased sensitization of the midbrain dopamine system which 
has been shown to be attenuated by KOPr activation (Glick et al., 1996; Archer et al., 
1996). Also, studies by Chefer and colleagues (2005) have shown that KOPr gene 
deletion in mice increases DA levels and decreases DA re-uptake in the NAc. The same 
study also showed that KOPr knock-out mice remained in persistent cocaine sensitized 
state following a single cocaine injection (Chefer et al., 2005). Thus indicating that the 
KOPr systems might be implicated in controlling the dopaminergic effects produced by 
cocaine and activating KOPr could prevent the development and progression of cocaine 
addiction during the initial stages of the addiction cycle (Shippenberg et al., 2001; 2007; 
Mysels and Sullivan, 2009; Bruijnzeel, 2009; Fig 4.1).   
Withdrawl from drug use has been associated with increased CREB 
phosphorylation in the NAc and the production of depressive like symptoms in 
laboratory animals (Nestler and Carlezon, 2001). KOPr activation has also been shown 
to enhance CREB phosphorylation in the NAc (Pliakas et al., 2001). A decrease in DA 
levels in the NAc during abstinence from the drug use has also been reported (Weiss et 
al., 1992). KOPr agonists have been shown to produce stress and depressive like 
symptoms in laboratory animals (Carlezon et al., 1998; 2006; Mague et al., 2003). On 
the other hand, KOPr antagonism enhances extracellular DA levels and decreases 
phosphorylated CREB levels in the NAc (Mague et al., 2003; Plaikas et al., 2001; 
Spanagel et al., 1990). KOPr antagonists also produce anti-depressant like effects in 
pre-clinical models (Spanagel et al., 1992; Mague et al., 2003; Nestler and Carlezon, 
2006). Therefore, antagonizing KOPr signalling during the withdrawal stage of 
addiction cycle might be useful as replacement therapy to aid in preventing relapse to 
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drug use (Shippenberg et al., 2007; Prisinzano, 2008). As there are no current 
pharmacotherapies available for cocaine addiction, manipulating the endogeneous KOPr 
systems might be a novel mechanism towards finding the treatment for cocaine 
addiction (Shippenberg et al., 2007; Mysels and Sullivan, 2009; Bruijnzeel, 2009; Fig 
4.1). The present study addresses the first part of the problem, that is, developing safer 
KOPr agonists which could assist in breaking the addiction cycle with fewer KOPr 
agonists related adverse effects.   
Reinstatement of extinguished cocaine self-administration by the presentation of 
stressors (foot-shock, forced swim stress; Erb et al., 1996) has been used pre-clinically 
to screen the anti-addictive potential of KOPr antagonists (Beardsley et al., 2005; 2010). 
Additionally, reinstatement of cocaine via stressors requires prior KOPr activation as 
KOPr knockout mice were insensitive to stress-produced reinstatement (Mclaughlin et 
al., 2003; Redila and Chavkin, 2008). KOPr antagonist administration does not 
modulate cocaine prime induced drug-seeking in laboratory rats (Beardsley et al., 2005). 
Furthermore, data from Chapter 2 shows that nor-BNI pre-treatment completely 
reversed Sal A (Fig 2.2b), DS1 (Fig 2.6b) and nalmefene (Fig 2.11b) produced 
attenuation of cocaine prime induced reinstatement. KOPr activation has also been 
shown to potentiate stress induced reinstatement in mice (Redila and Chavkin, 2008). 
Taken together, these findings suggest that the reinstatement of extinguished cocaine-
seeking initiated by a priming injection of cocaine is attenuated by KOPr activation. In 
contrast, blocking KOPr signalling attenuates reinstatement of extinguished cocaine 
seeking initiated by presentation of environmental stressors. This effect might reflect a 
possible difference in the central neuronal circuit involved in drug prime vs. stress 
induced reinstatement (Kreibich and Blendy, 2004) and activating or deactivating KOPr 
systems may modulate these behaviours in an opposing manner (Schenk et al., 1999; 
Redila and Chavkin, 2008; Beardsley et al., 2005). Given the fact that both these 
154 | P a g e  
 
paradigms have been applied extensively to study cocaine reinstatement pre-clinically, 
they can also be used to evaluate the utility of KOPr agonists and antagonists as anti-
cocaine agents.  
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Fig.4.1. KOPr system modulation in addiction cycle 
KOPr activation antagonises cocaine produced hedonic state and therefore could prove 
useful in managing the progression of the addiction cycle. KOPr antagonists, on the 
other hand produce anti-depressive effects and therefore antagonising KOPr systems 
could be useful in preventing relapse.  
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4.2. Limitations of classical KOPr agonists: rationale for Salvinorin A 
screening. 
As described in Chapter 1 (section 1.5), the major limiting factor in developing 
synthetic KOPr agonists is the adverse effects associated with them (Prisinzano et al., 
2005; Shippenberg et al., 2007; Wee and Koob, 2010). KOPr activation also produces 
dysphoria and psychotomimetic effects in humans (Walsh et al., 2001b; Pfeiffer et al., 
1986). Salvia divinorum leaves have been used by the natives from Oaxaca, Mexico for 
the purpose of divination (Siebert et al., 1992; Ott, 1995; Valdes et al., 1994; 
Vorthermes and Roth, 2006). Also, its use as a recreational hallucinogen has recently 
gained widespread popularity among adolescents in the western countries (Vorthermes 
and Roth, 2006; Griffin et al., 2008; Kelly, 2011). With the discovery that Sal A 
produces its pharmacological effect via selectively binding and activating KOPr has 
opened new avenues in KOPr research (Roth et al., 2002; Prisinzano, 2005; Prisinzano 
et al., 2005; Pravett-Smith and Prisinzano, 2010). With this as a primary objective, 
several research groups have worked towards exploring the behavioural pharmacology 
of Sal A at KOPr (Carlezon et al., 2006; McCurdy et al., 2005; Fantagrossi et al., 2005; 
Zhang et al., 2005; Braida et al., 2007; 2008; 2009; Baker et al., 2009). However, few 
studies have aimed at comparing the anti-addiction pharmacology of Sal A to traditional 
KOPr agonists.  
Sal A has been shown to attenuate cocaine prime induced reinstatement and 
suppress cocaine induced hyperactivity in laboratory animals (Chartoff et al., 2008; 
Morani et al., 2009). We have shown in this study that the Sal A induced attenuation of 
cocaine reinstatement has no effect on either natural reward reinforcements or 
suppression of motor function (Morani et al., 2009). On the other hand, the classical 
KOPr agonists U50488H and spiradoline attenuated cocaine produced behaviours in a 
non-selective manner (Glick et al., 1995; Wadenberg, 2003). A study by Chavkin and 
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colleagues (2004) showed that Sal A had a similar efficacy for KOPr to DYN whereas; 
it was more potent than both U50488H and U69593. Also the same study showed that 
Sal A had more affinity for KOPr compared to U50488H and U69593 (Chavkin et al., 
2004). As Sal A has a different structure to traditional KOPr agonists (Fig 1.5), we 
hypothesized that Sal A might produce a better tolerated anti-addiction profile 
compared to classical KOPr agonists. If so, then compounds based on the structure of 
Sal A possessing better pharmacokinetics could be developed as potential anti-addiction 
agents. With this as a central hypothesis of this thesis, initial preliminary screenings 
were designed for Sal A, its structural analogues and nalmefene (MOPr antagonist/ 
partial KOPr agonist) aimed at exploring their behavioural anti-addiction pharmacology. 
The behavioural screening was extended further to measure the adverse effect profile of 
these KOPr compounds.   
 
4.3. Pharmacological profiling of novel KOPr agonists.  
The behavioural experiments used to screen Sal A, its analogues and nalmefene 
is shown in Fig 4.2. The initial aim of this thesis was to determine if Sal A, its structural 
analogues (DS1, MOM Sal B, EOM Sal B, herkinorin) and nalmefene produced anti-
addiction behaviours in a similar way to traditional KOPr agonists. This was done using 
the cocaine prime-induced within reinstatement model (Fig 4.2). This model was 
initially reported by Worley et al, (1994) and has been used previously to screen 
traditional KOPr agonists for anti-addiction effects (Schenk et al., 1999; 2000; Morani 
et al., 2009). Our results show that Sal A (0.3, 1.0 mg/kg), DS1 (0.3, 1.0 mg/kg), MOM 
Sal B (0.3 mg/kg) and nalmefene (0.3, 1.0 mg/kg) all significantly attenuate cocaine 
prime induced drug seeking (Tab 4.1).  
Once these compounds were shown to attenuate cocaine-seeking, the next step 
was to determine the selectivity in attenuation of cocaine-seeking behaviour.  To do this 
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we determined if sedative effects occurred. Motor function was determined by 
measuring cocaine produced hyperactivity in animals self-administering cocaine and the 
suppression of natural reward seeking behaviour was measured using the sucrose 
reinforcement test (Morani et al., 2009; Fig 4.2). Our results show that none of the 
compounds tested (Sal A, DS1, MOM Sal B, nalmefene) produced motor suppression 
during the reinstatement tests (Tab 4.1). Also, Sal A, DS1 and nalmefene pre-treatment 
did not suppress sucrose reinforcement. However MOM Sal B did decrease sucrose 
reinforcement (Tab 4.1). These results showed us that Sal A, DS1 and nalmefene 
induced attenuation of cocaine-seeking behaviour in a selective manner.   
The compounds which selectively attenuated cocaine seeking behaviour were 
further tested for their pharmacological activation of KOPr in attenuating cocaine 
seeking Our results showed that Sal A, DS1 and nalmefene induced attenuation of 
cocaine-seeking were mediated via KOPr activation (Tab 4.1) and this effect was 
prevented when KOPr activation was blocked by selective KOPr antagonist nor-BNI 
(Fig 4.2).  
These KOPr compounds were also tested for their behavioural adverse effects. 
Since KOPr agonists have been shown to cause aversion, motor suppression and 
depressive effects, we applied CTA, spontaneous open field activity and FST 
respectively to test these behaviours (Fig 4.2). Sal A and DS1 pre-treatment did not 
suppress motor function or produce taste aversions (Tab 4.1). Although, nalmefene did 
not produce taste aversions, it significantly suppressed motor function (Tab 4.1). 
However, all three compounds produced depressive like effects in FST (Tab 4.1). These 
data showed that Sal A and DS1 showed better adverse effect profile than nalmefene. 
The effect of blocking SERT on Sal A and DS1 induced depressive behaviour in 
FST was also assessed (Fig 4.2). SERT antagonism via sub-chronic FLX treatment 
significantly improved Sal A and DS1 induced depressive effects in the FST (Tab 4.1). 
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To further quantify the effect of Sal A, DS1 and U50488H on modulating SERT 
function, we used in vitro ASP+ uptake paradigm in cells (Fig 4.2). Sal A and DS1 had 
no effect on SERT function, whereas U50488H pre-treatment decreased SERT function. 
This indicates a potential difference in the modulation of SERT function by classical 
and Sal A like KOPr agonists (Fig 4.2; Tab 4.1). However further studied are needed to 
clarify this possibility. 
The effects of Sal A and DS1 were also tested for cocaine produced locomotion 
(acute, behavioural sensitization and stereotypy) to further characterize the behavioural 
effects of these compounds (Fig 4.2). Acute DS1 pre-treatment suppressed the 
expression of cocaine behavioural sensitization and locomotion activity following acute 
cocaine exposure (Tab 4.1). Although, Sal A attenuated cocaine sensitization, it 
potentiated motor function induced by acute cocaine (Tab 4.1). Overall, from this 
pharmacological profiling, we fleshed out three lead compounds Sal A, DS1 and 
nalmefene which can be further characterized for their anti-addiction effects.   
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Fig 4.2. Pharmacological profiling of novel KOPr agonists. 
Novel KOPr agonists were initially screened for their anti-cocaine profile followed by 
their selectivity in attenuation of cocaine-seeking. The compounds were further tested 
for their behavioural adverse effects. KOPr agonists Sal A and DS1 were also tested for 
their role in modulating serotonin transporter function and cocaine produced 
locomotion activity.    
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Tab 4.1. Pharmacological screening of KOPr agonists  
Sal A DS1 MOM 
Sal B
EOM 
Sal B
Herkinorin Nalmefene
ANTI-ADDICTION 
PROFILE
Cocaine induced 
reinstatement
NE NE
Motor suppression  during 
reinstatement test.
NE NE NE - - NE
Sucrose reinforcements NE NE - - NE
Cocaine induced 
hyperactivity
Behavioural Sensitization
ADVERSE EFFECT 
PROFILE
Motor function NE NE NE - -
Taste aversion NE CTP - - NE
Immobility time in FST - - -
Effect of FLX pre-
treatment on immobility 
Effect on ASP+ 
accumulation 
NE NE
 
        -  attenuates/suppresses;     - potentiates/ produces; NE - no effect 
Effect of KOPr agonists were tested for their anti-addiction profile and side effect 
profile. KOPr agonists Sal A and DS1, having similar affinity for KOPr produced 
similar behavioural anti-addiction profile and adverse effect profile. More potent and 
long lasting Sal A analogue, MOM Sal B produced anti-addiction behaviour but also 
produced anhedonia. Mixed KOPr compound herkinorin had no effect on cocaine 
induced reinstatement. MOPr antagonist/ partial KOPr agonist, nalmefene produced 
anti-addiction behaviours without producing anhedonia and aversion. However, 
nalmefene produced motor suppression and depressive effects when tested in drug naive 
rats.   
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4.4. Significance of current results 
In Tab 4.2, we compare the binding affinity and efficacy at KOPr (and MOPr for 
nalmefene and herkinorin) with the KOPr compounds ability to attenuate cocaine 
seeking behaviours. Both Sal A and DS1 which have a similar affinity for- and potency 
at- KOPr successfully attenuated cocaine seeking behaviour in a selective manner (Tab 
4.2). The dose at which both these compounds attenuated cocaine reinstatement was 
also similar (0.3, 1.0 mg/kg). However, longer acting and more potent Sal A analogues 
such as EOM Sal B and MOM Sal B were ineffective in modulating cocaine seeking 
behaviour in a desirable manner. At 0.3 mg/kg dose, EOM Sal B showed a trend to 
increase responding which was an opposite effect to Sal A. Although, MOM Sal B 
attenuated cocaine-seeking at 0.3 mg/kg dose, this effect was non selective as it also 
suppressed natural reward. Therefore, the ability of neoclerodane diterpene KOPr 
agonists to selectively modulate cocaine induced behaviour may be dependent on the 
KOPr potency of these compounds.  
It has been hypothesized that KOPr ligands with mixed affinity for other opioid 
receptors have the potential to be developed as anti-addiction pharmacotherapies 
(Stevenson et al., 2004; Archer et al., 1996; Bart et al., 2005; Kreek et al., 2005). With 
this in mind we performed an initial preliminary screening of nalmefene (MOPr 
antagonist/partial KOPr agonist) and herkinorin (MOPr/KOPr agonist) using cocaine 
prime induced drug seeking model. Acute nalmefene attenuated cocaine induced 
reinstatement in rats without suppressing sucrose reinforcements or producing taste 
aversion. Nalmefene has shown to bind with higher affinity to KOPr than MOPr and is 
an antagonist at MOPr (Bart et al., 2005; Tab 4.2). The endogeneous MOPr and KOPr 
activation produces opposing tonic effects (Pan, 1998). Additionally, as mentioned in 
Chapter 1 (Section 1.6), KOPr agonists and MOPr antagonists attenuated MOPr 
agonist-induced rewarding behaviours and -increase in DA levels in the NAc (Spanagel 
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et al., 1992). Therefore, nalmefene may have an application in modulating the 
progression and development of cocaine addiction.  
Considerable evidence supports the idea for the development of compounds that 
reverse the decrease in central monoamine activity as they are have potential abilities in 
preventing relapse following withdrawal from chronic drug use. Ideally by activating 
DA and 5HT receptors (Gorelick et al., 2004; Grabowski et al., 2004; Karila et al., 2008; 
Rothman et al., 2008). However, serious adverse effects associated with agonists at 
monoamine transporters have also opposed this theory (Mello and Negus, 2000). 
Developing agents which indirectly modulate monoaminergic systems may decrease the 
adverse effects associated with direct monoaminergic activators (Mello and Negus, 
2000; Lin et al., 2010). We show in this study that acute herkinorin treatment has no 
effect on cocaine-seeking (Tab 4.1). Although a higher dose of herkinorin (0.3, 1.0 
mg/kg) showed a trend to suppress responses in a non-significant manner (Tab 4.2). As 
herkinorin binds with greater affinity to MOPr than KOPr and is an agonist at both the 
opioid receptors (Tidgewell et al., 2006; Tab 4.2), it has potential to be developed as a 
maintenance therapy that may prevent relapse. Thus, both nalmefene and herkinorin 
could potentially have an application as anti-addictives but at different stages of the 
addiction cycle. Further studies, are needed to test this hypothesis.  
KOPr activation is associated with aversive and depressive effects (Carlezon et 
al., 1998; 2006; Todtenkopff et al., 2004; Mague et al., 2003; Ebnar et al., 2010) and the 
current results support this (Chapter 3; Tab 4.2). All three compounds tested showed 
depressive behaviours in drug naïve as well as cocaine exposed animals (Tab 3.3). The 
cocaine exposed animals were however abstinent from cocaine for a longer period of 
time (Tab 3.1). Abstinence from cocaine use has been shown to produce 
neuroadaptations which results in depressive behaviours (Carlezon et al., 1998; Nestler 
and Carlezon, 2006). Therefore, it might be possible that the depressive effects 
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produced in cocaine self-administering animals might be an additive effect of cocaine 
abstinence and KOPr activation. As KOPr agonists are proposed to break the hedonic 
stage of addiction cycle (Shippenberg et al., 2007; Mysels and Sullivan, 2009). A 
detailed study is required to evaluate the depressive effects produced by acute KOPr 
exposure in self-administering rats which have not been subjected to any abstinence or 
withdrawal. In the present thesis, FLX pre-treatment attenuated the time spent immobile 
in animals exposed to Sal A and DS1. This finding has the potential to reduce the 
depressive effects produced by KOPr agonists when used to break the addiction cycle. 
Moreover, recent findings suggest that FLX (3, 10 mg/kg) attenuates cue-induced and 
cocaine prime induced reinstatement in rats self-administering cocaine (Burmeister et 
al., 2003). Therefore, it would be interesting to determine the effect of co-administration 
of KOPr agonists with FLX on cocaine prime induced reinstatement and self-
administration. It would also be interesting to see if this proposed combination of 
treatments modulates central monoamine neurotransmission. This study may identify 
potential solution to the depressive side-effects associated with the use of KOPr 
agonists as anti-addiction pharmacotherapies.  
Initial ASP+ uptake experiments identify a potential difference in the modulation 
of SERT by classical- and neoclerodane diterpene-KOPr agonists (Tab 4.1). Therefore, 
detailed studies are required to explain the role of the 5HT system modulation by 
classical and novel KOPr agonists and associate them to the observed depressive 
behaviours. Such studies could utilise in vitro models to allow manipulation of 
signalling systems and proteins.   
In conclusion, this study has identified Sal A, DS1 and nalmefene as lead 
compounds which can be further characterized for their anti-addiction profile. 
Furthermore, Sal A and DS1 attenuated cocaine behavioural sensitization. One of the 
aims of this thesis was to identify if any longer-acting structural analogues of Sal A 
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could retain anti-addiction effects with fewer adverse effects. Our findings indicate that 
DS1 may be such an analogue. The favourable results with Sal A, DS1 and nalmefene 
from this thesis encourages a detailed behavioural profiling for their anti-addiction- and 
adverse-effects. Moreover, this study has utilised several experimental models to 
pharmacologically screen KOPr compounds for their anti-addiction behaviour. Using 
these preliminary experiments (Fig 4.2), we aim to screen more novel analogues for 
their anti-addiction pharmacology. This line of research has the potential to identify 
novel neoclerodane diterpenes as possible leads for the development of 
pharmacotherapies to treat psychostimulant addiction. 
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Tab 4.2. Binding affinities and efficacy for KOPr and its effect on 
cocaine seeking behaviour.   
Compound Binding 
affinity at 
KOPr Ki 
(nM) 
Binding 
affinity at 
MOPr Ki 
(nM) 
Potency 
 at KOPr 
EC50 
(nM)  
Potency 
at MOPr 
(nM)  
 
Cocaine seeking 
behaviour dose 
(mgkg) 
Salvinorin A 2.4 ± 0.4b  
1.9 ± 0.2a 
>10000 1.8 ± 0.5c 
40 ± 10d 
 0.3, 1.0 (selective 
attenuation) 
DS-1 2.3 ± 0.1 a 6820 ± 660a 30 ± 5d  0.3, 1.0 (selective 
attenuation) 
Nalmefene 0.083 ± 
0.0008 b  
 
0.24±0.006b  
 
EC50 = 
4.2±1.6c 
IC50 = 
18±1.0c   
IC50 = 
13±2.3c  
 
0.3, 1.0 (selective 
attenuation) 
EOM Sal B 0.32 ± 0.02b ND 0.14 ± 0.01c  0.03 (no effect); 0.1, 
0.03 (trend to 
increase responding) 
MOM Sal B 0.6 ± 0.07b ND 0.40 ± 0.04c  0.03, 0.1 (trend to 
increase responding) 
0.3 (non-selective 
attenuation)  
Herkinorin 90 ± 2 a 12.1 ± 1a 1320±150d  0.3, 1.0 (non-
significant trend to 
decrease responding)  
 
aData expressed as ± SD; bData expressed as ± SEM; ND= not defined.cEnhancement of 
[35S]GTP γS binding to Chinesse Hamster Ovary - human KOPr; EC50 ± SEM  (nM). 
d[35S]GTP γS functional assay carried out in stably transfected Chinesse Hamster Ovary cells 
containing DNA for human KOPr ;EC50 ± SD nM. Data for Sal A, DS1 and herkinorin, 
modified from Harding et al., 2005; data for MOM Sal B , EOM Sal B, modified from Munro et 
al., 2008; data for nalmefene modified from Bart et al., 2005.    
 
 
 
 
 
 
 
167 | P a g e  
 
4.5. Future directions 
 Results obtained from this thesis have opened new avenues to further quantify 
the behavioural anti-addiction and side effect profiles for the lead compounds Sal A, 
DS1 and nalmefene. Additionally, there is a need to determine the mechanisms by 
which these compounds produced their anti-addiction and depressive behaviours. The 
following section gives a brief description of future possible studies with these 
compounds.   
Effect of KOPr agonists in models of cocaine self-administration and reinstatement. 
As discussed in Chapter 2 (Section 2.5, discussion), there is a need to test the 
lead KOPr compounds using models which show a well defined set of alterations in 
neuronal adaptations seen in pre-clinical studies (Self et al., 2004). To do this additional 
studies will be required to test the effects of Sal A, DS1 and nalmefene on cocaine 
prime induced reinstatement following extended extinction times or utilising a between-
sessions reinstatement paradigm (Stretch et al., 1971; Ferragud et al., 2009). Keeping in 
mind the rationale for using KOPr agonists as cessation agents for cocaine self-
administration, it would be imperative to test the effects of these lead compounds (Sal A, 
DS1 and nalmefene) on cocaine self-administration in animals’ stably self-
administering cocaine (Glick et al., 1996). Also, it would be interesting to observe the 
effects of these lead compounds on altering the monoamine transporter functions in 
animals self-administering cocaine. This can be achieved by measuring DAT and SERT 
function by using rotating disc electrode voltammetry (RDEV) in NAc and CPU brain 
regions. These tests would idealy be performed on animals following cocaine self-
administration and reinstatement tests.      
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Endogenous KOPr antagonism on cocaine prime induced reinstatement.  
As mentioned in Chapter 2 (Section 2.5, discussion), KOPr antagonism by nor-
BNI reversed KOPr agonists induced attenuation of drug seeking behaviour. However, 
the effect of KOPr antagonism by itself on cocaine-seeking was not performed. Ideally 
this can be measured by determining the effects of KOPr antagonism with traditional 
(nor-BNI, JDTic) and novel antagonists on cocaine-prime induced -within-session 
reinstatement and -reinstatement after prolonged period of abstinence in rats (Worley et 
al., 1994; Beardsley et al., 2005). Such experiments could prove useful, as KOPr 
antagonists are proposed as maintainence agents to prevent relapse (Section 4.1). Also, 
determining the DAT and SERT functions in NAc and CPU regions by using RDEV in 
animals subjected to the reinstatement tests could help explain the mechanism of the 
observed behaviours.   
Effect of KOPr antagonists on stressors induced cocaine seeking. 
As explained in Section 4.1, reinstatement of extinguished cocaine self-
administration by presentation of environmental stressors has been used for 
pharmacological evaluation of KOPr antagonists. Therefore, this paradigm could be 
useful in pharmacological screening of novel KOPr antagonists as agents to prevent 
relapse induced by stress. The reinstatement of cocaine-seeking could be initiated by the 
presentation of foot-shock stressors or forced swim stress in rats (Beardsley et al., 2005; 
McLaughlan et al., 2005a; 2005b). Also, determining the function of DAT and SERT in 
the NAc and CPU could help explain the mechanism of KOPr antagonists in this model. 
Such experiments could be performed using RDEV following reinstatement testing.  
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Effect of KOPr agonists on FST in cocaine self-administering animals.  
As mentioned earlier (Section 4.4), KOPr agonists have shown to produce 
depressive like symptoms (increased immobility time) in animals self-administering 
cocaine (Fig 3.6; Tab 3.3; Chapter 3). However, these rats were abstained from cocaine 
(Tab 3.1). Therefore, in order to quantify the depressive effects produced by KOPr 
activation, effects of Sal A, DS1 and nalmefene need to be measured using FST in 
cocaine self-administering animals which have not been subjected to any abstinence. In 
addition to the measurement of the behaviours, determining the DAT, SERT function in 
brain regions subjected to reward (dorsal and ventral striatum) could explain the 
mechanism of depressive effects following KOPr activation (Section 1.5.5.3; 1.5.5.4). 
These experiments could be performed using the RDEV technique.   
Effect of KOPr agonists on cocaine motor sensitization after prolonged abstinence. 
The results from this present study showed the efficacy of both Sal A and DS1 
to attenuate expression of locomotion sensitization when animals were challenged with 
the cocaine injection after a short period of abstinence (4 days). Previous reports suggest 
that expression of sensitization is a model which represents alteration in underlying 
neuronal circuits mediating psychomotor function and craving potential of the 
psychostimulants (Stekette, 2005; Robinson and Berridge, 2000; 2003; 2008). Also, 
challenging sensitized animals with a low dose of cocaine even after a long period of 
abstinence has shown to express locomotor sensitization (Heidbreder et al., 1995). 
Therefore, it would be interesting to test the effect of Sal A and DS1 on expression of 
sensitization after a prolonged period of abstinence (15, 30, 45 days). Additionally, the 
DAT and SERT function in NAc and CPU could be determined in these sensitized 
animals using RDEV. This experiment has the potential to provide evidence to link the 
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alteration induced by KOPr agonists in the monoamine transporter function at midbrain 
reward circuit with cocaine motor sensitization.  
Effect of KOPr agonists on cocaine induced stereotypy. 
 KOPr agonists, Sal A and DS1 have shown to attenuate motor sensitization 
produced by high dose of cocaine (20 mg/kg; Tab 4.2). However, both Sal A and DS1 
pre-treatment showed a non-significant enhancement in cocaine-induced stereotypy (Fig 
2.4c, 2.8c). As suppression in forward locomotion by KOPr agonists might reflect an 
enhanced stereotypy, a detailed study on cocaine produced stereotypic behaviours is 
warranted. With similar experimental procedure to induce motor sensitization 
(mentioned in Section 2.2; Chapter 2), effect of KOPr compounds on cocaine produced 
stereotypic behaviours could be measured. The stereotypic behavioural counts could be 
determined using methods described by Kalivas et al., (1988) and Szumlinski et al., 
(2000).        
Effect of SSRI+ KOPr agonists in cocaine prime induced drug-seeking 
Both KOPr agonist and SERT antagonist, FLX treatment has shown to attenuate 
cocaine prime induced reinstatement in laboratory animals (Burmeister et al., 2003). 
Moreover, sub-chronic FLX pre-treatment attenuated KOPr agonists produced 
depressive behaviours in FST (Tab 4.1). Therefore, it would be interesting to test the 
effect of co-administration of FLX with Sal A/DS1 on cocaine-seeking behaviour. To 
test this, an initial screening could be performed using the within-session reinstatement 
model (Worley et al., 1994). Preliminary results from such experiment could open a 
new avenue of research using SERT antagonists in combination with KOPr agonists in 
tackling cocaine addiction without producing KOPr activation induced depressive 
effects.     
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Pre-clinical models to quantify behavioural despair induced by KOPr agonists 
With the limitations of the FST paradigm (discussed in Chapter 3; Section 3.5), 
it would be interesting to characterize KOPr activation produced behavioural despair 
using paradigms which have been previously applied to study anhedonia pre-clinically. 
Such tests could be performed using social interaction effect (Sams-Dodd, 1997), 
sucrose drinking (Muscat and Wilner, 1992) and ICSS test in rats (Todtenkopff et al., 
2004; Ebnar et al., 2010). The measurement of ICSS thresholds have been previously 
used to evaluate anhedonia like effects of Sal A (Ebnar et al., 2010) and hence could be 
useful in evaluating DS1 and nalmefene produced behavioural despair.    
Herkinorin as maintenance therapy  
Herkinorin is the only synthetic Sal A analogue with more affinity for MOPr and 
weak affinity for KOPr. Also, herkinorin is an agonist at MOPr and KOPr. The results 
from this thesis showed that herkinorin did not potentiate cocaine seeking in within 
session reinstatement test (Tab 4.1). This led to the hypothesis that neoclerodane 
diterpenes acting as agonists at MOPr and KOPr could be effective in relapse 
prevention. To prove this hypothesis, experiments could be performed by looking at the 
effect of herkinorin pre-treatment on cocaine prime induced reinstatement after a 
prolonged period of withdrawal (Ferragud et al., 2009). Also, by measuring the function 
of DAT and SERT in NAc and CPU could help explain the mechanism of action of 
herkinorin. Such experiments could be performed using RDEV technique. The 
preliminary results from such experiments with herkinorin have the potential to develop 
a new class of neoclerodanes diterpenes aimed at preventing relapse to cocaine use.    
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4.6. Summary and conclusions 
This study shows that the novel KOPr activating neoclerodane diterpenes Sal A, 
DS1 and MOM Sal B attenuate cocaine induced behaviours in a similar way to 
traditional KOPr agonists. This effect was also observed for partial KOPr agonist/MOPr 
antagonist, nalmefene. However, longer acting and more potent Sal A analogue, MOM 
Sal B produced anhedonia which was not seen with either Sal A, DS1 or nalmefene. 
Also, Sal A and DS1 showed better adverse effect profile than nalmefene in drug naive 
rats. However, all three compounds tested (Sal A; DS1 and nalmefene) produced 
depression and preliminary evidence has been presented to suggest that Sal A and DS1 
induced depression may involve serotonin neurotransmission. Finally, preliminary in 
vitro cell studies show KOPr activation by traditional agonist U50488H directly 
modulates serotonin transporter function. However, Sal A analogues may regulate 
SERT in a different manner compared to traditional KOPr agonists. Further studies are 
needed to determine the extent of these differences.         
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Appendix 
Appendix for Chapter 2 
1. Test for patency of catheters (Pentobarbital test) 
• Initially try and withdraw some blood from the catheter using a syringe which 
has penicillin in heparinised saline.  
• If you observe blood in the syringe, the line is OK. Flush back blood with 0.1 
mL of heparinised penicillin solution. 
•  If you don’t observe blood, then infuse 0.1 mL of pentobarbital (Provet, 
Auckland; 5 mg/mL). If the animal becomes unconscious, then the line is still 
OK. If the animal does not get unconscious, then the rat has either a chest leak 
or head leak and needs unblocking of its line. 
• The cather patency test was performed when rats were not being trained for 
self-administration sessions.   
Appendix for Chapter 4 
1. Recipe for LB Broth (for 500 mL) 
• Tryptone (OXOID, UK) 5 g 
• Sodium Chloride  (LabServ) 5 g 
• Yeast Extract (Sigma) 2.5 g 
• Add distilled water and autoclave it. 
2. Recipe for Agar plates (200 mL; each plate takes approx 20 mL) 
• Agar (Fischer Scientific)2 g  
• Tryptone 2 g 
• Sodium Chloride 2 g 
• Yeast Extract 1 g 
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• Add distilled water and autoclave it. After autoclaving, cool the flask (until the 
flask is slightly warm) then add appropriate antibiotic, ie Ampicillin (Sigma, 
MO) for KOPr plasmid preparation (100 µg/mL) and Kanamycin (Tocris, UK) 
for SERT plasmid (50 µg/mL). 
• Slightly shake the flask for gently mixing and then pour in the agar plates. Allow 
the agar to set for few hours and then store it in refrigerator. These plates can be 
stored up to 2 months. 
3. Method for GFP-hSERT and myc-rKOPr plasmid Preparation:  
• Day 1:- Take a scraping of the frozen transformed bacteria transfected with 
cDNA for GFP-hSERT (generous gift from Dr. Samanda Ramamoorthy) and 
myc-rKOPR (generous gift from Dr. Lakshmi Devi) from the vial stored at     -
80 °C. Plate the bacteria on a fresh agar plate. Incubate the plate for 24 hr at 
37 °C and allow the bacterial colony to grow on agar plate in humid condition 
(place some water in a conical flask in the incubator). 
• Day 2:- Add 2 mL of sterile LB broth in a sterile 15 mL tube which contains 
100 µg/mL of ampicillin (for myc-rKOPr) and 50 µg/mL of kanamycin (for 
GFP-hSERT). Select a middle sized colony of bacteria from the agar plate and 
transfer it using a sterile pipette into the 15 mL tube and incubate for 24 hr at 
37 °C with constant shaking at 280 rotation per minute in humid condition. 
• Day 3:- Add 200 µL of the bacterial culture to 200 mL of LB broth which 
contains appropriate antibiotic in proper concentrations and incubate for 24 hr at 
37 °C with constant shaking at 280 rotation per minute in humid condition. 
• Day 4:- Centrifuge samples for 15-25 min at 4 °C. (Dupont Centrifuge, RC5C; 
GSA 1 rotor; rotor code: 10; Sorvall Instruments). Dispose off the supernatant 
and keep the pellet on ice. Then follow the instructions mentioned in the 
manufacturer’s catalogue (Quagen) 
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4. Media for HEK-293 cells. (for 100 mL) 
• Dulbecco Modified Eagle’s Medium (Gibco, Invitrogen) 89 mL. 
• Fetal Calf Serum 10 mL (Invitrogen) 
• Penstrap (Invitrogen)1 mL. 
5. Media for HEK-293 cells. (without penstrap; for 100 mL) 
• Dulbecco Modified Eagle’s Medium 90 mL. 
• Fetal Calf Serum 10 mL. 
6. Transient transfection of HEK-293 cells with myc-rKOPr and GFP-SERT. 
• Mix A:- 3 µL Lipofectamine (Invitrogen) + 47 µL OptiMEM (Invitrogen) (Keep 
it for 5 min). 
• Mix B:- (0.4 µg/mL GFP-hSERT + 0.6 µg/mL myc-rKOPr) + make volume 
upto 50 µL using OptiMEM. 
• Mix A + Mix B (Keep this for 20 min) 
• Add 100 µL of Mix A + Mix B to each culture dish (1 mL/dish) and return dish 
back to incubator. 
7. Krebs Ringer Herpes buffer (KRH). 
• Sodium Chloride 130mM 
• Potassium Chloride (LabServ) 1.3mM 
• Calcium Chloride (Fischer Scientific) 2.2mM 
• Magnesium sulphate (LabServ) 1.2mM 
• Potassium Dihydrogen Phosphate (LabServ) 1.2mM 
• HEPES (Sigma) 10mM 
• D-Glucose (Sigma) 10mM 
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Drug-seekingOur previous work indicated that pretreatment with the selective kappa-opioid receptor (KOPr) agonist,
U69593, attenuated the ability of priming injections of cocaine to reinstate extinguished cocaine-seeking
behavior. The present study expanded these initial tests to include other traditional KOPr agonists, U50488H,
spiradoline (SPR), and salvinorin A (Sal A), an active constituent of the plant Salvia divinorum. Following
acquisition and stabilization of cocaine self-administration, cocaine-produced drug-seeking was measured.
This test was conducted in a single day and comprised an initial phase of self-administration, followed by a
phase of extinguished responding. The final phase examined reinstatement of extinguished cocaine self-
administration followed by a priming injection of cocaine (20.0 mg/kg, intraperitoneal (I.P.)) in combination
with the various KOPr agonists. Cocaine-induced drug-seeking was attenuated by pretreatment with U69593
(0.3 mg/kg, subcutaneous (S.C.)), U50488H (30.0 mg/kg, I.P.), SPR (1.0, 3.0 mg/kg, I.P.) and Sal A (0.3, 1.0 mg/
kg, I.P.). Sal A (0.3, 1.0 mg/kg, I.P.) had no effect on operant responding to obtain sucrose reinforcement or on
cocaine-induced hyperactivity. These findings show that Sal A, like other traditional KOPr agonists attenuates
cocaine-induced drug-seeking behavior.64 4 463 5402.
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Prior studies have demonstrated that KOPr agonists attenuate some
of the neuro-chemical and behavioral effects of drugs of abuse
(Heidbreder et al., 1993, 1995; Shippenberg et al., 1996; Thompson
et al., 2000). These effects might be due to the interactions between
KOPr and dopaminergic systems since pretreatment with kappa-opioid
agonists decreased dopamine (DA) concentrations in terminal regions
(Devine et al., 1993; Shippenberg et al., 1994; Maisonneuve et al., 1994;
Heidbreder and Shippenberg, 1994; Heidbreder et al., 1996) and
attenuated cocaine- (Shippenberg et al., 1994), amphetamine- (Gray
et al., 1999) and heroin- (Xi et al., 1998) induced DA release in the
ventral striatum. Also,manybehavioral effects of psycho-stimulants like
cocaine (Heidbreder et al., 1993, 1995), amphetamine (Gray et al., 1999)
and nicotine (Hahn et al., 2000)were decreased by prior administration
of KOPr agonists. Additionally, pretreatment with KOPr activating
compounds attenuated cocaine (Glick et al., 1995; Mello and Negus,
1996, 1998;Neguset al., 1997; Schenket al., 1999; SchenkandPartridge,
2001), morphine (Glick et al., 1995) and heroin (Xi et al., 1998) self-
administration in laboratory animals. These findings suggest thepossible role of KOPr agonists as pharmacotherapeutics in the treatment
of addiction (Mello and Negus, 1998; Prisinzano et al., 2005; Shippen-
berg et al., 2007; Willmore-Fordham et al., 2007; Prisinzano and
Rothman, 2008; Tomasiewicz et al., 2008).
During a binge of cocaine self-administration in abusers there is
tolerance to many of the subjective effects (Fischman et al., 1985).
Self-administration and drug craving, however, continue relatively
unabated. Since exposure to cocaine produces craving for more
cocaine (Jaffe et al., 1989), it is possible that continued exposure to
cocaine during a binge maintains a cycle of drug-seeking and drug-
taking, even after tolerance develops. If so, identification of factors
that reduce the ability of cocaine to produce drug-seeking would be
an important step in the development of effective treatments for
cocaine abuse.
Animal models of drug-seeking have contributed greatly to
investigations of these factors. A number of laboratories have used
procedures developedbydeWit and Stewart (1981) to demonstrate the
ability of cocaine to reinstate extinguished cocaine self-administration
behavior. This effect appears to be mediated, at least in part, by
dopaminergic mechanisms since cocaine-produced drug-seeking was
attenuated by pretreatment with dopaminergic agonists and antago-
nists (Self et al., 1996; Khroyan et al., 2000, 2003; Alleweireldt et al.,
2002).
Pretreatment with the kappa-opioid receptor agonist, U69593
attenuated cocaine-produced reinstatement of extinguished cocaine-
245A.S. Morani et al. / Pharmacology, Biochemistry and Behavior 94 (2009) 244–249taking behavior (Schenk et al., 1999, 2000). This effect was somewhat
specific since reinstatement produced by experimenter-administered
injections of the dopamine uptake inhibitors, GBR 12909 orWIN 35428,
was not attenuated by pretreatmentwith U69593 (Schenk et al., 2000).
The attenuation of drug-seeking involved effects at central KOPrs, as
prior intracerebroventricular administration of nor-BNI, a kappa-opioid
antagonist, reversed the effects of U69593 (Schenk et al., 1999).
Sal A, a neoclerodane diterpene, is an active constituent of the
hallucinogenic sage, Salvia divinorum, and has been used in traditional,
spiritual and ethnopharmacological practices by theMazatec Indians of
Oaxaca, Mexico (Valdes et al., 1983; Valdes, 1994; Siebert, 1994). Sal A
binds selectively to the KOPr (Roth et al., 2002; Yan and Roth, 2004;
Prisinzano, 2005) with greater efficacy than U69593 and U50488H
(Chavkin et al., 2004). It has a rapid onset of action and a short
elimination half life (56.6±24.8 min) (Schmidt et al., 2005; Butelman
et al., 2009). Accordingly, there has been recent interest in understand-
ing the neuropharmacology of Sal A and comparing it with traditional
KOPr agonists.
Sal A dose dependently produced antinociception in tail flick, hot
plate and acetic acid induced writhing in mice that was antagonized by
nor-BNI (McCurdy et al., 2006; John et al., 2006). Sal A also produced
discriminative stimulus effect in rats (Willmore-Fordham et al., 2007;
Baker et al., 2009) and rhesus monkeys (Butelman et al., 2004),
decreased mobility in the forced swim test (Carlezon et al., 2006) and
producedmotor inco-ordination inmice (Fantegrossi et al., 2005; Zhang
et al., 2005). The aim of our current studywas to determinewhether Sal
A has similar effects to other KOPr agonists, U69593, U50488H and SPR
on cocaine-produced drug-seeking in rats.
2. Methods
2.1. Subjects
Male Sprague–Dawley rats weighing 325–350 g were used. They
were housed individually in hanging polycarbonate cages. The humidity
(55%) and temperature (19–21 °C) were controlled and food and water
were freely available except during testing. Animals tested for sucrose
self-administrationhad free access towater at all timeswithin thehome
cage and were maintained at approximately 85% of their initial feeding
weight during the experiments by restricting access to food. The animal
colony was maintained in the animal facility at School of Psychology,
Victoria University of Wellington. All the experiments were conducted
in accordance with the guidelines of the Animal Ethics Committee of
Victoria University of Wellington. Lights were maintained on a 12:12 h
cycle with lights on at 0700.
2.2. Surgery
Underdeep anesthesiaproducedbyketamine/xylacine (90/9 mg/kg,
I.P.), a silastic catheter was placed in the right jugular vein. The external
jugular vein was isolated, the catheter was inserted and the distal end
(22 gauge stainless steel tubing) was passed subcutaneously to an
exposed portion of the skull where it was fixed to embedded jeweler's
screws with dental acrylic.
Each day, the catheters were infused with 0.1 ml of a sterile saline
solution containing heparin (30.0 U/ml), penicillin G Potassium
(250,000 U/ml) and streptokinase (8000 U/ml) to prevent infection
and the formation of clots and fibroids. The rats were allowed five
days post surgery for recovery.
2.3. Apparatus
2.3.1. Cocaine self-administration
Self-administration testing was carried out in a humidity (55%) and
temperature (19–21 °C) controlled environment in standard operant
chambers (Med Associates, ENV-001) equipped with 2 levers. Depres-sion of one lever (the active lever) resulted in a 0.l ml intravenous
infusion of cocaine HCl dissolved in sterile physiological saline contain-
ing heparin (3.0 U/ml). Infusionswere of 12 s duration. Coincident with
drug delivery was the illumination of a stimulus light located directly
above the active lever. This stimulus light remained illuminated
throughout each 12 s infusion. Depression of the other lever (the
inactive lever) was without programmed consequence.
Rats were maintained in the animal colony except during testing.
Immediately prior to eachdaily test, the catheter lineswere infusedwith
0.1 ml of the heparin–penicillin–streptokinase solution. The stainless
steel catheter was connected to a length of microbore tubing and
connected to the syringe. At the end of each test, the lines were again
infused with 0.1 ml of the heparin–penicillin–streptokinase solution,
the stainless steel tubingwaspluggedand the animalwas returned to its
home cage. Drug delivery and data acquisition were controlled by Med
Associates software. Cocaine deliveries were made via mechanical
pumps (Razel, Model A with 1.0 rpm motor equipped with 20 ml
syringe).
2.3.2. Sucrose self-administration
Training and testing procedures were conducted in eight standard
operant chambers (Med Associates, ENV001) in an unlit, sound
attenuating room. Operant chambers were equipped with two
retractable levers and a sucrose bottle delivering 0.1 ml of 10% sucrose
solution onto a tray on the chamber wall according to the imposed
schedule of reinforcement. Sucrose delivery and data acquisition were
controlled by Med Associates software. Experiments were conducted
between 0900 and 1600 hours.
2.3.3. Locomotor activity tests
Eight open field chambers (Med Associates) equipped with two
banks of sixteen photocells on each wall were used to measure
horizontal locomotion. The open field boxes were interfaced with a
microcomputer located in an adjacent laboratory. Testing was
conducted in the dark between 1000 and 1600 hours. White noise
was continually present to mask extraneous disturbances.
2.4. Procedure
2.4.1. Cocaine self-administration training
Acquisition of cocaine self-administration was monitored during
daily 2 h sessions. Each session began with an experimenter-delivered
infusion of cocaine (0.5 mg/kg/infusion). Thereafter, depression of the
active lever produced automated cocaine infusions according to an FR-1
schedule of reinforcement. The criterion for acquisition of cocaine self-
administration consisted of at least 20 reinforced responses (10 mg/kg)
during the 2 h session and a ratio of active:inactive lever responses of at
least 2:1. Self-administration was considered acquired when these
criteria were met for three consecutive days. Following acquisition, the
response requirements were increased to FR-5. Daily 2 h sessions were
conducteduntil therewas less than20%variation in respondingon three
consecutive days. During training, the cocaine infusion was always
paired with the illumination of a house light located directly above the
active lever.
2.4.2. Cocaine reinstatement test
Once responding on the FR-5 schedule was stable, the effect of prior
administration of the kappa-opioid agonists, U69593, U50488H, SPR
and Sal A on drug-seeking produced by cocaine was measured. As with
our previous studies (Schenk et al., 1999, 2000), this testwas conducted
in a single day and consisted of three phases. The first phase was
comprised of a 1 h period of cocaine self-administration (0.5 mg/kg/
infusion, FR-5 schedule of reinforcement) in which the light stimulus
was paired with cocaine infusions. After the 1 h self-administration
period, the cocaine solution was replaced with heperanized saline and
responding was reinforced with this vehicle infusion (FR-5 schedule of
Fig. 1. Number of lever press responses (+SEM) during Phases 1 (cocaine self-
administration) and 2 (extinction) (n=6). During phase 1, responding is high (97.0+
6.1) and by the end of phase 2, after the cocaine solution had been replaced with saline,
fewer than 20 responses per hour were produced (16.3+1.3).
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during this phase was measured for 3h. At the start of the third phase
during which responding was again reinforced according to an FR-5
schedule of reinforcement with an infusion of vehicle solution and
illumination of the light stimulus, separate groups of rats (n=5–7 per
group) received an injection of U69593 (0.03, 0.1 or 0.3 mg/kg, S.C.),
U50488H (3.0, 10.0 or 30.0 mg/kg, I.P.), SPR (0.3, 1.0 or 3.0 mg/kg, I.P.),
Sal A (0.1, 0.3 and 1 mg/kg, I.P.) or vehicle. These injections were
administered either 5 (Sal A), 15 (U69593) or 30 (U50488H, SPR) min
prior to an injection of cocaine HCl (20 mg/kg, I.P.). Responding was
measured for 60 min following the cocaine injection.
2.4.3. Sucrose reinforcement training and test
Animals were trained to self-administer sucrose using an auto-
shaping procedure. Training sessions were 45 min duration on each of
10 training days. Once stable responding was produced, the animals
were maintained on an FR1 schedule of reinforcement during which
depression of the active lever (left lever) delivered 0.1 ml of a 10%
sucrose solution. Following acquisition, the response requirements
were increased to FR-5. Daily 1 h sessions were conducted until there
was less than 20% variation in responding for three consecutive days.
Once responding on the FR-5 schedule was stable, the effect of Sal A on
sucrose-reinforced responding was measured. Rats received an injec-
tion of either Sal A (0.3 or 1.0 mg/kg, I.P.) or vehicle 5 min prior to
sucrose self-administration testing and the number of responses was
measured for 60 min.
2.4.4. Procedure for cocaine-produced locomotor activity
On the test day, separate groups of rats (n=6per group) received an
injection of Sal A (0.0 or 0.3 mg/kg, I.P.) 5 min prior to an injection of
cocaine (20 mg/kg, I.P.). Immediately following the second injection, the
rats were placed in the activity chambers and total activity, a
compilation of horizontal and vertical activity, was measured for a
period of 60 min.
2.5. Data analysis
Thenumberof responsesproducedduring the1 hperiod following the
cocaine injection (20 mg/kg, I.P.) at the start of phase 3 was measured.
Sucrose-reinforced responding was measured for a 1 h period following
Sal A or vehicle exposure. Statistical analysis for cocaine-induced
reinstatement and sucrose reinforcement consisted of one-way ANOVAs
followed by Tukey post-hoc comparisons where appropriate. Student t-
test was applied for locomotion test.
2.6. Drugs
Cocaine HCl (Merck Pharmaceuticals, Palmerston North, New Zeal-
and), SPR and U50488H (Sigma-Aldrich, St. Louis, MO) were dissolved in
physiological saline. U69593 (National Institute of Drug Abuse) was
dissolved inanaqueous solutionof25%propyleneglycol. SalA(isolatedby
Dr. Thomas E. Prisinzano, University of Kansas, Lawrence, KS) was
suspended in 75%DMSO. Sucrosewas dissolved in tapwater. Intravenous
infusions were in a volume of 100 µl and S.C. or I.P. injections were in a
volume of 1 ml/kg. All drug weights refer to the salt.
3. Results
Fig. 1 shows the respondingduringphases 1 and2 for a representative
group of rats from the present study. During the 1 hperiod of cocaine self-
administration, responding was high. When saline was substituted for
cocaine during phase 2, responding decreased to less than 20 responses
during hour 3.
Fig. 2 shows the number of saline-reinforced responses produced
during the 1 h period following the injection of cocaine at the start of
phase 3 for rats that received systemic administration of the KOPragonists, U69593, U50488H, SPR and SalA. Each of the KOPr agonists
produced a dose-dependent reduction of cocaine-produced reinstate-
ment (U50488H: F(3,17)=4.277, p<0.05; U69593: F(3,20)=3.103,
p<0.05); SPR: (F(3,21)=7.899, p<0.01; Sal A: (F(3,23)=79.33,
p<0.0001). Doses of 30.0 mg/kg U50488H, 0.3 mg/kg U69593, 1.0 or
3.0 mg/kg SPR and 0.3 or 1.0 mg/kg Sal A significantly decreased drug-
seeking (p<0.05).
Fig. 3 shows the number of sucrose-reinforced responses produced
during the 1 h period following the injection of Sal A (0.3 and 1.0 mg/kg,
I.P.). Sal A did not significantly decrease sucrose self-administration (F
(2,27)=0.06, NS).
Fig. 4 shows the effect of Sal A (0.0 or 0.3 mg/kg, I.P.) on cocaine-
produced locomotor activity. Sal A failed to decrease cocaine-
produced hyperactivity.4. Discussion
As has previously been shown, cocaine reinstated extinguished
cocaine-taking behavior (Worley et al., 1994; Schenk and Partridge,
1999; Schenk et al., 1999). This effect was attenuated by pretreatment
with KOPr agonists. High doses of SPR might have produced a non-
selective effect on motor behavior as suggested by the decreased
responding observed in a drug discrimination study (Holtzman et al.,
1991). The attenuation of drug-seeking was also produced by a dose of
SPR (1.0 mg/kg) that didnotdecrease responding in adrugdiscrimination
task (Holtzman, 2000). It is thereforeunlikely that thedecrease incocaine-
seeking represents a generalized inability to perform the lever press
operant at the dose used in this study. Similarly, decreased drug-seeking
was produced by doses of U69593 and U50488H that failed to produce a
generalized decrease in motor activity (Schenk et al., 1999; unpublished
findings).
In a previous study, U50488H administered to mice 60 min prior to
cocaine potentiated cocaine-induced conditioned place preference (CPP)
butwhen administered 15 minprior to cocaine it suppressed the cocaine-
CPP (McLaughlin et al., 2006). In this studywemeasured cocaine-induced
drug-seeking during a 60 min period following U50488H administration
and also observed a small but non-significant increase in responding.
In drug discrimination tests, Sal A and its synthetic derivatives
substituted completely for U69593 (Baker et al., 2009), suggesting an
effectmediatedby theKOPr. Because of the interactionbetweenKOPr and
dopaminergic mechanisms, a focus on the effects of Sal A on dopamine-
mediated behaviors has been of interest. Cocaine-seeking has been
Fig. 2. Responses (+SEM) produced during phase 3 following injection of KOPr agonists and cocaine. Numbers in parentheses represent sample sizes for each group. *<0.05.
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idea that Sal Amodulates the effects of cocaine through interactions with
D1 receptor mediated signaling in the dorsal striatum (Chartoff et al.,
2008; Gehrke et al., 2008). Low doses of Sal A (40 µg/kg) increased DA
levels in nucleus accumbens (NAc) (Braida et al., 2008) whereas higher
doses decreased NAc DA levels (Zhang et al., 2005). Thus, the ability of
moderate to high doses of Sal A to decrease cocaine-produced drug-
seeking might be due to its effects on the dopaminergic system.
Alternatively, the decrease in drug-seeking might reflect a non
specific effect. This possibility was tested by examining the effects of
Sal A on respondingmaintained by a sucrose reinforcer. Conditions forFig. 3. Number of sucrose-reinforced responses (+SEM) produced by rats for 60 min
after treatment with Sal A (0.3 and 1.0 mg/kg, I.P.). Numbers in parentheses represent
sample sizes for each group.this test were comparable to conditions of the reinstatement tests. In
this experiment, responding maintained by sucrose was high and
comparable to responding maintained by cocaine. Doses of Sal A (0.3,
1.0 mg/kg I.P.) that decreased cocaine-seeking failed to alter sucrose-
reinforced responding.
Additionally, KOPr activation has shown to produce motor inco-
ordination (Fantegrossi et al., 2005). A more recent report, however,
failed tofindany effect of Sal A on locomotor activity (Baker et al., 2009).
The effect of Sal A on cocaine-produced hyperactivity was measured in
the present study under conditions that were comparable to the
conditions of the reinstatement tests. Sal A did not attenuate cocaine-
produced hyperactivity. Therefore, the decrease in drug-seeking
produced by Sal A cannot be attributed to either a generalized inability
to perform the lever press operant or a disruption of motor activity.Fig. 4. Effect of Sal A (0 and 0.3 mg/kg, I.P.) on cocaine-induced locomotion. Symbols
represent total ambulatory counts (+SEM) during the 60 min period following the
cocaine injection (n=6).
248 A.S. Morani et al. / Pharmacology, Biochemistry and Behavior 94 (2009) 244–249Reinstatement of conditioned place preference (CPP) following
extinction has also been used as a model of drug-seeking (Kreibich and
Blendy, 2004) and a modulation of drug-seeking behaviors by traditional
KOPr agonists has been demonstrated using this model. The effects
appear, however, to be opposite to those producedwhen drug-seeking in
a self-administration paradigm is measured. For example, foot-shock or
forced swim stress was effective in reinstating both extinguished place
preference (McLaughlin et al., 2003, 2006; Redila and Chavkin, 2008) and
self-administration (Beardsley et al., 2005). Theeffect in theCPPparadigm
was, however, blocked by pretreatment with the KOPr antagonist, nor-
BNI (Redila andChavkin, 2008;McLaughlin et al., 2003). Theeffect ofKOPr
antagonists might depend on the drug-seeking stimulus since the KOPr
antagonist, JDTic, inhibited stress induced drug-seeking but had no effect
on cocaine-produced reinstatement (Beardsley et al., 2005).
Further, KOPr knock out mice were insensitive to stress-produced
reinstatement, as measured in the CPP paradigm, supporting the idea
that reinstatement of CPP required KOPr activation. A further
difference in the role of KOPr in reinstatement as measured in the
CPP and self-administration paradigms is that U50488H potentiated
the cocaine-produced place preference whereas it decreased drug-
seeking following extinction of self-administration (present study).
Additional studies will have to be conducted in order to tease apart
the different aspects of the two paradigms.
In conclusion, Sal A, like traditional KOPr agonists attenuated
cocaine-induced cocaine-seeking. Further studies on Sal A and its
structural derivatives will help us understand the mechanism by
which KOPr agonists attenuate drug-seeking behaviors and to
determine whether Sal A produces the same magnitude of adverse
effects that have limited the development of other KOPr agonists as
anti-addiction pharmacotherapies.Acknowledgements
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